Cost-Effectiveness in Modern Oncology: An Economic Analysis of Genomic, AI-Driven, and Traditional Testing Approaches

Abstract

This article provides a comprehensive analysis of the cost-effectiveness of evolving cancer testing modalities, tailored for researchers, scientists, and drug development professionals. It explores the foundational economic principles and the shifting paradigm towards precision medicine. The analysis delves into methodological frameworks for economic evaluation and presents real-world applications across various cancer types, including non-small cell lung cancer (NSCLC), colorectal cancer, and prostate cancer. It further addresses key challenges in implementation and optimization strategies, such as biomarker prevalence and technology integration. Finally, the article offers a comparative validation of testing strategies—from comprehensive genomic profiling and liquid biopsy to artificial intelligence (AI)-assisted pathology—synthesizing evidence on their value in improving patient outcomes and optimizing healthcare resource allocation.

The Economic Imperative and Evolving Paradigm of Cancer Diagnostics

The Rising Global Burden of Cancer and Healthcare Costs

Cancer remains a leading cause of global mortality, with an estimated 10 million deaths annually worldwide, creating substantial economic burdens on healthcare systems [1]. National costs for cancer care in the United States alone are projected to exceed $245 billion by 2030 [2]. This economic burden stems from multiple factors, including late-stage diagnosis, expensive targeted therapies, and the complex management of advanced disease. In this challenging landscape, cost-effectiveness analysis has emerged as a critical tool for evaluating healthcare interventions, balancing clinical benefits against economic constraints.

The emergence of genomic technologies represents a paradigm shift in oncology, offering unprecedented opportunities for personalized medicine through improved risk stratification, earlier detection, and more targeted treatment approaches. This article provides a comparative analysis of the cost-effectiveness of various cancer testing modalities, including comprehensive genomic profiling, multicancer early detection tests, and genetic risk-stratified screening, to inform researchers, scientists, and drug development professionals about their value in contemporary cancer care.

Comparative Analysis of Cancer Testing Modalities

Table 1: Cost-Effectiveness Comparison of Advanced Cancer Testing Approaches

Testing Modality	Cancer Type/Context	Incremental Cost-Effectiveness Ratio (ICER)	Key Clinical Benefits
Comprehensive Genomic Profiling (CGP)	Advanced Non-Small-Cell Lung Cancer (US)	$174,782 per life-year gained [3]	Improved average overall survival by 0.10 years compared to small panel testing [3]
Comprehensive Genomic Profiling (CGP)	Advanced Non-Small-Cell Lung Cancer (Germany)	$63,158 per life-year gained [3]	Higher percentage of patients receiving targeted therapies [3]
Multicancer Early Detection (MCED) + Usual Care	Multiple cancer types (US, age 50-79)	$66,048 per QALY gained [2]	Shifted 7200 cancers to earlier stages at diagnosis per 100,000 individuals [2]
Polygenic Risk Score (PRS) Stratified Screening	Breast Cancer (Taiwan)	$75.71 per QALY gained [4]	Enables tailored screening intensity based on genetic risk [4]
CGP (with increased treatment access)	Advanced Non-Small-Cell Lung Cancer (US)	$86,826 per life-year gained [3]	Demonstrated improved cost-effectiveness with broader treatment access [3]

Table 2: Testing Performance Characteristics and Economic Parameters

Testing Modality	Sensitivity Range by Stage	False Positive Rate	Test Cost/Price	Population Studied
Multicancer Early Detection (MCED)	Stage I: 22-61% (varies by cancer); Stage IV: 95-96% [2]	0.5% [2]	$949 [2]	Adults aged 50-79 years [2]
Comprehensive Genomic Profiling	Not explicitly stated in results	Not specified	Not specified	Patients with advanced non-small-cell lung cancer [3]
Polygenic Risk Score Screening	Not specified	Not specified	Not specified	35-year-old Taiwanese women without family history of breast cancer [4]

Methodologies in Cost-Effectiveness Research

Partitioned Survival Modeling

The partitioned survival model (PSM) has become a standard methodology for evaluating the cost-effectiveness of cancer interventions. This approach was utilized in multiple studies analyzed in this review [3] [5] [6]. The PSM typically incorporates three distinct health states: progression-free survival (PFS), progressive disease (PD), and death [5]. Patients transition between these states based on transition probabilities derived from clinical trial data.

In practice, researchers extract survival curve data from clinical trials using tools like GetData Graph Digitizer software, then reconstruct and simulate survival curves using various distribution models including Weibull, log-logistic, Gompertz, gamma, exponential, and log-normal distributions [5]. The optimal distribution is selected based on statistical criteria such as the Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC), complemented by visual inspection to ensure clinical validity [5].

Hybrid Cohort-Level Modeling for Early Detection

For evaluating multicancer early detection tests, researchers have developed hybrid cohort-level models that combine state transitions with decision tree analysis [2]. This approach compares annual MCED testing plus usual care screening against usual care alone for cancer detection over a lifetime horizon. The model estimates cancer diagnoses in the usual care arm based on age-specific and stage-specific incidence rates for each cancer type, typically sourced from comprehensive registries like the Surveillance, Epidemiology, and End Results (SEER) program [2].

These models incorporate stage shift analysis, where MCED testing enables earlier detection and diagnosis of cancer compared to usual care alone. The magnitude of stage shifting is estimated by accounting for MCED testing frequency, sensitivity, and cancer progression speed (dwell time) by cancer type and stage [2]. Advanced models also consider differential survival based on cell-free DNA detectability status, recognizing that cancers detectable by MCED tests may have different biological aggressiveness [2].

Network Meta-Analysis for Comparative Effectiveness

When direct comparative evidence between interventions is limited, network meta-analysis (NMA) provides a valuable methodological approach. This technique was employed in the evaluation of first-line treatments for recurrent or metastatic head and neck cancer, enabling indirect comparison of multiple treatment strategies across different clinical trials [6]. NMA extends beyond traditional pairwise comparisons by simultaneously evaluating and ranking multiple treatment strategies in terms of overall efficacy, making it increasingly valuable in pharmacoeconomic evaluations [6].

Cost-Effectiveness Analysis Workflow

Key Research Reagents and Technologies

Table 3: Essential Research Reagents and Technologies in Genomic Cancer Testing

Reagent/Technology	Primary Function	Application in Research
Cell-free DNA (cfDNA) Methylation Patterns	Detection of shared cancer signals across multiple cancer types [2]	Multicancer early detection testing [2]
Polygenic Risk Scores (PRS)	Aggregate risk assessment based on multiple single nucleotide polymorphisms (SNPs) [4]	Risk-stratified screening for breast cancer [4]
Comprehensive Genomic Profiling (CGP)	Broad genomic analysis to identify targetable mutations [3]	Guidance for matched targeted therapies in advanced cancers [3]
Programmed Death-Ligand 1 (PD-L1) Staining	Assessment of tumor immunogenicity and prediction of immunotherapy response [5] [6]	Patient selection for immune checkpoint inhibitor therapies [5] [6]
Next-Generation Sequencing Panels	Simultaneous analysis of multiple cancer-related genes [3]	Identification of actionable genomic alterations in tumor tissue [3]

Signaling Pathways in Cancer Testing and Treatment

Testing-Informed Treatment Pathways

Discussion

Economic Value Across Testing Modalities

The cost-effectiveness of genomic testing varies significantly across cancer types, stages, and healthcare systems. Comprehensive genomic profiling in advanced non-small-cell lung cancer demonstrates substantially different ICERs between the United States ($174,782 per life-year gained) and Germany ($63,158 per life-year gained), highlighting the importance of regional healthcare economics in determining value [3]. This disparity may reflect differences in drug pricing, healthcare delivery systems, and implementation costs between countries.

For early detection, MCED testing presents a compelling economic value proposition at $66,048 per QALY gained, primarily through substantial reductions in late-stage cancer diagnoses and associated high treatment costs [2]. The test's ability to detect over 50 cancer types, particularly those without recommended screening protocols, addresses a significant gap in current cancer control strategies. Similarly, risk-stratified screening using polygenic risk scores for breast cancer demonstrates exceptional cost-effectiveness at $75.71 per QALY gained, suggesting that precision prevention approaches may offer exceptional value in appropriate populations [4].

Methodological Considerations in Economic Evaluation

The partitioned survival model has emerged as the predominant analytical framework for evaluating cancer testing strategies, though specific implementations vary substantially between studies [3] [5] [6]. These models require careful consideration of transition probabilities, utility values, and long-term extrapolation beyond clinical trial observation periods. The selection of appropriate survival distributions (e.g., Weibull, log-logistic, Gompertz) significantly influences cost-effectiveness results and requires both statistical rigor and clinical validation [5].

Recent methodological innovations include the incorporation of differential survival based on molecular detectability status, recognizing that cancers detectable by emerging technologies like MCED tests may have different biological behaviors than undetectable cancers [2]. This represents an important advancement in the methodological sophistication of economic evaluations, moving beyond simple stage-shift models to incorporate the biological implications of testing technologies.

Implications for Research and Development

For researchers and drug development professionals, these findings highlight the growing importance of economic evidence in the development and adoption of new cancer technologies. The demonstrated cost-effectiveness of comprehensive genomic profiling supports continued investment in broad-panel molecular diagnostics, particularly for guiding targeted therapies in advanced cancers [3] [1]. Similarly, the exceptional economic value of risk-stratified screening approaches suggests significant potential for precision prevention strategies that optimize resource allocation based on individual risk [4].

Future research should address evidence gaps in low- and middle-income countries, where the cost-effectiveness of genomic medicine remains largely unexamined despite bearing 65% of global cancer mortality [1]. Additionally, more economic evaluations are needed for rare cancers and cancers of unknown primary, where genomic technologies may offer particularly significant clinical benefits despite current limited evidence [1].

The rising global burden of cancer and associated healthcare costs necessitates careful evaluation of the economic value of emerging testing technologies. Current evidence demonstrates that comprehensive genomic profiling, multicancer early detection tests, and genetic risk-stratified screening can provide cost-effective approaches to cancer care across various clinical contexts and healthcare systems. The substantial regional variation in cost-effectiveness highlights the importance of local economic conditions and healthcare infrastructures in technology adoption.

For researchers and drug development professionals, these findings underscore the critical relationship between molecular testing, treatment personalization, and economic value in contemporary oncology. As genomic technologies continue to evolve, ongoing economic evaluations will be essential for guiding their responsible integration into healthcare systems, ensuring that scientific advancements translate into sustainable improvements in cancer outcomes despite growing economic pressures.

Precision medicine represents a fundamental shift in oncology, moving away from the traditional one-size-fits-all approach toward therapies tailored to the unique molecular characteristics of a patient's tumor. This approach recognizes that cancers with similar histology may harbor different genetic drivers, requiring different therapeutic strategies. By leveraging advanced genomic technologies, precision medicine aims to match patients with treatments that target the specific molecular alterations driving their cancer, potentially leading to improved outcomes and reduced toxicity.

The concept of 'precision cancer medicine' (PCM) stands as one of the most promising frontiers in the evolving landscape of oncology. By tailoring treatment to the unique genetic and molecular profile of each patient's tumor, PCM offers a vision of cancer treatment that is more effective, less toxic, and personalized [7]. However, it is crucial to distinguish between 'precision medicine' and 'personalized medicine,' terms often used interchangeably but with important distinctions. True personalized medicine would involve a comprehensively tailored treatment based on the predictive power from a joint analysis of all possible biomarkers, not only genomics, and selected from all available drugs [7]. In contrast, current precision medicine primarily focuses on genomics-guided approaches that stratify patients into subgroups based on molecular characteristics [7].

Comparative Analysis of Testing Approaches

Economic and Performance Characteristics of Genomic Testing Modalities

Table 1: Comparison of Genomic Testing Approaches in Oncology

Testing Approach	Typical Gene Coverage	Cost-Effectiveness Threshold	Key Applications	Strengths	Limitations
Single-Gene Tests	1 gene	Cost-effective for single biomarkers	Testing for individual high-impact mutations (e.g., EGFR in NSCLC)	Inexpensive, readily accessible, fast turnaround	Only detects a single mutation; inefficient when multiple biomarkers needed
Targeted NGS Panels	2-52 genes	Cost-effective when 4+ genes require assessment [8] [9]	Comprehensive biomarker profiling for treatment selection; residual disease monitoring	Simultaneous detection of multiple biomarkers; reduces turnaround time and healthcare staff requirements [8] [9]	Limited to predefined gene sets; may miss novel biomarkers
Comprehensive Genomic Profiling (CGP)	Hundreds of genes	Generally not cost-effective for routine use [8] [9]	Research settings; complex diagnostic cases; clinical trial enrollment	Unbiased discovery; identifies rare alterations; broad molecular portrait	Higher cost; complex data interpretation; uncertain clinical utility for many findings
Whole Genome/Exome Sequencing	Entire exome or genome	Not yet cost-effective for routine clinical care	Discovery research; diagnosis of rare cancers; tertiary care centers	Most comprehensive coverage; identifies non-coding variants	Highest cost; extensive data storage needs; majority of findings of unknown significance

Methodological Framework for Economic Evaluation

The assessment of precision medicine interventions relies on standardized health economic methodologies. Cost-effectiveness analysis in healthcare typically uses quality-adjusted life years (QALYs), which incorporate both the quality and the quantity of life gained from healthcare interventions. The incremental cost-effectiveness ratio (ICER) is the primary metric, representing the additional cost per QALY gained [10]. Thresholds for cost-effectiveness are often set between $50,000 and $150,000 per QALY in the United States, representing the amount generally considered reasonable to gain one additional year of life in perfect health [10].

Economic evaluations of precision medicine must account for multiple cost components beyond the initial test price, including:

• Direct testing costs: Reagents, equipment, and personnel for test administration
• Downstream treatment costs: Targeted therapies guided by test results
• Healthcare system costs: Staff requirements, hospital visits, and infrastructure
• Long-term outcomes: Survival benefits, quality of life improvements, and reduced adverse events

Holistic analysis demonstrates that next-generation sequencing reduces turnaround time, healthcare staff requirements, number of hospital visits, and hospital costs, providing economic advantages beyond simple test cost comparisons [8] [9].

Evidence Base: Precision Medicine in Practice

Clinical and Economic Outcomes Across Cancer Types

Table 2: Cost-Effectiveness Evidence for Precision Medicine Applications

Cancer Type/Context	Precision Medicine Approach	Comparative Intervention	Incremental Cost-Effectiveness Ratio (ICER)	Key Outcomes
Non-Small Cell Lung Cancer (EGFR+)	EGFR testing + gefitinib	Conventional chemotherapy	$110,000-$150,000 per QALY [10]	Improved progression-free survival and quality of life; at upper end of cost-effectiveness threshold
Advanced NSCLC (CGP vs. small panels)	Comprehensive Genomic Profiling	Small panel testing (SP)	$174,782 per life-year gained (US); $63,158 (Germany) [11]	Improved overall survival (0.10 years); higher percentage receiving targeted therapies
Hereditary Breast/Ovarian Cancer	NGS for BRCA + personalized risk assessment	Conventional risk assessment	Cost-effective in specific situations [12]	Favorable ICER (<$50,000/QALY) in high-risk populations; cost savings from avoided cancer cases
Pediatric High-Risk Cancer	Multi-omics profiling (WGS, RNAseq, methylation)	Conventional diagnostic workup	$12,743 per patient for program access [13]	Identifies molecular causes and actionable targets in refractory childhood cancers
Lung Cancer Screening (High-risk)	Liquid biopsy (EarlyCDT-Lung)	Standard clinical diagnosis	$75,436 per QALY (Brazilian context) [14]	Exceeded local cost-effectiveness thresholds; potentially cost-effective in populations with >4% prevalence

Implementation Considerations and Real-World Evidence

The real-world implementation of precision medicine reveals substantial variability in costs and outcomes. The Zero Childhood Cancer Precision Medicine Programme in Australia demonstrated costs of $12,743 per patient for program access, $14,262 per identification of molecular cause, and $21,769 per multidisciplinary tumor board recommendation [13]. These figures highlight the significant infrastructure and expertise required for comprehensive precision oncology.

The clinical impact of precision medicine extends beyond traditional cost-effectiveness metrics. Comprehensive genomic profiling in advanced non-small cell lung cancer has been shown to change management and improve survival in real-world settings [11]. However, the percentage of patients who ultimately benefit from genomics-guided precision medicine remains limited, as many tumors lack actionable mutations, and inherent or acquired treatment resistance is often observed [7].

Experimental Approaches and Methodologies

Technical Workflows in Precision Oncology

Table 3: Essential Research Reagents and Platforms for Precision Medicine Studies

Research Reagent/Platform	Primary Function	Application in Precision Medicine
Next-Generation Sequencers	High-throughput DNA/RNA sequencing	Whole genome, exome, transcriptome, and targeted panel sequencing for mutation detection
Whole Genome Sequencing (WGS)	Comprehensive analysis of entire genome	Identification of coding and non-coding variants, structural rearrangements
RNA Sequencing	Transcriptome analysis	Gene expression profiling, fusion detection, alternative splicing analysis
Methylation Arrays	Epigenetic profiling	Methylation pattern analysis for classification and prognostic stratification
High-Throughput Drug Screening (HTS)	In vitro drug sensitivity testing	Functional assessment of treatment response in patient-derived cells
Patient-Derived Xenografts (PDX)	In vivo drug efficacy testing	Evaluation of treatment response in animal models maintaining tumor heterogeneity
Circulating Tumor DNA Assays	Liquid biopsy analysis	Non-invasive tumor genotyping, monitoring treatment response, minimal residual disease detection

Computational Analysis and Clinical Interpretation Workflow

The following diagram illustrates the core workflow for precision oncology analysis, from sample collection to clinical reporting:

Precision Medicine Analysis Workflow

This workflow represents the standardized process for implementing precision medicine in oncology, beginning with sample collection of tumor and matched normal tissue, proceeding through comprehensive molecular profiling and computational analysis, and culminating in clinical interpretation and reporting through multidisciplinary tumor boards [13].

Future Directions and Implementation Challenges

Addressing Current Limitations

While precision medicine shows significant promise, several challenges remain. Currently, only a minority of patients benefit from genomics-guided precision medicine [7]. Many tumors lack actionable mutations, and even when targets are identified, inherent or acquired treatment resistance often occurs. The concept of precision medicine is sometimes overstated in public discourse, as true personalized medicine would require integration of multiple biomarker layers beyond genomics, including pharmacokinetics, pharmacogenomics, other 'omics' biomarkers, imaging, histopathology, patient nutrition, comorbidity, and concomitant medications [7].

Additional limitations include the need for better clinical trial designs to demonstrate utility. Many current trials of tumor-agnostic approaches report surrogate endpoints rather than true clinical benefit, with considerable attrition at each step of the process and difficulty drawing definitive conclusions due to heterogeneous patient populations and lack of control groups [7]. More selective patient recruitment based on comprehensive tumor biology knowledge, earlier intervention in the treatment course, and combination therapies targeting multiple genomic aberrations represent promising directions for future research [7].

Advancing Toward Truly Personalized Cancer Medicine

The future evolution of precision medicine will require integrating multiple data layers to create comprehensive patient-specific models. This includes:

• Multi-omics integration: Combining genomic, transcriptomic, proteomic, and metabolomic data
• Pharmacokinetic and pharmacogenomic factors: Enabling individualized drug dosing
• Microbiome analysis: Understanding how commensal organisms influence drug metabolism and efficacy
• Digital health technologies: Continuous monitoring of treatment response and toxicity
• Artificial intelligence: Identifying complex patterns across diverse data types to predict treatment response

Only when bringing information from many such biomarkers into complex, AI-generated treatment predictors will precision medicine advance toward truly personalized cancer medicine [7]. Principles for such an approach have been outlined and should form the basis for future clinical trials [7].

Precision medicine represents a transformative approach to oncology that increasingly demonstrates both clinical benefit and economic viability in specific contexts. The evidence base supports the cost-effectiveness of targeted genetic testing in high-risk populations, NGS panels when multiple genes require assessment, and comprehensive genomic profiling in advanced cancers where therapeutic matching improves outcomes. However, significant challenges remain in expanding the proportion of patients who benefit, integrating multidimensional data sources, and demonstrating value across diverse healthcare systems and populations. As the field evolves toward increasingly personalized approaches, continued rigorous economic evaluation alongside clinical validation will be essential to ensure the sustainable implementation of these transformative technologies.

In an era of advancing but often expensive medical technologies, health economic evaluations have become indispensable for informing resource allocation decisions, particularly in oncology. These analyses provide a structured framework to compare the value of different healthcare interventions. At the core of this evaluation lie three fundamental metrics: the Quality-Adjusted Life Year (QALY), the Incremental Cost-Effectiveness Ratio (ICER), and the Willingness-to-Pay (WTP) Threshold. Together, these metrics form a standardized methodology for assessing whether a new intervention, such as a novel cancer testing approach, provides sufficient health benefit to justify its cost. The QALY serves as the standardized measure of health benefit, integrating both survival and quality of life. The ICER then calculates the cost to achieve each unit of this benefit compared to an alternative. Finally, the WTP threshold provides the decision-making benchmark against which the ICER is judged. For researchers and drug development professionals in oncology, understanding the interplay of these metrics is crucial for demonstrating the value proposition of new technologies within constrained healthcare budgets.

The Quality-Adjusted Life Year (QALY)

Definition and Calculation

The Quality-Adjusted Life Year (QALY) is a generic measure of disease burden that combines both the quality and the quantity of life lived into a single index number [15]. It is the primary outcome measure used in cost-utility analysis, a form of economic evaluation that allows for comparisons across different disease areas and treatments [16]. The core principle of the QALY is that a year of life lived in perfect health is assigned a value of 1.0 QALY, whereas a year of life lived in a state of less than perfect health is assigned a value between 0 (equivalent to death) and 1 [17] [18]. Health states considered "worse than death" can theoretically have negative values [15].

The calculation of QALYs is mathematically straightforward. It involves multiplying the utility weight (a measure of health-related quality of life) associated with a particular health state by the duration of time spent in that state [16] [17]. The formula is:

QALYs = Utility Weight × Time (in years)

For example, if a patient lives for 5 years with a utility weight of 0.8 (indicating a health state valued at 80% of perfect health), they would accumulate 4 QALYs (5 × 0.8) [17]. Similarly, 1 year of life lived with a utility of 0.5 yields 0.5 QALYs, meaning the individual values that year of compromised health as much as half a year in perfect health [15].

Measurement of Utilities

The utility weights central to QALY calculation are typically derived from multi-attribute utility (MAU) instruments [18]. These instruments consist of a questionnaire that patients complete to describe their health state and a scoring algorithm, based on public preferences, that converts this description into a utility value.

Common MAU instruments include [18]:

• EQ-5D (EuroQol 5-Dimension): Covers mobility, self-care, usual activities, pain/discomfort, and anxiety/depression [17] [15].
• SF-6D (Short-Form 6-Dimension): Derived from the SF-36 or SF-12 health surveys.
• HUI (Health Utilities Index): A comprehensive system for measuring health status and health-related quality of life.

When clinical trials do not include these MAU instruments, researchers may use statistical mapping to predict utility values from other clinical outcome assessments (COAs), thereby bridging the evidence gap for cost-effectiveness analysis [18].

Conceptual Workflow of QALY Calculation

The following diagram illustrates the logical process of calculating QALYs, from defining the health state to arriving at the final metric.

The Incremental Cost-Effectiveness Ratio (ICER)

Definition and Calculation

The Incremental Cost-Effectiveness Ratio (ICER) is a statistic that summarizes the cost-effectiveness of a healthcare intervention [19]. It represents the additional cost required to generate one additional unit of health benefit (measured in QALYs) when compared to an alternative treatment, typically the current standard of care [20]. The ICER is the fundamental output of a cost-utility analysis and is used by health technology assessment (HTA) bodies worldwide to inform reimbursement decisions.

The ICER is calculated using the following formula [19]:

ICER = (Cost of New Intervention − Cost of Comparator) / (Effectiveness of New Intervention − Effectiveness of Comparator)

Where:

• Cost includes all relevant healthcare costs associated with the interventions.
• Effectiveness is measured in QALYs gained.

For example, if a new digital product for managing heart failure costs £4,000 more than the standard care and generates 4 additional QALYs, the ICER would be £1,000 per QALY gained (£4,000 / 4 QALYs) [17].

Use in Decision-Making and Controversies

The ICER provides a common denominator that allows decision-makers to compare diverse health interventions across different disease areas [19]. For instance, the ICER can help determine whether a new cancer drug provides better value for money than a new surgical technique or a public health initiative.

However, the use of ICERs is not without controversy. A primary concern is that it can be seen as a form of healthcare rationing [19]. Critics argue that using a strict cost-per-QALY threshold may limit patient access to treatments, particularly for those with severe illnesses or rare conditions. Due to these ethical concerns, the use of QALYs and ICERs in the United States for Medicare coverage decisions was prohibited by the Affordable Care Act [19] [15]. In response to such limitations, some HTA bodies, like England's NICE, have implemented higher, flexible thresholds for end-of-life care and treatments for rare diseases [19].

ICER Decision Framework

The following diagram outlines the logical process of using the ICER to inform healthcare reimbursement decisions, from calculation to the final funding decision.

Willingness-to-Pay (WTP) Thresholds

Definition and Purpose

The Willingness-to-Pay (WTP) Threshold represents the maximum amount a healthcare system is willing to pay for one additional QALY gained [21]. It serves as the critical decision rule or benchmark against which the ICER is judged [19]. If the ICER of a new intervention falls below this threshold, it is typically deemed "cost-effective" and is a candidate for funding. Conversely, if the ICER exceeds the threshold, the intervention is considered poor value for money and is unlikely to be recommended for reimbursement [19].

The establishment of a WTP threshold is fundamentally about opportunity cost—the health benefits that are forgone when resources are allocated to one intervention instead of another. By setting a threshold, payers aim to maximize the total health benefits delivered to the population from a limited budget [21].

Variations in Thresholds Across Health Systems

There is no universal WTP threshold, and values vary significantly between countries and healthcare systems. Different methodologies are used to set these thresholds, including benchmarking against past decisions, using multiples of a country's GDP per capita, or attempting to estimate the health displaced by new expenditures [21].

Table: Examples of Willingness-to-Pay Thresholds in Different Jurisdictions

Country/Region	WTP Threshold (per QALY)	Notes	Source
England and Wales (NICE)	£20,000 - £30,000	Standard range; higher thresholds for end-of-life and rare diseases.	[17] [19]
Canada (CADTH)	$50,000 (CAD)	Used for both oncology and non-oncology drugs since late 2020.	[22]
United States	~$100,000 - $150,000	Commonly cited informal threshold, though not used for Medicare.	[20]
International Survey	$36,000 - $77,000 (USD)	Range found in a multi-country study (UK, US, Japan, etc.).	[21]

The table above illustrates the lack of global consensus. For example, Canada's CADTH employs a threshold of $50,000 CAD per QALY for all drugs, a level that has been shown to necessitate significant price reductions for many oncology products [22]. In contrast, decision-makers in the United States often reference an informal threshold of approximately $100,000 per QALY [20]. International surveys reveal an even wider variation, with estimates ranging from $36,000 per QALY in the UK to $77,000 per QALY in Taiwan when adjusted for comparative price levels [21].

Interrelationship and Application in Cancer Testing

The Integrated Decision-Making Framework

In practice, QALYs, ICERs, and WTP thresholds function as an integrated system for health technology assessment. The logical flow begins with the estimation of QALYs for the intervention and comparator, which is used to calculate the ICER. This ICER is then evaluated against the pre-determined WTP threshold to arrive at a reimbursement recommendation. This framework is applied globally by HTA bodies like NICE in England and the Canadian Agency for Drugs and Technologies in Health (CADTH) to determine access to new cancer therapies and diagnostics [22] [17] [18].

Impact on Oncology Drug Access

The application of this framework, particularly the WTP threshold, has a direct and measurable impact on patient access to new oncology drugs. A study of CADTH recommendations between 2020 and 2022 revealed that to meet the $50,000 per QALY threshold, 57% (59/103) of oncology drug assessments required a price reduction of greater than 70% off the list price [22]. Furthermore, 8% (8/103) were deemed not cost-effective even at a 100% price reduction [22]. This demonstrates the powerful influence of these metrics on pricing and market access.

The study also found a temporal impact: the median time to price negotiation for assessments requiring at least a 70% price reduction was 4.8 months, compared to 2.6 months for those requiring a smaller reduction [22]. This shows that the degree of cost-effectiveness, as measured by the required price reduction to meet the WTP threshold, can directly affect the speed at which new treatments reach patients.

Case Study: Cost-Effectiveness of Genomic Profiling in NSCLC

A concrete application of these metrics in cancer testing is illustrated by a 2025 cost-effectiveness analysis of Comprehensive Genomic Profiling (CGP) versus Small Panel (SP) testing in patients with advanced non-small-cell lung cancer (NSCLC) in the United States and Germany [3].

Table: Cost-Effectiveness Results for CGP vs. SP Testing in Advanced NSCLC

Parameter	United States	Germany	Notes
Incremental Overall Survival	0.10 years	0.10 years	Model input from real-world data.
Base Case ICER	$174,782 per LY	$63,158 per LY	LY = Life Year.
ICER (Scenario: More Patients Treated)	$86,826 per LY	$29,235 per LY	More patients receiving targeted therapy.

The study used a partitioned survival model informed by real-world data. It found that while CGP improved average overall survival, it was also associated with higher costs due to more patients receiving matched targeted therapies [3]. The resulting ICER was $174,782 per life-year gained in the US and $63,158 in Germany [3]. These figures would be judged differently against each country's informal WTP benchmarks. The analysis also showed that the ICER was highly sensitive to model parameters; when the scenario assumed a higher proportion of patients received treatment, the ICER became more favorable, falling to $86,826 in the US [3]. This case highlights how these key metrics are used to quantify the value of advanced cancer testing and how results can vary by healthcare system and underlying assumptions.

Researchers conducting cost-effectiveness analyses in oncology require a specific set of tools and resources to generate robust evidence on QALYs and ICERs. The following table details key research reagents and their functions.

Table: Key Research Reagent Solutions for Cost-Effectiveness Analysis

Tool/Resource	Function in Research	Relevance to Metrics
Multi-Attribute Utility (MAU) Instruments (e.g., EQ-5D, SF-6D, HUI)	Standardized questionnaires to measure health-related quality of life and generate utility weights.	Foundational for calculating QALYs. Essential for populating economic models.	[17] [18]
PROQOLID Database	A comprehensive online database providing detailed information on over 7,000 clinical outcome assessments (COAs), including their development, validity, and translations.	Aids in selecting the most appropriate COA or MAU for a given study population and therapeutic area.	[18]
HERC Mapping Database	A database from the Health Economics Research Centre that catalogs studies which have statistically mapped non-preference-based COAs to utility instruments like the EQ-5D.	Crucial for deriving utility values when a MAU instrument was not used in a clinical trial, enabling QALY calculation.	[18]
Partitioned Survival Model	A common type of health economic model that uses survival curves to partition a patient cohort into different health states over time (e.g., progression-free, progressed, dead).	The primary framework for estimating long-term survival (life-years) and assigning utility values to different health states, leading to QALY estimation. Used to calculate the ICER.	[3]
Real-World Evidence (RWE)	Data derived from electronic health records, registries, and other non-randomized sources that reflect routine clinical practice.	Informs key model parameters (e.g., overall survival, treatment patterns) with data from real-world settings, making the resulting ICER more generalizable.	[3]

The metrics of QALYs, ICERs, and WTP thresholds form the cornerstone of modern health economic evaluation, providing a standardized, though not uncontested, framework for assessing the value of medical interventions. For researchers and developers in the field of oncology, a deep understanding of these concepts is critical. The QALY integrates survival and quality of life into a single measure of benefit. The ICER quantifies the economic efficiency of a new technology compared to existing standards. Finally, the WTP threshold represents the societal or systemic benchmark for value, completing the chain from clinical research to reimbursement policy. As the case of cancer testing and therapeutics demonstrates, the interaction of these metrics directly influences which innovations reach patients and at what price. While debates about their methodological limitations and ethical implications continue, their role in guiding resource allocation in increasingly constrained healthcare systems worldwide is likely to grow.

Precision oncology represents a paradigm shift in cancer care, moving away from empirical chemotherapy towards treatments tailored to the genomic profile of a patient's tumor. This approach leverages advanced diagnostic technologies like comprehensive genomic profiling (CGP) to identify targetable mutations and select optimal targeted therapies. While these advancements have improved patient outcomes, they have also introduced significant economic challenges. The rising costs of cancer care, projected to exceed $245 billion in the U.S. by 2030, have intensified the focus on understanding the specific drivers of expense throughout the precision oncology pipeline [23]. For researchers and drug development professionals, analyzing these cost components is essential for developing more efficient technologies, optimizing resource allocation, and demonstrating the value of genomic-guided treatment approaches.

This analysis examines the cost structures of two fundamental components of modern oncology: the diagnostic sequencing process that enables treatment selection, and the targeted therapeutics that constitute the treatment itself. By dissecting these cost drivers and presenting comparative cost-effectiveness data, this guide provides a framework for evaluating the economic efficiency of different approaches to precision cancer medicine.

Cost Drivers in Diagnostic Sequencing

Microcosting Analysis of Genomic Profiling

Advanced molecular diagnostics form the foundation of precision oncology by identifying the genetic alterations that drive cancer progression. A detailed microcosting study of genomic profiling within Norway's National Infrastructure for Precision Diagnostics revealed a total cost of $2,944 per sample using the TruSight Oncology 500 broad gene panel, with costs ranging from $2,366 to $4,307 when accounting for estimation uncertainties [24].

Table 1: Cost Breakdown for Genomic Profiling in Precision Cancer Medicine

Cost Category	Percentage of Total Cost	Key Findings
Consumables	Major driver	Highest material cost component across workflow
Personnel	Major driver	Significant contributor across analyses; potential bottleneck for scaling
Equipment/Overhead	Variable component	Automation adds cost but enables higher throughput
Bioinformatics	21.3%-58.3%	Highly variable; bespoke analyses increase cost substantially

The study developed a flexible costing framework that calculated expenses by workflow steps and cost categories, identifying consumables and personnel as the most resource-intensive cost categories across all analyses [24]. Importantly, the research highlighted how operational factors influence overall costs, noting that automating the resource-intensive library preparation step enabled a higher weekly batch size with slightly lower costs per sample ($2,881) despite the additional equipment investment [24].

Bioinformatics and Specialized Analysis Costs

The bioinformatics component of genomic sequencing represents a substantial and highly variable cost driver. Research on genome sequencing for Indigenous children with suspected rare diseases found that bioinformatics accounted for 21.3% to 58.3% of total costs, with bespoke analyses required due to underrepresentation in reference genome libraries significantly increasing expenses [25]. With standard bioinformatics, costs ranged from C$3,645 for singletons to C$7,402 for trios. However, with advanced, bespoke bioinformatics, costs increased to C$5,344 for singletons and C$9,760 for trios [25]. The time required for these analyses ranged from 71 hours for standard analyses to 215 hours for advanced analyses, highlighting the substantial personnel resources involved in data interpretation [25].

Cost Drivers in Targeted Cancer Therapeutics

Escalating Prices for Targeted Therapies

Targeted cancer therapies command premium prices that have escalated substantially over the past decade. In the U.S., the average monthly launch price for targeted therapies has increased from approximately $10,950 during 2012-2014 to over $27,800 by 2025—representing a 150% increase in just over a decade [26]. Some therapies now exceed $30,000 per month, creating significant financial burdens for healthcare systems and patients [26].

Several factors drive these rising costs, including extensive research and development expenses, complex manufacturing processes for biological therapies, and market dynamics that limit competition for targeted agents. Additionally, the targeted nature of these treatments means they are developed for smaller patient populations, requiring higher prices to recoup development costs [26].

International Price Variations

Significant international price variations for targeted therapies reveal how healthcare systems and pricing policies influence costs. Comparative data shows Germany's average monthly cost is approximately $5,900, while Canada offers therapies in the $3,000-$4,000 monthly range [26]. Australia's pricing before subsidies ranges from $5,000-$11,000 monthly [26]. These differences reflect varying approaches to drug price negotiation, healthcare financing, and value assessment across healthcare systems.

Cost-Effectiveness Analysis of Testing Approaches

Comprehensive Genomic Profiling vs. Small Panel Testing

A critical consideration in precision oncology is whether the additional information provided by broader genomic testing approaches justifies their higher upfront costs compared to more limited testing. A 2025 cost-effectiveness analysis compared comprehensive genomic profiling (CGP) versus small panel (SP) testing in patients with advanced non-small-cell lung cancer using real-world data from the Syapse study [3].

Table 2: Cost-Effectiveness Analysis: CGP vs. Small Panel Testing in Advanced NSCLC

Parameter	United States	Germany	Notes
Overall Survival Benefit	+0.10 years	+0.10 years	Consistent benefit observed
Incremental Cost-Effectiveness Ratio (ICER)	$174,782/LYG	$63,158/LYG	Base case scenario
ICER with More Patients Treated	$86,826/LYG	$29,235/LYG	Increased treatment rates improve cost-effectiveness
Key Cost Driver	Higher percentage of patients receiving targeted therapies	Higher percentage of patients receiving targeted therapies	Drug costs primary factor

The analysis demonstrated that CGP improved average overall survival by 0.10 years compared with SP testing. The resulting incremental cost-effectiveness ratio (ICER) was $174,782 per life-year gained in the U.S. and $63,158 in Germany [3]. Scenario analyses revealed that increasing the number of patients receiving matched targeted therapies significantly improved cost-effectiveness, decreasing ICERs to $86,826 in the U.S. and $29,235 in Germany [3].

Value-Based Assessment and Considerations

When evaluating the economic value of precision oncology approaches, researchers must consider both quantitative metrics and qualitative factors. The U.S. cost-effectiveness ratios for some targeted therapies exceed $174,000 per life-year gained, necessitating careful value assessment [26]. Quality-Adjusted Life Year (QALY) considerations incorporate both survival and quality of life, providing a more comprehensive measure of therapeutic value [26].

The economic evaluation must balance clinical benefits against financial impact, considering not only drug costs but also potential reductions in unnecessary treatment, improved resource allocation, and the value of hope for patients with limited alternatives. This balanced approach is essential for drug development professionals seeking to optimize the value proposition of new targeted therapies and diagnostic approaches.

Experimental Protocols and Methodologies

Microcosting Methodology for Genomic Profiling

The microcosting study from Norway employed a comprehensive methodology to capture all cost components associated with genomic profiling [24]. Site visits and structured discussions with staff at Oslo University Hospital informed the diagnostic workflow, validation of the costing framework, and resource use inputs. The research team developed a flexible costing framework that enabled calculation of costs per sample, by workflow steps and cost categories. Sensitivity analyses addressed alternative resource use estimates, higher batch sizes, and investment costs for automation of the library preparation step. This rigorous methodology provides a template for researchers conducting similar economic evaluations of diagnostic technologies.

Cost-Effectiveness Analysis Design

The cost-effectiveness analysis of CGP versus small panel testing utilized a partitioned survival model to estimate life years and drug acquisition costs associated with each testing strategy [3]. Key model parameters were informed by real-world data derived from the Syapse study. The analysis considered three patient pathways: those receiving matched targeted therapy, matched immunotherapy, or no matched therapy. Scenario analyses tested the robustness of the findings, and sensitivity analyses explored the impact of varying key parameters. This methodology demonstrates how real-world evidence can be incorporated into economic evaluations of precision oncology approaches.

Visualizing Cost Drivers and Workflows

Precision Oncology Cost Driver Analysis

Comprehensive vs Small Panel Testing Value Assessment

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Research Reagents and Platforms for Precision Oncology

Reagent/Platform	Function	Application in Research
TruSight Oncology 500	Broad gene panel for genomic profiling	Identification of targetable mutations in cancer [24]
PEG-based Hydrogels	3D cell culture matrix	Creating more physiologically relevant cancer models for drug testing [27]
CellTiter-Glo 3D	Viability assay for 3D cultures	Measuring treatment efficacy in complex disease models [27]
Producer Cell Lines	Viral vector production	Gene therapy development; potential for cost reduction [28]
Affinity Chromatography	Purification technology	Selective capture of full capsids in viral vector manufacturing [28]
Organotypic Models	Advanced 3D culture systems	Studying metastasis and tumor microenvironment interactions [27]

The economic landscape of modern oncology is characterized by significant investments in both diagnostic technologies and targeted therapeutics. The primary cost drivers identified—consumables and personnel in genomic profiling, and drug acquisition costs for targeted therapies—present opportunities for optimization through technological innovation and operational improvements. For researchers and drug development professionals, understanding these cost structures is essential for advancing the field in an economically sustainable manner. The growing precision oncology market, projected to reach $158.9 billion by 2029, underscores both the financial stakes and the opportunity for continued innovation [29]. Future progress will depend on developing more efficient technologies, implementing value-based care models, and demonstrating the economic as well as clinical benefits of precision approaches to cancer care.

The landscape of cancer diagnostics has expanded significantly, moving beyond traditional tissue biopsy to include minimally invasive liquid biopsy, comprehensive genomic profiling (CGP), and artificial intelligence (AI)-assisted tools. These modalities offer complementary approaches for tumor characterization, treatment selection, and disease monitoring within precision oncology. The integration of these technologies into clinical practice requires careful consideration of their respective technical capabilities, clinical applications, and economic impacts. Health technology assessments now must evaluate not only clinical benefits and costs but also factors such as test feasibility, journey for patients and physicians, wider implications of diagnostic results, laboratory organization, and scientific spillover [30]. This guide provides an objective comparison of these testing modalities, focusing on their performance characteristics, experimental protocols, and cost-effectiveness to inform researchers and drug development professionals.

Technical Comparison of Testing Modalities

Tissue Biopsy vs. Liquid Biopsy

Table 1: Comparative Analysis of Tissue and Liquid Biopsy

Parameter	Tissue Biopsy	Liquid Biopsy
Invasiveness	Invasive surgical procedure	Minimally invasive (blood draw)
Analytes Detected	Tumor tissue, cancer cells	ctDNA, cfRNA, CTCs, EVs, TEPs [31]
Tumor Heterogeneity	Limited to sampled region	Captures heterogeneity from multiple tumor sites [31]
Clinical Applications	Gold standard for initial diagnosis and molecular profiling [31]	Monitoring treatment response, detecting MRD, tracking resistance [31] [32]
Turnaround Time	Typically longer (days to weeks)	Shorter (days) [31]
Sensitivity in Early-Stage Cancer	High (direct tissue examination)	Limited due to low analyte concentration [31]
Spatial Information	Preserved	Lost
Feasibility of Serial Sampling	Limited due to invasiveness	High, enabling real-time monitoring [31] [32]
Tumor Evolution Tracking	Single time point	Dynamic, captures clonal evolution [31]

Tissue biopsy remains the gold standard for initial cancer diagnosis and characterization, providing essential histopathological information and material for molecular testing [31]. However, liquid biopsy has emerged as a complementary revolutionary tool that analyzes circulating tumor DNA (ctDNA), cell-free RNA (cfRNA), circulating tumor cells (CTCs), extracellular vesicles (EVs), and tumor-educated platelets (TEPs) [31]. The most significant advantage of liquid biopsy is its capacity for real-time monitoring of tumor dynamics, assessment of treatment response, and detection of minimal residual disease (MRD) or early recurrence [31]. Serial sampling of biofluids allows clinicians to track tumor evolution, monitor disease progression, and gain insights into tumor heterogeneity and clonal evolution [31]. A key limitation of liquid biopsy is reduced sensitivity in early-stage cancers due to low concentrations of circulating analytes [31].

Small Panel Testing vs. Comprehensive Genomic Profiling

Table 2: Small Panel Testing vs. Comprehensive Genomic Profiling

Parameter	Small Panel (SP) Testing	Comprehensive Genomic Profiling (CGP)
Number of Genes	Limited (often 10-50 genes)	Extensive (≥200 genes, WES, or WGS) [30]
Technologies	IHC, FISH, Sanger sequencing, targeted NGS panels [30]	Large NGS panels, Whole Exome Sequencing (WES), Whole Genome Sequencing (WGS) [30]
Tissue Requirements	Lower	Higher
Diagnostic Cost	$63-$526 (depending on tumor type) [30]	Approximately $2,925 per cancer patient [30]
Actionable Targets Identified	Limited to predefined alterations	Broad, including rare and novel biomarkers
Therapy Guidance	Standard targeted therapies	Personalized therapy, clinical trial matching [3] [11]
Turnaround Time	Shorter	Longer
Incidental Findings	Minimal	More likely, requiring interpretation

Small panel testing includes single-gene technologies such as immunohistochemistry (IHC), Sanger sequencing, fluorescence in situ hybridization (FISH), and targeted next-generation sequencing (NGS) panels [30]. These approaches are often part of standard care assays for biomarker testing. In contrast, comprehensive genomic profiling (CGP) includes NGS panels containing ≥200 genes, whole exome sequencing (WES), or whole genome sequencing (WGS) [30]. The diagnostic costs for these approaches vary significantly, with CGP costing approximately €2,925 per cancer patient compared to €63-€526 for targeted approaches depending on tumor type [30]. CGP provides more comprehensive genomic information, potentially identifying more actionable targets for personalized therapy and clinical trial matching [3] [11].

Cost-Effectiveness Analysis of Testing Approaches

Economic Evaluations of Genomic Testing

Table 3: Cost-Effectiveness Evidence for Genomic Testing Modalities

Testing Modality	Cancer Type	Incremental Cost-Effectiveness Ratio (ICER)	Key Outcomes
Comprehensive Genomic Profiling (CGP)	Advanced NSCLC (US)	$174,782 per life-year gained [3] [11]	Improved OS by 0.10 years vs. SP; higher percentage receiving targeted therapies [3] [11]
Comprehensive Genomic Profiling (CGP)	Advanced NSCLC (Germany)	$63,158 per life-year gained [3] [11]	More cost-effective than in US setting [3] [11]
Liquid Biopsy (Autoantibody test)	Lung cancer screening (Brazil)	$75,435.63 per QALY [33]	Exceeded willingness-to-pay threshold in Brazil; only cost-effective if prevalence >4.0% [33]
Genomic Medicine	Breast and ovarian cancer	Likely cost-effective for prevention and early detection [1]	Convergent evidence supports cost-effectiveness [1]
Genomic Medicine	Colorectal and endometrial cancers	Likely cost-effective for prevention and early detection [1]	Strong evidence for Lynch syndrome applications [1]

Cost-effectiveness analyses provide critical insights for healthcare decision-makers evaluating genomic testing technologies. A 2025 study comparing CGP versus small panel testing in advanced non-small cell lung cancer (NSCLC) demonstrated that CGP improved average overall survival by 0.10 years compared to SP testing [3] [11]. This survival benefit resulted from a higher percentage of patients receiving matched targeted therapies with CGP (cohort A in the Syapse study) [11]. The incremental cost-effectiveness ratio (ICER) of CGP versus SP was $174,782 per life-year gained in the United States and $63,158 per life-year gained in Germany [3] [11]. The study noted that increasing the number of patients receiving treatment decreased the ICERs ($86,826 in the United States and $29,235 in Germany), while switching from immunotherapy plus chemotherapy to chemotherapy alone increased the ICERs ($223,226 in the United States and $83,333 in Germany) [3] [11].

For liquid biopsy, a cost-effectiveness assessment of an autoantibody test (EarlyCDT-Lung) for early lung cancer detection in Brazil found an ICER of $75,435.63 per quality-adjusted life year (QALY) gained, which far exceeded the willingness-to-pay threshold in Brazil ($7,017.54-21,052.62/QALY) [33]. The analysis concluded that liquid biopsy screening would only become cost-effective in contexts where lung cancer prevalence exceeds 4.0%, assuming no significant cost reductions or accuracy improvements [33].

A broader systematic review of genomic medicine in cancer control found convergent cost-effectiveness evidence for the prevention and early detection of breast and ovarian cancer, and for colorectal and endometrial cancers (particularly Lynch syndrome) [1]. For cancer treatment, the use of genomic testing for guiding therapy was highly likely to be cost-effective for breast and blood cancers [1].

AI-Assisted Tools in Cancer Diagnostics

Table 4: Economic Impact of AI in Healthcare Applications

AI Application	Clinical Context	Economic Outcome	Key Findings
ML-based Risk Prediction	Atrial fibrillation screening	ICER: £4,847-£5,544 per QALY [34]	Substantially below NHS threshold of £20,000 per QALY [34]
AI-driven Screening	Diabetic retinopathy	ICER: $1,107.63 per QALY [34]	Reduced per-patient screening costs by 14-19.5% [34]
AI Feature Selection	Oncology	Significant cost reductions [34]	Improved economic performance through enhanced clinical precision [34]
AI Integration	Liquid Biopsy	Improved diagnostic accuracy [31]	Multimodal approaches combining multiple biomarkers show promise [31]

Artificial intelligence is demonstrating significant potential to improve the economic value of cancer diagnostics. A systematic review of cost-effectiveness and budget impact of AI in healthcare found that AI interventions improve diagnostic accuracy, enhance quality-adjusted life years, and reduce costs—largely by minimizing unnecessary procedures and optimizing resource use [34]. Several interventions achieved incremental cost-effectiveness ratios well below accepted thresholds [34]. In oncology specifically, AI-driven feature selection demonstrated significant cost reductions through enhanced clinical precision and resource utilization [34].

AI integration has also shown promise in enhancing the diagnostic accuracy of liquid biopsy. Recent advancements in artificial intelligence have improved diagnostic accuracy by integrating data, and multimodal approaches that combine multiple biomarkers such as ctDNA, CTCs, EVs, and TEPs show promise in providing a more comprehensive view of tumor characteristics [31]. The global AI in cancer diagnostics market, calculated at $1.07 billion in 2024 and expected to reach $2.61 billion by 2034, reflects the growing investment and adoption of these technologies [35].

Experimental Protocols and Methodologies

Liquid Biopsy Workflow and Protocols

The liquid biopsy workflow involves several critical steps from sample collection to data analysis. For circulating tumor cell (CTC) isolation, the FDA-approved CellSearch system uses a two-step process: first, sample centrifugation to eliminate blood components, followed by CTC detection using anti-EpCAM antibodies conjugated with magnetic ferrofluid beads; second, an immunofluorescence step to further purify CTCs from contaminant blood cells using anti-cytokeratin antibodies and DAPI nuclear staining [31]. The cells are scanned to detect EpCAM+/Cytokeratin+/DAPI+/CD45− cells, which are considered CTC candidates [31]. A limitation of this approach is that it primarily identifies epithelial CTCs and may miss mesenchymal CTCs that have undergone epithelial-mesenchymal transition (EMT) [31].

Alternative technologies include ScreenCell, which isolates and sorts cells by size from blood samples using a microporous membrane filter [31]. Additionally, novel approaches like immunomagnetic beads conditioned with graphene nanosheets (protein corona disguised immunomagnetic beads, or PIMBs) have been developed to enhance CTC enrichment [31]. These conditioned beads can be disguised with blood proteins to prevent absorption and subsequent detection of non-specific proteins [31]. PIMBs disguised with Human Serum Albumin (HSA) demonstrated a leukocyte depletion percentage of approximately 99.996%, obtaining 62 to 505 CTCs from 1.5 mL of blood from cancer patients [31].

For ctDNA analysis, the general workflow involves blood collection in specialized tubes, plasma separation, nucleic acid extraction, library preparation, sequencing, and bioinformatic analysis. The choice of specific protocols depends on the intended application, such as mutation detection, copy number variation analysis, or epigenetic profiling.

Liquid Biopsy Workflow

Comprehensive Genomic Profiling Methodology

Comprehensive genomic profiling requires robust experimental protocols to ensure accurate and reproducible results. The general workflow begins with sample acquisition, either from tissue or liquid biopsy sources, followed by DNA/RNA extraction, quality control, library preparation, sequencing, and comprehensive bioinformatic analysis.

For tissue-based CGP, the process typically involves:

• Sample Selection and Macrodissection: Pathologist-reviewed FFPE tissue sections with adequate tumor content (>20-30% tumor cellularity)
• Nucleic Acid Extraction: DNA and/or RNA extraction using validated kits
• Quality Control: Assessment of DNA/RNA quantity, quality, and fragmentation
• Library Preparation: Construction of sequencing libraries with unique molecular identifiers (UMIs) to reduce errors
• Target Enrichment: Hybridization-based capture using comprehensive gene panels
• Sequencing: High-throughput sequencing on NGS platforms
• Bioinformatic Analysis: Pipeline for alignment, variant calling, annotation, and interpretation

For liquid biopsy CGP, the protocol is similar but requires additional sensitivity to detect low-frequency variants, often employing unique molecular identifiers (UMIs) and error-suppression algorithms to distinguish true somatic variants from sequencing artifacts.

CGP Testing Workflow

Research Reagent Solutions and Essential Materials

Table 5: Key Research Reagents for Cancer Testing Modalities

Reagent/Material	Function	Application Context
Anti-EpCAM Antibodies	Immunomagnetic capture of CTCs	CTC isolation in liquid biopsy [31]
Magnetic Ferrofluid Beads	Cell separation using magnetic fields	CTC enrichment in CellSearch system [31]
Anti-cytokeratin Antibodies	CTC identification via immunofluorescence	CTC purification from blood cells [31]
DAPI Nuclear Stain	Nuclear staining for cell identification	CTC confirmation (nucleated cells) [31]
CD45 Antibodies	Leukocyte marker (negative selection)	Exclusion of hematopoietic cells in CTC analysis [31]
Graphene Nanosheets	Surface conditioning for beads	Protein corona disguised immunomagnetic beads (PIMBs) [31]
Human Serum Albumin (HSA)	Protein disguise for beads	Prevention of non-specific protein absorption in PIMBs [31]
Next-Generation Sequencing Kits	Library preparation and target enrichment	CGP and small panel testing [30]
Unique Molecular Identifiers (UMIs)	Error suppression and quantification	Liquid biopsy CGP to detect low-frequency variants

The essential reagents for cancer testing modalities vary by technology platform. For CTC isolation, key reagents include anti-EpCAM antibodies for immunomagnetic capture, magnetic ferrofluid beads for cell separation, anti-cytokeratin antibodies for CTC identification via immunofluorescence, DAPI nuclear stain for cell confirmation, and CD45 antibodies for negative selection of leukocytes [31]. Novel reagent solutions such as graphene nanosheets and Human Serum Albumin (HSA) are used in protein corona disguised immunomagnetic beads (PIMBs) to prevent non-specific protein absorption and enhance CTC enrichment efficiency [31].

For genomic profiling approaches, essential materials include next-generation sequencing kits for library preparation and target enrichment, unique molecular identifiers (UMIs) for error suppression and accurate quantification of low-frequency variants in liquid biopsy, and various bioinformatic tools for data analysis and interpretation [30].

The spectrum of cancer testing modalities offers complementary approaches with distinct advantages and limitations. Tissue biopsy remains essential for initial diagnosis, while liquid biopsy provides unprecedented opportunities for longitudinal monitoring and assessment of tumor dynamics. Small panel testing offers a cost-effective approach for focused biomarker assessment, whereas comprehensive genomic profiling enables broad detection of actionable alterations across many genes. AI-assisted tools are enhancing the accuracy and efficiency of all testing modalities while demonstrating improved cost-effectiveness in various clinical applications.

The choice between these modalities depends on clinical context, cancer type, stage, and specific clinical questions. Economic evaluations indicate that while advanced technologies like CGP and liquid biopsy may have higher upfront costs, they can provide value through improved patient outcomes and more targeted treatment selection. Future developments in testing technologies, coupled with more sophisticated AI integration and reduced sequencing costs, are likely to further transform the cancer diagnostic landscape, enabling more personalized and effective cancer care.

Frameworks and Real-World Applications in Cost-Effectiveness Analysis

In the field of health technology assessment, mathematical models serve as critical tools for evaluating the cost-effectiveness of cancer interventions, including screening programs and therapeutic agents. These models project long-term health outcomes and economic impacts by simulating disease progression and intervention effects within defined populations. Within oncology, two distinct yet complementary modeling approaches have emerged as standards for economic evaluations: partitioned survival models (PSMs) and microsimulation models such as the Microsimulation SCreening Analysis (MISCAN) platform [36] [37]. PSMs are commonly employed for technology appraisals of pharmaceutical products, directly utilizing survival curves from clinical trials to estimate time spent in different health states [37] [38]. In contrast, microsimulation models like MISCAN-Colon operate at the individual level, simulating the life courses of many simulated persons to capture heterogeneous disease pathways and complex intervention scenarios, particularly in cancer screening [39] [40]. The selection between these approaches significantly influences cost-effectiveness results, with each offering distinct advantages for addressing specific research questions in cancer control.

Table 1: Fundamental Characteristics of Modeling Approaches

Feature	Partitioned Survival Model (PSM)	Microsimulation Model (MISCAN)
Model Structure	Cohort-level approach	Individual-level simulation
Analytical Foundation	Direct analysis of aggregate survival curves (PFS, OS)	Simulation of discrete event state transitions in continuous time [39]
Disease Process Representation	Limited to defined health states (e.g., progression-free, progressed, death)	Comprehensive natural history from adenoma initiation to cancer death [39] [40]
Handling of Heterogeneity	Limited to subgroup analysis	Incorporates individual characteristics (age, sex, race, lesion location) [39]
Primary Applications	Drug reimbursement decisions, clinical trial extrapolation	Cancer screening evaluation, public health policy planning [39] [36]

Theoretical Foundations and Model Structures

Partitioned Survival Modeling Framework

Partitioned Survival Models (PSMs) employ a relatively straightforward structure that divides overall survival into mutually exclusive health states, typically progression-free, post-progression, and death [41]. The membership in these health states is determined directly from clinical trial survival curves without modeling transitions between states. Specifically, the proportion of patients in the progression-free state is defined by the progression-free survival (PFS) curve, while the proportion in the post-progression state is calculated as the difference between the overall survival (OS) and PFS curves [37]. This approach directly utilizes the primary endpoints collected in oncology trials, providing transparency and requiring fewer structural assumptions than state-transition models. However, PSMs lack a structural link between intermediate clinical endpoints (like disease progression) and survival, which limits the ability to explore how changes in time-to-progression might impact overall survival in sensitivity analyses [37] [38].

The PSM framework possesses notable advantages in terms of transparency and implementation efficiency. Because PSMs directly use investigator-assessed endpoints from clinical trials, they offer a clear audit trail connecting model inputs to trial results. This characteristic makes them particularly accessible to decision-makers who need to understand the relationship between trial data and model projections [37]. Additionally, PSMs can be developed without access to individual patient data, relying instead on published survival curves. This practical advantage has contributed to their widespread adoption for reimbursement submissions of oncology drugs. However, this simplicity comes with analytical limitations, particularly when attempting to model complex treatment sequences or disease processes with multiple possible pathways [37].

Microsimulation Modeling Framework

Microsimulation models, exemplified by MISCAN-Colon, operate on fundamentally different principles than PSMs. Rather than tracking cohort aggregates, microsimulation models generate virtual populations in which each simulated individual experiences a unique life history with multiple possible health events [39] [40]. The MISCAN-Colon model specifically implements discrete event state transitions in continuous time, simulating the complete natural history of colorectal cancer from adenoma initiation through potential cancer development and progression [39]. This approach begins by generating a time of birth and non-CRC death for each simulated individual, then modeling adenoma development through a non-homogeneous Poisson process that depends on age, sex, and race [39].

The MISCAN framework incorporates sophisticated disease biology by modeling two distinct adenoma types—progressive and nonprogressive—with different malignant potential [39]. Progressive adenomas can transition through three size categories (small, medium, large) before potentially developing into preclinical cancer stages (I-IV). Each adenoma is assigned a specific location within the large intestine, and transition probabilities between states can depend on multiple factors including lesion location, age, sex, and calendar time [39]. This granular representation enables the model to capture the complex interplay between individual risk factors, screening test characteristics, and disease progression, making it particularly valuable for evaluating screening interventions that act at different points in the natural history of cancer development.

Diagram 1: Structural comparison of partitioned survival, state transition, and microsimulation modeling approaches. PSMs derive health state membership directly from survival curves, while state transition models use explicit transition probabilities (TPs). Microsimulation models simulate multiple potential pathways for each individual, including competing mortality risks.

Methodological Implementation and Experimental Protocols

MISCAN-Colon Model Implementation

The MISCAN-Colon model employs a sophisticated microsimulation framework that generates virtual individuals with specific demographic characteristics and simulates their potential colorectal cancer pathways through continuous time [39]. The model implementation follows a structured protocol beginning with the generation of a hypothetical population resembling the target demographic (typically the U.S. population) in terms of life expectancy and CRC risk [36]. For each simulated person, the model first generates a time of birth and a time of death from causes other than colorectal cancer, establishing the individual's lifespan framework without cancer mortality [39]. The model then simulates adenoma development using a non-homogeneous Poisson process, where the individual-level hazard rate ratio is drawn from a gamma distribution and may depend on sex and race [39].

Once initiated, each adenoma progresses through the model's natural history framework, being assigned to one of seven locations within the large intestine and categorized into three size classifications: small (1-5 mm), medium (6-9 mm), and large (10+ mm) [39]. A critical feature of MISCAN-Colon is its differentiation between progressive and nonprogressive adenomas, with only progressive adenomas having the potential to develop into cancer. The probability that an adenoma is progressive depends on the age of adenoma onset [39]. Progressive medium and large adenomas can transition to stage I preclinical cancer, with progression rates faster for larger adenomas. Preclinical cancers then progress through stages I-IV, with the possibility of clinical diagnosis at any stage due to symptom development or screening detection [39].

Table 2: MISCAN-Colon Model Parameters and Input Sources

Parameter Category	Specific Parameters	Data Sources
Demographic Inputs	Age-specific mortality, population distribution	National vital statistics, census data
Adenoma Natural History	Adenoma incidence, progression rates, size distribution	Epidemiological studies, autopsy studies [39]
Cancer Progression	Sojourn times by stage, stage distribution	SEER registry data, clinical studies [39]
Test Characteristics	Sensitivity by lesion size/type, specificity	Clinical validation studies [36]
Survival Outcomes	Stage-specific CRC survival, other-cause mortality	SEER program data, clinical trials [39]

Partitioned Survival Model Implementation

The implementation of Partitioned Survival Models follows a more direct approach focused on extrapolating clinical trial endpoints. The experimental protocol begins with obtaining time-to-event data from clinical trials, typically in the form of Kaplan-Meier curves for progression-free survival (PFS) and overall survival (OS) [37]. The first critical step involves selecting appropriate parametric survival distributions (e.g., exponential, Weibull, log-normal, log-logistic, generalized gamma) to fit the observed trial data. Statistical goodness-of-fit measures such as Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC) guide the selection of the most appropriate distribution for each endpoint [37].

Once suitable survival functions are established, the model calculates the proportion of patients in each health state at discrete time intervals (typically weekly or monthly cycles) throughout the model time horizon. The proportion in the progression-free state is directly given by the PFS curve at each time point. The proportion in the death state is calculated as 1 minus the OS curve. The proportion in the post-progression state is derived as the difference between the OS and PFS curves [41] [37]. These state membership proportions are then used to calculate cumulative costs and quality-adjusted life years (QALYs) by applying state-specific cost and utility weights. Unlike microsimulation models, PSMs do not typically model individual patient characteristics or transitions between health states, instead operating at the aggregate cohort level [37].

Experimental Protocol for Screening Evaluation

The application of MISCAN-Colon for evaluating colorectal cancer screening strategies follows a rigorous experimental protocol designed to compare multiple screening modalities and intervals [36]. A recent study exemplifies this approach by evaluating innovative CRC tests including capsule endoscopy, computed tomographic colonography (CTC), multi-target stool DNA (mtSDNA), and methylated SEPT9 DNA plasma assay (mSEPT9) alongside established tests like colonoscopy and fecal immunochemical test (FIT) [36]. The experimental protocol simulates a hypothetical cohort of average-risk individuals aged 50 years through 75 years, with perfect adherence to screening, diagnostic follow-up, and surveillance recommendations assumed for the base case analysis [36].

For each screening strategy, the model projects long-term outcomes including quality-adjusted life-years gained (QALYG), CRC cases averted, CRC deaths averted, and the number of colonoscopies required [36]. The model incorporates test-specific performance characteristics including sensitivity for different lesion types (small adenomas, large adenomas, CRC) and specificity, as drawn from published clinical studies [36]. For example, the mSEPT9 blood test was modeled with CRC sensitivity of 68.2%, advanced adenoma sensitivity of 21.6%, and specificity of 78.8%, based on the PRESEPT trial data used for FDA approval [36]. Cost-effectiveness is evaluated through incremental cost-effectiveness ratios (ICERs), calculated by dividing the additional costs by the additional QALYs compared to the next less costly alternative strategy, with a willingness-to-pay threshold typically set at $100,000 per QALYG [36].

Comparative Applications in Cancer Research

Colorectal Cancer Screening Evaluation

Microsimulation models like MISCAN-Colon have demonstrated particular utility in evaluating colorectal cancer screening strategies, where they can incorporate complex natural history and multiple screening modalities. A comprehensive cost-effectiveness analysis using MISCAN-Colon compared innovative CRC screening tests—including capsule endoscopy (PillCam), computed tomographic colonography (CTC), multi-target stool DNA test (mtSDNA/Cologuard), and methylated SEPT9 DNA plasma assay (mSEPT9/Epi proColon)—against established methods like colonoscopy and fecal immunochemical test (FIT) [36]. The analysis revealed that among alternative tests, CTC every 5 years, annual mSEPT9, and annual mtSDNA screening had incremental cost-effectiveness ratios of $1,092, $63,253, and $214,974 per QALYG, respectively [36]. Other screening strategies were found to be more costly and less effective than combinations of these three approaches.

The study provided critical insights for clinical practice and policy decisions, particularly for underserved populations reluctant to undergo established screening methods. While the alternative tests were not cost-effective compared with FIT and colonoscopy for the general population, they offer potential value for individuals unwilling to participate in standard screening [36]. The mSEPT9 blood test, despite its high colonoscopy referral rate (51% after 3 years, 69% after 5 years), emerged as a promising option for those who decline stool-based tests or invasive procedures [36]. This application demonstrates how microsimulation can model complex screening scenarios with multiple tests, adherence patterns, and follow-up protocols to inform nuanced policy decisions that accommodate diverse patient preferences and behaviors.

Drug Treatment Evaluation

Partitioned Survival Models have become the standard methodology for health technology assessment of oncology drugs, particularly in submissions to reimbursement bodies such as England's National Institute for Health and Care Excellence (NICE) [37]. A case study comparing Osimertinib with pemetrexed-platinum chemotherapy for advanced non-small cell lung cancer illustrates the typical application of PSMs in drug evaluation [41]. The analysis developed three economic models—PSM, 3-health state transition model (3-STM), and 5-health state transition model (5-STM)—to estimate life-years (LY) and quality-adjusted life-years (QALY) over a seven-year time horizon [41]. The PSM and 3-STM produced similar incremental outcomes (0.889 vs. 0.899 LY, 0.827 vs. 0.840 QALY), while the 5-STM, which incorporated brain metastasis as separate health states, yielded slightly higher incremental LY (0.910) but lower incremental QALY (0.695) [41].

This case study highlights both the practical advantages and limitations of PSMs in drug evaluation. The similarity between PSM and 3-STM results suggests that PSMs can provide reasonable estimates for conventional three-state applications [41]. However, the divergent results from the 5-STM indicate that PSMs may be insufficient for capturing outcomes when diseases involve heterogeneous health states with substantially different costs and quality of life implications [41]. This limitation is particularly relevant in oncology, where treatments may have differential effects on specific metastatic sites or molecular subtypes. The structural simplicity of PSMs that makes them accessible to decision-makers also constrains their ability to model complex disease pathways and treatment sequences [37].

Table 3: Performance Comparison in Case Study Applications

Application Context	Model Type	Key Outcomes	Strengths	Limitations
CRC Screening Evaluation [36]	MISCAN-Colon (Microsimulation)	Identified cost-effective screening alternatives for non-adherent populations	Models complete natural history; handles multiple tests and adherence scenarios	Complex implementation; computationally intensive
NSCLC Drug Evaluation [41]	Partitioned Survival Model	0.889 incremental LY; 0.827 incremental QALY	Direct use of trial endpoints; transparent for decision-makers	Limited capture of health state heterogeneity
NSCLC Drug Evaluation [41]	5-State Transition Model	0.910 incremental LY; 0.695 incremental QALY	Captures complex metastasis pathways; models continuing treatment after progression	Requires robust transition probability estimation

Analytical Considerations for Model Selection

Structural Uncertainty and Validation Approaches

The choice between modeling approaches introduces structural uncertainty into economic evaluations, which can significantly influence study conclusions. Comparative analyses have demonstrated that PSMs and state transition models (STMs) can produce substantively different survival extrapolations, with each approach susceptible to different assumptions and limitations [37]. Extrapolations from STMs are heavily influenced by the specification of underlying survival models for individual health-state transitions, while PSMs lack a structural connection between progression and survival that limits exploration of clinical uncertainties in the extrapolation period [37]. The National Institute for Health and Care Excellence (NICE) recommends using STMs alongside PSMs to support assessment of clinical uncertainties, particularly regarding post-progression survival [37].

Model validation represents a critical component of both approaches, though the methods differ substantially. Microsimulation models like MISCAN-Colon typically undergo face validation (review by clinical experts), internal validation (reproducing input parameters), cross-validation (comparison with other models), and external validation (comparison with empirical trial results) [39] [36]. The MISCAN-Colon model has been validated through its application in informing screening recommendations for organizations including the U.S. Preventive Services Task Force and the American Cancer Society [36]. PSMs more commonly rely on goodness-of-fit statistics for survival curves and predictive validation against observed trial data, though their simpler structure provides fewer opportunities for comprehensive validation against external data sources [37].

Practical Implementation and Resource Requirements

The practical implementation of these modeling approaches entails substantially different resource requirements and technical challenges. Microsimulation models demand extensive development time, specialized programming expertise, and substantial computational resources to simulate large populations [39] [40]. The MISCAN-Colon model requires detailed estimation of numerous natural history parameters, often derived from multiple data sources including epidemiological studies, clinical trials, and cancer registries [39]. This complexity creates significant upfront costs but provides greater flexibility for analyzing complex interventions and heterogeneous populations. The model's ability to incorporate individual risk factors, such as obesity, smoking, and dietary factors, enables more personalized evaluation of screening strategies [39].

In contrast, PSMs offer significantly lower implementation barriers, requiring less specialized expertise and computational resources [37]. This accessibility advantage has contributed to their dominance in pharmaceutical reimbursement submissions. However, PSMs present their own analytical challenges, particularly regarding the extrapolation of survival curves beyond the observed trial period. Decision makers must carefully scrutinize survival predictions from both approaches, assessing whether model predictions are credible based on trial data, external evidence, and clinical opinion [37] [38]. Recent reviews of NICE appraisals indicate that such critical assessment of state-specific survival predictions does not consistently occur in current practice [37].

Research Reagent Solutions and Essential Materials

The implementation of both partitioned survival and microsimulation models requires specific analytical tools and data resources. The following table details key "research reagents" essential for conducting rigorous model-based economic evaluations in oncology.

Table 4: Essential Research Reagents for Cancer Modeling Approaches

Reagent Category	Specific Tools/Resources	Function in Modeling Process
Data Resources	SEER Program Data	Provides population-based cancer incidence, stage distribution, and survival statistics for model calibration [39]
Data Resources	Clinical Trial Databases (e.g., FDA submissions)	Source for progression-free and overall survival endpoints for partitioned survival models [37]
Data Resources	National Vital Statistics Systems	Provides competing mortality risks independent of cancer [39]
Software Platforms	Statistical Programming (R, SAS)	Enables survival analysis, curve fitting, and model implementation [41]
Software Platforms	Specialist Modeling Software (TreeAge, Arena)	Provides frameworks for implementing state transition and microsimulation models
Validation Tools	Goodness-of-fit Measures (AIC, BIC)	Guides selection of appropriate parametric survival distributions [37]
Methodological Guidelines	NICE Technical Support Documents	Provides standards for model structure, validation, and uncertainty analysis [37]

Partitioned survival models and microsimulation approaches represent complementary methodologies for economic evaluation of cancer interventions, each with distinct strengths and applications. PSMs offer practical advantages for drug evaluations, with transparent connections to clinical trial endpoints and lower implementation barriers [37]. Microsimulation models like MISCAN-Colon provide superior capabilities for evaluating complex screening interventions, capturing heterogeneous disease pathways, and modeling personalized risk factors [39] [36]. The choice between approaches should be guided by the specific research question, with PSMs better suited for drug reimbursement analyses based on trial data, and microsimulation preferred for public health planning of screening programs. Future methodological development should focus on reconciling structural differences between approaches, improving transparency, and validating long-term projections against real-world evidence.

Cancer treatment costs pose a significant global economic burden, driving the need for cost-effective diagnostic strategies. In advanced non-small-cell lung cancer (aNSCLC), molecular testing guides targeted therapy, offering potential for both improved outcomes and reduced healthcare costs. This case study objectively compares the cost-effectiveness of Comprehensive Genomic Profiling (CGP) versus small panel (SP) testing for patients with aNSCLC, using recent real-world evidence. The analysis is framed within a broader research context on the economic evaluation of cancer testing modalities, providing researchers, scientists, and drug development professionals with a detailed comparison of performance, methodologies, and practical research considerations.

The primary data supporting this comparison originates from a real-world evidence study that utilized a partitioned survival model to estimate life years and drug acquisition costs [3] [11]. This model was developed in Microsoft Excel and informed by real-world data from the Syapse study, which included observational data collected from community healthcare centers [3] [11].

• Model Type: Partitioned survival model.
• Software Used: Microsoft Excel.
• Data Source: Real-world data from the Syapse study.
• Objective: To estimate life years (LYs) and lifetime drug acquisition costs associated with CGP versus SP testing.
• Patient Cohorts: The model stratified patients into three subcohorts based on therapy receipt:
  • Patients receiving matched targeted therapy for biomarkers (OncoKB levels 1 and 2).
  • Patients receiving matched immunotherapy for PD-L1.
  • Patients who either did not receive matched therapy or were untreated [11].
• Geographical Scope and Time Horizon: The analysis was conducted from a healthcare system perspective for the United States and Germany, with a lifetime horizon [3] [11].
• Key Outputs: Incremental Cost-Effectiveness Ratio (ICER), expressed as cost per life-year gained (LYG).

Testing Platforms and Comparators

• Comprehensive Genomic Profiling (CGP): A broad genomic test that identifies a wide range of actionable biomarkers, facilitating matched targeted therapy and immunotherapy.
• Small Panel (SP) Testing: A more limited genomic test that searches for a narrower set of pre-specified biomarkers.

Results and Data Analysis

Clinical Outcomes and Cost-Effectiveness

The base-case analysis revealed significant differences in clinical outcomes and economic value between CGP and SP testing strategies.

Table 1: Base-Case Cost-Effectiveness Results for CGP vs. SP

Outcome Measure	United States	Germany
Incremental Overall Survival (OS)	+0.10 years [3]	+0.10 years [3]
Incremental Cost-Effectiveness Ratio (ICER)	$174,782 per LYG [3] [11]	$63,158 per LYG [3] [11]

CGP was associated with higher overall healthcare costs, primarily due to a higher percentage of patients receiving more expensive targeted therapies. However, it also provided a survival benefit, resulting in the ICERs detailed above [3] [11]. The study concluded that CGP is a cost-effective strategy compared to SP testing in both countries [3] [11].

Scenario and Sensitivity Analyses

The researchers conducted scenario analyses to test the robustness of the base-case findings and understand how different factors influence cost-effectiveness.

Table 2: Impact of Scenario Analyses on ICER

Scenario	ICER (United States)	ICER (Germany)
Base Case	$174,782 per LYG [3] [11]	$63,158 per LYG [3] [11]
Increased patient treatment access	$86,826 per LYG [3]	$29,235 per LYG [3]
Switch to chemotherapy alone	$223,226 per LYG [3]	$83,333 per LYG [3]

These analyses demonstrated that the cost-effectiveness of CGP is highly sensitive to the number of patients who ultimately receive matched therapies and the specific treatment regimens used [3]. Broader access to targeted treatments improves cost-effectiveness, while a shift away from immunotherapy to chemotherapy alone diminishes it.

Visualizing the Testing and Treatment Pathway

The following diagram illustrates the logical workflow of the partitioned survival model used in the study, from the initial testing decision to the final economic and clinical outcomes.

Testing Pathway and Economic Model

For researchers aiming to conduct similar cost-effectiveness analyses in oncology, the following tools and resources were central to this study.

Table 3: Essential Reagents and Resources for Cost-Effectiveness Analysis

Item	Function in the Analysis
Partitioned Survival Model	A decision-analytic framework used to simulate patient survival (in different health states) and estimate long-term outcomes like life years and costs [3] [11].
Real-World Data (RWD)	Observational data from routine clinical practice (e.g., the Syapse study) used to inform model parameters, providing a more realistic representation of clinical benefits compared to hypothetical scenarios [3] [11].
OncoKB Precision Oncology Knowledge Base	A tool used to classify biomarkers and define which patients received "matched targeted therapy" for levels 1 and 2 alterations, standardizing therapy assignment in the model [11].
Microsoft Excel	The software platform used to develop and run the partitioned survival model for this analysis [11].

Discussion

This analysis demonstrates that CGP provides a clinical advantage over SP testing by improving the rate of matched therapy and consequently extending patient survival. While CGP increases upfront testing and subsequent drug acquisition costs, it represents a cost-effective strategy within the context of the US and German healthcare systems [3] [11]. The significant difference in ICERs between the two countries underscores how health system structures, treatment norms, and pricing shape the economic value of precision oncology [42].

A critical finding for drug development professionals and policymakers is that the cost-effectiveness of CGP is not static. It improves significantly as more patients gain access to and receive matched therapies, highlighting the importance of building healthcare infrastructure and coverage policies that support the broader uptake of targeted treatments [3] [42]. This creates a virtuous cycle where improved diagnostic capability drives targeted therapy use, which in turn enhances the value proposition of the diagnostic itself.

Comprehensive Genomic Profiling demonstrates a superior clinical value proposition compared to small panel testing in advanced NSCLC, offering a cost-effective strategy that improves patient survival. The real-world evidence and robust modeling presented provide a strong foundation for informed decision-making by researchers, clinicians, and healthcare payers. The sustainability and value of precision oncology depend on integrating advanced diagnostics with systems that ensure patient access to corresponding targeted therapies.

Colorectal cancer (CRC) remains a significant global health challenge, ranking as the third most common cancer worldwide with approximately 1.9 million new cases and 1 million deaths reported in 2020 [43] [44]. The effectiveness of screening in reducing CRC mortality is well-established, with studies demonstrating that regular screening can prevent approximately 60% of CRC deaths [44]. While colonoscopy is often considered the clinical gold standard for structural examination of the colon, non-invasive tests have emerged as crucial tools for population-based screening, particularly for average-risk individuals who may be reluctant to undergo invasive procedures [45].

The landscape of CRC screening has evolved significantly with the introduction of novel molecular-based technologies. Blood-based biomarkers like the methylated Septin9 (mSEPT9) test and stool-based multi-target DNA (mtSDNA) tests represent innovative approaches that leverage epigenetic and genetic alterations specific to colorectal carcinogenesis [43] [44]. These tests offer the advantage of convenience and potentially higher participation rates while maintaining respectable diagnostic performance characteristics. The mSEPT9 test, commercially available as Epi proColon, was the first blood-based CRC screening test approved by the US FDA in 2016 for average-risk individuals aged over 50 who are unwilling or unable to undergo colonoscopy or other recommended CRC screenings [43]. Meanwhile, multi-target stool DNA tests like COLOTECT have demonstrated enhanced sensitivity for detecting both CRC and precancerous lesions [45].

Economic considerations are paramount in evaluating screening strategies, as healthcare systems must balance effectiveness with resource constraints. Cost-effectiveness analyses provide critical evidence for policymakers to allocate resources efficiently while maximizing health outcomes. This case study provides a comprehensive economic and performance evaluation of these innovative screening technologies within the broader context of cancer screening cost-effectiveness research.

Performance Comparison of Screening Modalities

Diagnostic Performance Metrics

The clinical utility of any screening test depends fundamentally on its diagnostic accuracy, characterized primarily by sensitivity and specificity. The table below summarizes the performance characteristics of various CRC screening modalities based on current literature:

Table 1: Performance Characteristics of Colorectal Cancer Screening Tests

Screening Test	Sensitivity for CRC	Specificity for CRC	Advanced Adenoma Detection	Key Study Details
mSEPT9 (1/3 algorithm)	76.4%–78% [46] [44]	84% [44]	25.26% (advanced adenoma) [43]	Western China study, n=300 [46]
mSEPT9 (2/3 algorithm)	73% [44]	96% [44]	Not reported	Meta-analysis of 25 studies [44]
COLOTECT (mtSDNA)	88.0% [45]	92.0% [45]	Higher than FIT	Hong Kong population study [45]
FIT	73.3%–79% [45] [44]	90.3%–96.4% [45] [44]	Limited sensitivity	Meta-analysis data [44]
Colonoscopy	~95% (direct visualization)	High (with polypectomy)	Gold standard	Reference method [45]

The performance of the mSEPT9 test varies significantly depending on the algorithm used for interpretation. The 1/3 algorithm (one positive result out of three PCR replicates) provides higher sensitivity (78%) at the cost of lower specificity (84%), making it potentially more suitable for screening applications where false negatives are particularly concerning [44]. In contrast, the 2/3 algorithm (two positive results out of three PCR replicates) offers a better balance between sensitivity (73%) and specificity (96%), which may be more appropriate for diagnostic confirmation [44]. A recent study from Western China demonstrated that mSEPT9 showed better performance than traditional serum markers including carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), with an area under the ROC curve (AUC) of 0.860 for CRC detection [46].

The multi-target stool DNA test COLOTECT, which analyzes methylation markers of Syndecan-2 (SDC2), ADHFE1, and PPP2R5C genes, has demonstrated superior sensitivity for CRC (88.0%) compared to FIT (73.3%) while maintaining high specificity (92.0%) [45]. This enhanced performance comes with the advantage of detecting abnormal DNA methylation patterns associated with colorectal carcinogenesis, potentially enabling earlier intervention.

Early-Stage Cancer Detection

The ability to detect early-stage CRC is particularly important for screening tests, as early detection significantly improves treatment outcomes and survival rates. The novel ColonUSK assay, a multiplex Septin9 methylation test that simultaneously evaluates two CpG-rich subregions in the promoter of the Septin9 gene, has demonstrated a sensitivity of 77.34% for CRC and 25.26% for advanced adenoma [43]. Notably, its detection rate for high-grade intraepithelial neoplasia increased to 54.29%, suggesting potential for identifying precancerous lesions [43]. This represents an improvement over earlier mSEPT9 assays that had relatively lower sensitivity for early-stage CRC detection [43].

The mSEPT9 test has demonstrated reasonable effectiveness for detecting early-stage CRC, with one meta-analysis reporting that it "is effective for the detection of early-stage CRC" [44]. However, comparative studies have found that while mSEPT9 presented larger or equal sensitivity for stage II-IV CRCs, the fecal immunochemical test (FIT) showed better sensitivity for stage I CRCs [46]. This highlights the ongoing challenge of detecting very early-stage malignancies with blood-based biomarkers alone.

Economic Evaluation Framework

Cost-Effectiveness Analysis Methodology

Economic evaluations of healthcare interventions typically employ decision-analytic models to compare costs and health outcomes of alternative strategies over a specified time horizon. For CRC screening, Markov models are commonly used to simulate the natural history of colorectal carcinogenesis and the impact of various screening modalities on disease progression [45] [47]. These models incorporate transition probabilities between health states (normal, adenoma, preclinical cancer, clinical cancer, death) and account for test performance characteristics, adherence rates, and costs associated with screening, diagnosis, and treatment.

The primary outcome measure in cost-effectiveness analyses is the incremental cost-effectiveness ratio (ICER), which represents the additional cost per additional unit of health benefit gained, typically measured in quality-adjusted life-years (QALYs) [47]. The ICER is calculated as the difference in costs between two strategies divided by the difference in their effectiveness. Strategies are compared against a willingness-to-pay threshold to determine cost-effectiveness.

Recent studies have emphasized the importance of incorporating real-world adherence patterns rather than assuming perfect adherence, as adherence significantly impacts the cost-effectiveness of screening strategies [48] [47]. Additionally, analyses should consider varying adherence rates across demographic groups, as disparities in screening participation may exacerbate existing health inequities.

Cost-Effectiveness of Innovative Tests

Table 2: Economic Outcomes of Colorectal Cancer Screening Strategies

Screening Strategy	Incremental Cost-Effectiveness Ratio (ICER)	Life-Years Saved	CRC Cases Prevented	Study Context
COLOTECT (annual)	USD 82,206 per QALY [45]	2,295 (per 100,000)	1,272 (per 100,000)	Hong Kong population
FIT (annual)	USD 108,952 per QALY [45]	337 (per 100,000)	146 (per 100,000)	Hong Kong population
Colonoscopy (10-year)	USD 160,808 per QALY [45]	Not reported	Not reported	Hong Kong population
CT Colonography	Most cost-effective for Black adults [48]	Not reported	Not reported	US population, real-world adherence
mt-sRNA (every 3 years)	USD 95,250 per QALY (preferred with test-specific adherence) [47]	Not reported	Not reported	US population

A recent cost-effectiveness analysis in the Hong Kong population demonstrated that the COLOTECT mtSDNA test was more cost-effective than both FIT and colonoscopy, with a lower ICER (USD 82,206 per QALY) compared to FIT (USD 108,952 per QALY) and colonoscopy (USD 160,808 per QALY) [45]. The COLOTECT strategy resulted in substantially more CRC cases prevented (1,272 vs. 146 per 100,000) and life-years saved (2,295 vs. 337) compared to FIT [45]. This superior economic profile was attributed to COLOTECT's higher detection rate of CRC (39.3% vs. 4.5% for FIT) and its potential for higher participation rates due to non-invasiveness [45].

In the United States context, a 2025 study found that all recommended screening strategies were cost-effective compared with no screening [47]. Under assumptions of perfect adherence, colonoscopy every 10 years was the preferred strategy. However, when real-world adherence patterns were considered, every-3-year multitarget stool RNA (mt-sRNA) testing emerged as the preferred cost-effective strategy with an ICER of USD 95,250 per QALY [47]. This highlights the critical importance of accounting for actual patient behavior in economic evaluations.

Adherence and Health Disparities

Screening adherence substantially influences the cost-effectiveness of CRC screening strategies. Research indicates that CT colonography (CTC) may be particularly valuable for addressing disparities in screening participation. A 2025 Neiman Health Policy Institute study found that CTC was the most cost-effective screening strategy for Black adults when real-world adherence patterns were considered [48]. This population experiences disproportionately higher rates of CRC and faces unique barriers to traditional screening methods [48]. The study noted that "Black adults are more willing to undergo CTC," highlighting its potential to reduce disparities in CRC outcomes [48].

The economic impact of screening test adherence extends beyond the immediate healthcare system. Low adherence to recommended screening contributes to delayed diagnoses, which typically require more extensive and expensive treatments. One study estimated that the medical costs for CRC in the United States would reach $26 billion in 2025 [48], underscoring the substantial economic burden that could be mitigated through effective screening strategies with high participation rates.

Experimental Protocols and Methodologies

mSEPT9 Testing Methodology

The laboratory protocol for mSEPT9 testing involves specific steps for sample processing, DNA extraction, bisulfite conversion, and methylation-specific PCR detection:

Table 3: Key Research Reagents for mSEPT9 Testing

Reagent/Equipment	Function	Specifications
BD Vacutainer K2EDTA tubes	Blood collection and preservation	Prevents coagulation, preserves cell-free DNA
Udx ctDNA kit	Plasma DNA extraction	Isulates circulating tumor DNA from plasma
Septin9 Gene Methylation Detection Kit	Methylation-specific PCR detection	Contains primers/probes for methylated SEPT9
Bisulfite conversion reagents	DNA modification	Converts unmethylated cytosines to uracils
Real-time PCR system	DNA amplification and detection	Enables fluorescence-based detection

Sample Collection and Processing: Venous blood samples are collected in EDTA-containing tubes and stored at 2–8°C before processing within 24 hours [43]. Plasma separation involves centrifugation at 1,500 × g for 10 minutes at room temperature, followed by careful transfer of plasma to avoid contact with the buffy coat layer [43]. Plasma samples are typically stored at -70°C prior to DNA extraction.

DNA Extraction and Bisulfite Conversion: Cell-free DNA is extracted from plasma using specialized kits (e.g., Udx ctDNA kit) [43]. The extracted DNA undergoes bisulfite conversion, which deaminates unmethylated cytosine residues to uracil while leaving methylated cytosines unchanged. This conversion allows for subsequent discrimination between methylated and unmethylated DNA sequences during PCR amplification.

PCR Amplification and Detection: The bisulfite-converted DNA is amplified using methylation-specific PCR assays targeting the methylated promoter region of the SEPT9 gene. Different algorithms (1/3, 2/3, or 1/1) may be employed for result interpretation based on the number of positive PCR replicates [44]. The ColonUSK assay, a novel multiplex Septin9 test, simultaneously evaluates two CpG-rich subregions in the SEPT9 promoter and an internal control in a single reaction, improving sensitivity compared to assays targeting a single region [43].

Multi-Target Stool DNA Testing

The protocol for mtSDNA testing like COLOTECT involves stool sample collection, DNA stabilization, extraction, and analysis of multiple molecular markers:

Sample Collection and Stabilization: Patients collect stool samples using standardized collection kits that contain DNA stabilization buffers to prevent degradation of nucleic acids during transport [45]. Proper stabilization is crucial for maintaining DNA integrity and ensuring accurate test results.

DNA Extraction and Purification: Bulk DNA is extracted from stabilized stool samples using commercial extraction kits designed to recover both human and bacterial DNA. The extraction process typically includes steps to remove PCR inhibitors that are common in stool specimens.

Multi-Target Analysis: The COLOTECT assay specifically analyzes methylation patterns of three genes: Syndecan-2 (SDC2), ADHFE1, and PPP2R5C [45]. These methylation markers have been selected based on their frequent association with colorectal carcinogenesis. The extracted DNA undergoes bisulfite conversion followed by quantitative PCR analysis to detect aberrant methylation patterns indicative of CRC or advanced adenomas.

The analytical sensitivity of these tests is continually improving. The COLOTECT assay has demonstrated a sensitivity of 88.0% and specificity of 92.0% for CRC detection, outperforming FIT in identifying cancerous and precancerous lesions [45].

The economic evaluation of innovative colorectal cancer screening tests reveals a complex landscape where diagnostic performance, cost considerations, and real-world adherence patterns collectively determine the optimal screening strategy. Blood-based mSEPT9 tests and stool-based mtSDNA tests offer non-invasive alternatives that can expand screening participation while maintaining respectable sensitivity and specificity profiles.

Based on current evidence, the mSEPT9 test demonstrates better performance than traditional serum biomarkers like CEA and CA19-9 for CRC detection and recurrence monitoring [46]. Its sensitivity is higher than CEA for monitoring CRC recurrence, suggesting clinical utility in post-treatment surveillance [46]. The development of improved mSEPT9 assays targeting multiple CpG-rich subregions, such as the ColonUSK test, has addressed previous limitations in sensitivity for early-stage CRC detection [43].

The multi-target stool DNA test COLOTECT represents a cost-effective screening strategy, particularly in scenarios where colonoscopy capacity is limited or patient acceptance of invasive procedures is low [45]. Its superior cost-effectiveness profile compared to FIT and colonoscopy in Asian populations, coupled with higher participation rates expected for non-invasive tests, suggests that mtSDNA testing could play a valuable role in population-based screening programs [45].

Future research directions should focus on refining risk stratification algorithms to optimize screening intervals based on individual risk profiles, developing even more sensitive biomarkers for detecting precancerous adenomas, and evaluating combined testing approaches that leverage the complementary strengths of different modalities. Additionally, more economic evaluations across diverse healthcare systems and populations will help establish context-specific implementation guidelines for these innovative CRC screening technologies.

The diagnosis of prostate cancer relies heavily on the histopathological examination of biopsy tissue, a process known for its subjectivity and inter-observer variability [49]. In challenging cases, pathologists frequently turn to immunohistochemistry (IHC), a special stain that helps identify the presence or absence of basal cells to distinguish benign glands from prostate adenocarcinoma [49]. While useful, IHC staining increases diagnostic costs, adds to laboratory workload, and extends turnaround times, ultimately delaying final diagnoses for patients [49]. Artificial intelligence (AI) applied to digital pathology presents a promising solution to this inefficiency. This case study examines the performance of an AI model specifically developed to reduce unnecessary IHC use in prostate cancer diagnosis, framing its findings within a cost-effectiveness analysis of cancer testing approaches [49].

Performance Comparison: AI vs. Standard Practice

A pivotal study published in Communications Medicine (2025) evaluated an AI model's ability to maintain diagnostic accuracy while reducing IHC use [49]. The research analyzed diagnostically challenging prostate core needle biopsies from three independent cohorts (Stavanger University Hospital, Synlab France, and Synlab Switzerland), where pathologists had originally required IHC to finalize the diagnosis [49]. The AI was applied to standard hematoxylin and eosin (H&E)-stained whole-slide images to classify atypical glands.

Table 1: Performance Metrics of the AI Model Across Independent Cohorts

Cohort	Sample Size (Slides)	Area Under the Curve (AUC)	IHC Reduction (Overall)	IHC Reduction (Benign Slides Only)	False Negatives
Stavanger University Hospital	234 (105 malignant, 129 benign)	0.993	44.4%	80.6%	0
Synlab France	112 (46 malignant, 66 benign)	0.983	42.0%	Information Not Specified	0
Synlab Switzerland	Information Not Specified	0.951	20.7%	Information Not Specified	0

The data demonstrates that the AI model achieved high diagnostic accuracy across all sites, with AUC values ranging from 0.951 to 0.993 [49]. By employing a sensitivity-prioritized threshold to avoid missing cancers, the model reduced the need for IHC staining by 20.7% to 44.4% without a single false negative prediction [49]. The most substantial reduction was observed on slides with a benign final diagnosis, where IHC use could be reduced by up to 80.6%, highlighting the AI's potential to eliminate unnecessary tests ordered for rule-out purposes [49].

Comparative Analysis with Other AI Applications

The performance of this pathology-specific AI can be contextualized alongside other AI applications in the prostate cancer pathway. The following table compares its function and impact with AI tools in imaging and digital pathology for tasks like grading.

Table 2: Comparison of AI Applications in Prostate Cancer Diagnosis and Management

Application Area	Primary Function	Key Performance Metric	Reported Impact
Pathology: IHC Reduction [49]	Classify benign vs. malignant glands on H&E to reduce IHC use.	44.4% reduction in IHC use with zero false negatives.	Reduces costs, workload, and diagnostic delays.
Pathology: Grading & Prognostics [50]	Analyze biopsy samples to predict cancer aggressiveness and guide treatment.	Provides a risk score for personalized treatment plans.	Aims to spare men low-risk cancer from unnecessary treatment and prioritize aggressive disease.
Radiology: MRI Diagnosis [51]	Detect clinically significant prostate cancer on biparametric MRI.	AUC of 0.91, surpassing expert radiologists (AUC 0.86).	50.4% fewer false positives and 20% fewer Grade Group 1 detections.
Radiology: Micro-US [51]	Interpret micro-ultrasound images for cancer detection.	AUC of 0.871, specificity of 68.1% (vs. 27.3% for clinical model).	Potential to curb unnecessary biopsies while maintaining high sensitivity.

Detailed Experimental Protocols

Study Design and Data Cohorts

The study was conducted retrospectively on prostate core needle biopsies from routine diagnostics at three different pathology sites [49]. The overarching methodology is summarized in the workflow below:

The research exclusively included diagnostically challenging cases where the original pathologist had required IHC staining targeting basal cells (e.g., HMWCK or p63) to finalize the diagnosis [49]. This design made IHC use a surrogate marker for diagnostic uncertainty on H&E stains alone. To ensure robust and generalizable results, the analysis used only held-out test data from patients who were not part of the initial AI model training or hyperparameter tuning [49]. The cohorts were:

• Cohort 1 (Stavanger University Hospital): Consecutive cases from routine diagnostics (2016-2018), digitized with a Hamamatsu S60 scanner [49].
• Cohort 2 (Synlab France): Consecutive cases from routine diagnostics (2020), digitized with a Philips IntelliSite Ultra Fast Scanner [49].
• Cohort 3 (Synlab Switzerland): An external cohort also digitized with a Philips IntelliSite Ultra Fast Scanner [49].

AI Model and Statistical Analysis

The AI model was trained on a large, multinational dataset of prostate biopsies for prostate cancer diagnosis and Gleason grading [49]. In this study, the model's primary task was binary classification—distinguishing between benign and malignant glands on routine H&E-stained whole-slide images.

The key analytical step was the application of sensitivity-prioritized diagnostic thresholds. This meant setting the AI's decision boundary to maximize sensitivity, ensuring that nearly all cancerous cases were flagged, thereby minimizing the risk of false negatives—a critical requirement for clinical safety [49]. The model's performance was assessed using the area under the receiver operating characteristic curve (AUC). The reduction in IHC use was calculated by determining the proportion of slides for which the AI's confident diagnosis on H&E alone would have ostensibly rendered IHC unnecessary, compared to the pathologist's original decision to use it [49].

The Scientist's Toolkit: Research Reagent Solutions

The implementation and validation of AI models in pathology rely on a foundation of specific hardware, software, and data resources. The following table details key components essential for research in this field.

Table 3: Essential Research Tools for AI in Pathology

Tool Category	Specific Examples	Function in Research
Digital Scanners	Hamamatsu S60, Philips IntelliSite Ultra Fast Scanner [49]	Converts glass slides into high-resolution whole-slide images (WSIs), the primary data source for AI analysis.
AI Software & Algorithms	Convolutional Neural Networks (CNNs) [52], "CLOVER" framework [53]	Provides the computational backbone for analyzing WSIs, from cancer detection to visual question-answering.
Cloud & Data Infrastructure	Cloud Computing Platforms, GPUs [54]	Offers scalable processing power and storage for handling large WSI datasets and training complex models.
Laboratory Information Systems	LIS, EHR with DICOM/API interfaces [54]	Ensures smooth integration of AI tools into clinical and research workflows and manages patient data linkage.
Clinical Validation Cohorts	Multi-site, international biopsy samples [49]	Provides the diverse, real-world data necessary to rigorously test AI model performance and generalizability.

Cost-Effectiveness and Research Context

The drive toward AI in pathology is underpinned by a compelling cost-effectiveness argument. The global AI in pathology market, valued at $1.22 billion in 2024, is projected to grow rapidly, reflecting increasing adoption [52]. A primary growth driver is the increasing need for personalized medicine, which demands more precise and efficient diagnostic tools [52].

The specific AI model discussed in this case study directly addresses several cost centers. By reducing IHC use by over 40%, it saves on reagent costs, laboratory processing time, and pathologist interpretation time for ancillary stains [49]. This efficiency translates into lower operational costs and faster diagnostic turnaround times, benefiting healthcare systems and patients alike [49]. Furthermore, AI demonstrates potential in streamlining other parts of the clinical pathway. In radiology, AI-assisted MRI reading has been shown to improve specificity, which could reduce unnecessary biopsies [51]. In pathology, AI tools that predict cancer aggressiveness, like the one being tested by Prostate Cancer UK, can guide better treatment decisions, preventing the costs and side-effects associated with overtreatment of low-risk disease [50].

The following diagram illustrates how AI integrates into the pathology workflow to create a more efficient and cost-effective diagnostic pathway.

While challenges remain—including the need for larger, diverse datasets and addressing public concerns about data privacy [55] [56]—the evidence indicates that AI-assisted pathology is a maturing field poised to deliver more cost-effective and standardized prostate cancer diagnostics.

Incorporating Diagnostic Testing into Economic Evaluations of Tumor-Agnostic Therapies

The emergence of tumor-agnostic therapies represents a paradigm shift in oncology, moving away from treatment decisions based on tumor location toward targeting specific genetic mutations regardless of anatomical origin. This revolutionary approach enables clinicians to use a single therapy across multiple cancer types when patients share a common molecular biomarker. However, this personalized strategy fundamentally depends on companion diagnostic testing to identify patients likely to respond to treatment, creating an inseparable test-treatment combination that must be evaluated economically as an integrated unit [57].

The incorporation of molecular diagnostics into health economic evaluations presents substantial challenges for healthcare systems worldwide, particularly regarding costs, accessibility, and infrastructure requirements. Economic models must account for these test-treatment combinations and consider shifts in treatment pathways compared to routine practice. Current literature reveals significant heterogeneity in how diagnostic testing is incorporated into cost-effectiveness models, with some studies excluding these costs entirely while others include them partially or fully [57]. This inconsistency underscores the need for robust frameworks to accurately assess the health economic value of tumor-agnostic therapies in the context of modern precision oncology.

Methodological Framework for Economic Evaluation

Core Components of Economic Models

Economic evaluations of tumor-agnostic therapies must integrate several unique components that distinguish them from traditional cancer therapy assessments. The diagnostic pathway becomes an integral part of the treatment continuum, requiring detailed modeling of test performance characteristics, including sensitivity, specificity, positive predictive value, and negative predictive value. These parameters directly impact both clinical outcomes and economic results [57].

The prevalence of target biomarkers across different tumor types significantly influences the cost-effectiveness profile. For low-prevalence biomarkers, the number needed to screen (NNS) to identify one eligible patient increases substantially, raising diagnostic costs per successfully treated patient. Economic models must therefore incorporate comprehensive testing cascades that reflect real-world clinical practice, including reflex testing protocols and potential repeat testing strategies [57].

Table 1: Key Components for Economic Models of Tumor-Agnostic Therapies

Model Component	Description	Data Sources
Diagnostic Test Performance	Sensitivity, specificity, PPV, NPV of companion diagnostic	Clinical validation studies
Biomarker Prevalence	Frequency of target molecular alteration across cancer types	Population-based genomic studies
Diagnostic Costs	Direct costs of testing, including sequencing and interpretation	Laboratory reimbursement schedules
Treatment Efficacy	Clinical response, PFS, OS in biomarker-positive patients	Pivotal clinical trials
Resource Utilization	Diagnostic workup, treatment administration, monitoring	Real-world evidence studies

Experimental Protocols for Diagnostic Test Evaluation

The evaluation of diagnostic tests for tumor-agnostic applications requires standardized methodologies to generate comparable data for economic models. The following protocols represent best practices for generating performance data:

Protocol 1: Analytical Validation

• Sample Collection: Obtain tumor tissue samples (fresh-frozen or FFPE) and matched normal tissue from diverse cancer populations.
• DNA/RNA Extraction: Use standardized kits (e.g., QIAamp DNA FFPE Tissue Kit) to ensure high-quality nucleic acid isolation.
• Library Preparation: Employ targeted sequencing panels (e.g., Illumina TruSight Oncology 500) covering relevant genomic alterations.
• Sequencing Analysis: Perform next-generation sequencing on platforms (e.g., Illumina NovaSeq) with minimum 500x coverage.
• Validation Metrics: Calculate sensitivity, specificity, precision, and reproducibility using reference materials with known mutation status.

Protocol 2: Clinical Validation

• Study Population: Recruit patients with advanced solid tumors across multiple histologies following IRB-approved protocols.
• Testing Procedure: Perform index test and reference standard test blinded to each other's results.
• Outcome Measures: Determine clinical sensitivity/specificity using objective response rate as the primary endpoint.
• Statistical Analysis: Calculate positive predictive value (PPV) and negative predictive value (NPV) with 95% confidence intervals.

Comparative Analysis of Testing Approaches

Multi-Cancer Early Detection (MCED) Testing

The Galleri multi-cancer early detection (MCED) test represents an innovative approach to cancer screening that has implications for tumor-agnostic treatment strategies. Recent data from the PATHFINDER 2 study, a prospective, multi-center interventional study with 35,878 participants, demonstrated that adding Galleri to standard screenings increased cancer detection more than seven-fold when combined with USPSTF A and B recommended screenings [58].

The test demonstrated a cancer signal detection rate of 0.93% and a cancer detection rate of 0.57%, with a positive predictive value of 61.6% - substantially higher than the previous PATHFINDER study. The test showed particular strength in detecting cancers that currently lack recommended screening tests, with approximately three-quarters of Galleri-detected cancers falling into this category [58]. The episode sensitivity for the 12 cancers responsible for two-thirds of cancer deaths in the U.S. was 73.7%, while overall sensitivity for all cancers was 40.4%. Specificity was 99.6%, translating to a false positive rate of only 0.4% [58].

Table 2: Performance Metrics of Galleri MCED Test from PATHFINDER 2 Study

Performance Metric	Result	Context
Cancer Signal Detection Rate	0.93%	216 participants
Cancer Detection Rate	0.57%	133 participants
Positive Predictive Value (PPV)	61.6%	Higher than previous study
Episode Sensitivity (12 deadly cancers)	73.7%	Cancers causing 2/3 of deaths
Episode Sensitivity (All cancers)	40.4%	All cancer types
Specificity	99.6%	False positive rate 0.4%
Cancer Signal Origin (CSO) Accuracy	92%	Correct tissue of origin
Early-Stage Detection (Stage I/II)	53.5%	More treatable stages

Risk-Adapted Screening Strategies

Risk-adapted screening approaches offer a methodological framework relevant to tumor-agnostic therapy evaluation by optimizing resource allocation based on individual patient risk profiles. The TARGET-C trial, a population-based colorectal cancer screening randomized controlled trial in China, compared colonoscopy, fecal immunochemical test (FIT), and risk-adapted screening across 19,582 participants aged 50-74 years [59].

The study implemented a composite risk score incorporating age, sex, family history of CRC, smoking status, and body mass index to stratify participants. High-risk individuals were referred for colonoscopy while low-risk participants received FIT. Results demonstrated that the risk-adapted approach achieved participation rates of 92.5%, significantly higher than colonoscopy (42.3%) though lower than FIT (99.8%) [59]. Most importantly, the detection rates for advanced neoplasms were comparable across all three strategies: 2.8% for colonoscopy, 2.3% for FIT, and 2.6% for risk-adapted screening, with no statistically significant differences (P > 0.05) [59].

The economic implications were substantial: colonoscopies needed to detect one advanced neoplasm were 15.4 for colonoscopy, 7.9 for FIT, and 9.3 for the risk-adapted approach. From a societal perspective, the cost for detecting one advanced neoplasm was 15,341 Chinese Yuan for colonoscopy, 21,754 for FIT, and 24,300 for risk-adapted screening [59]. Microsimulation modeling projected that over 15 years, risk-adapted screening would reduce incidence by 16.7% and mortality by 21.5% compared with no screening, slightly less effective than colonoscopy (24.6% and 24.8%, respectively) but with better resource utilization [59].

Community-Based Screening Implementation

The economic evaluation of diagnostic testing must consider implementation strategies that affect both cost and effectiveness. A community-based colorectal cancer screening program focused on African American populations demonstrated that on-site FIT kit distribution demonstrated greater cost-effectiveness than mailing upon request [60].

The overall community outreach program totaled $14,541 for a three-month period, with labor costs of $12,757 and nonlabor costs of $1,784. Individually, total costs for on-site distribution (n=110) and mailing of FIT upon request (n=99) strategies were estimated at $8,629 and $5,912, respectively [60]. The average implementation cost-effectiveness ratios were $70 per person enrolled, $246 per participant screened, and $969 per completed participant who tested positive. The incremental cost-effectiveness ratio was $129 for an additional percentage-point increase in colorectal cancer screening rates and $109 per additional person who completed the screening [60].

This analysis demonstrates how delivery method optimization can substantially influence the economic value of diagnostic approaches, a consideration equally relevant to tumor-agnostic therapy testing protocols.

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 3: Key Research Reagent Solutions for Diagnostic Test Development

Reagent/Material	Function	Example Products
Nucleic Acid Extraction Kits	Isolation of high-quality DNA/RNA from tumor samples	QIAamp DNA FFPE Tissue Kit, Maxwell RSC RNA Kit
Targeted Sequencing Panels	Enrichment of cancer-relevant genes for sequencing	Illumina TruSight Oncology 500, Thermo Fisher Oncomine
NGS Library Preparation	Preparation of sequencing libraries from extracted nucleic acids	Illumina DNA Prep, KAPA HyperPrep Kit
Reference Standards	Quality control and assay validation	Seraseq ctDNA Reference Materials, Horizon Multiplex I
Bioinformatics Pipelines	Analysis of sequencing data and variant calling	Illumina Dragen, GATK Best Practices
Cell Line Models	Functional validation of biomarker-therapy relationships	NCI-60 panel, patient-derived organoids

The integration of diagnostic testing into economic evaluations of tumor-agnostic therapies is methodologically challenging but essential for accurate value assessment. The reviewed evidence demonstrates that economic models must account for the complete test-treatment combination, considering diagnostic performance characteristics, biomarker prevalence, implementation strategies, and total pathway costs. As the field evolves, the development of robust frameworks and clear guidance on requirements are crucial to support sustainable and equitable healthcare decision-making [57].

Future economic evaluations should incorporate real-world evidence on test performance across diverse clinical settings and patient populations. Additionally, as diagnostic technologies continue to advance rapidly, economic models must remain flexible to accommodate emerging testing platforms with improved performance characteristics. Only through comprehensive economic evaluations that fully capture the diagnostic component can we ensure that tumor-agnostic therapies deliver sustainable value to healthcare systems and patients alike.

Navigating Challenges and Strategic Optimization for Value-Based Care

Addressing the Low-Prevalence Biomarker Challenge in Tumor-Agnostic Therapy

Tumor-agnostic therapies represent a paradigm shift in oncology, moving from tissue-based classification to molecular alteration-focused treatment. This approach targets specific molecular biomarkers across diverse cancer types, offering transformative potential for personalized cancer care. However, a significant challenge emerges: many actionable biomarkers exhibit extremely low prevalence across patient populations, creating substantial hurdles for drug development, clinical testing, and cost-effective implementation.

The regulatory approval of therapies like pembrolizumab for MSI-H/dMMR tumors and larotrectinib for NTRK fusions established the tumor-agnostic framework, validating that molecular alterations can supersede tumor histology as treatment determinants. This paper examines the challenge of low-prevalence biomarkers in tumor-agnostic therapy development, comparing detection strategies, analyzing clinical trial methodologies, and evaluating cost-effectiveness to provide frameworks for addressing this critical constraint in precision oncology.

The Low-Prevalence Biomarker Landscape: Quantitative Analysis

Prevalence Variation Across Tissue-Agnostic Indications

Comprehensive molecular profiling of 295,316 tumor samples reveals dramatic variability in the frequency of tissue-agnostic biomarkers, with prevalence ranging from minimal detection to near-universal presence in specific cancer types [61].

Table 1: Prevalence of Tissue-Agnostic Biomarkers Across Tumor Types

Biomarker	Overall Prevalence	Highest Prevalence Tumor Types	Low Prevalence Tumor Types
TMB-High	Variable (0-87%)	Basal cell skin cancer (87%)	Pituitary carcinoma (0%) [61]
MSI-High/dMMR	Variable	Endometrial, colorectal cancers	Multiple rare carcinomas [61]
BRAF V600E	Variable	Melanoma, hairy cell leukemia	Various rare tumors [61]
NTRK fusions	0.2% overall	NSCLC (1.1%)	Most tumors (0-0.3%) [61]
RET fusions	<0.3%	Thyroid cancer	Most tumor types [61]

This prevalence analysis indicates that with current FDA-approved tissue-agnostic indications, approximately 21.5% of all cancer patients qualify for tumor-agnostic therapy based on molecular profile. Within this population, biomarker distribution shows significant skew: 17% have single alterations, 3% have two alterations, and only 1% have three or more targetable alterations [61].

Clinical Uptake Challenges for Rare Biomarkers

The translational pathway from biomarker identification to therapeutic application demonstrates significant attrition for low-prevalence markers. Real-world evidence reveals that only approximately one-third of patients with NTRK fusions receive NTRK-targeting therapies in any given year, despite FDA approval of effective agents [61].

Analysis of electronic health records confirms this concerning trend, with only 37.8% (17/45) of NTRK fusion-positive patients receiving targeted treatment. Even within structured observational studies, treatment rates reach only 50% (14/28 subjects) [61]. This implementation gap suggests that biomarker rarity creates systematic barriers to clinical adoption, potentially due to testing limitations, recognition barriers, and competing treatment strategies (e.g., preferential use of checkpoint inhibitors in TMB-High or MSI-High patients) [61].

Methodological Comparisons: Detection Strategies for Rare Biomarkers

Risk-Adapted Screening Versus Universal Testing

Comparative studies in cancer screening provide relevant methodologies for addressing low-prevalence biomarker challenges. The TARGET-C randomized controlled trial compared three colorectal cancer screening approaches: colonoscopy, fecal immunochemical test (FIT), and risk-adapted screening [59].

Table 2: Performance Comparison of Screening Methodologies for Lesion Detection

Screening Method	Participation Rate	Advanced Neoplasm Detection Rate	Colonoscopies Needed per Detection	Cost per Detection (CNY)
Colonoscopy	42.3%	2.8%	15.4	15,341
Annual FIT	99.8%	2.3%	7.9	21,754
Risk-Adapted Screening	92.5%	2.6%	9.3	24,300

The risk-adapted approach used a composite risk score incorporating age, sex, family history, smoking status, and BMI to stratify patients into high-risk (referred for colonoscopy) and low-risk (referred for FIT) pathways [59]. This methodology achieved participation rates exceeding colonoscopy while maintaining detection rates comparable to both established methods, suggesting that risk stratification can optimize resource utilization when targeting low-prevalence conditions.

Biomarker Evaluation Framework

The National Institutes of Health biomarker evaluation process provides a structured framework for addressing low-prevalence biomarker challenges through a three-step validation methodology [62]:

• Analytical validation: Assessment of assay performance characteristics, including sensitivity, specificity, reliability, and reproducibility
• Qualification: Evaluation of evidence linking the biomarker to disease states and clinical outcomes
• Utilization: Contextual analysis of the biomarker's applicability for specific uses [62]

This framework emphasizes that biomarker evaluation must consider the specific context of use, with more stringent evidence requirements for definitive clinical applications versus exploratory uses [62].

Figure 1: Biomarker Evaluation Framework Process. This diagram illustrates the sequential three-step process for comprehensive biomarker evaluation from discovery to clinical application.

Innovative Trial Designs for Low-Prevalence Biomarker Research

Basket and Umbrella Trial Methodologies

Traditional trial designs face significant recruitment challenges when studying low-prevalence biomarkers. Innovative methodologies have emerged to address this limitation:

Basket trials investigate a single targeted therapy across multiple cancer types that share a common molecular alteration. This design efficiently pools patients with rare biomarkers across histological boundaries, accelerating recruitment and enabling evaluation of therapeutic efficacy across diverse tumor types [63] [64].

Umbrella trials evaluate multiple targeted therapies within a single cancer type, stratifying patients by molecular alterations into multiple sub-studies. This approach facilitates the study of multiple low-prevalence biomarkers simultaneously within a defined patient population [63].

Table 3: Notable Tumor-Agnostic Trial Designs and Their Characteristics

Trial Design	Trial Name	Target	Key Features
Basket	NCI-MATCH	Multiple actionable targets	Matched patients to therapies based on molecular profiling [63]
Basket	KEYNOTE-158	MSI-H/dMMR	Supported pembrolizumab approval as tissue-agnostic therapy [63]
Basket	Vitrakvi Basket Trials	NTRK fusions	Demonstrated efficacy across cancer types; led to FDA approval [63]
Umbrella	National Lung Matrix Trial	NSCLC biomarkers	Stratified NSCLC patients by biomarkers for targeted therapies [63]
Umbrella	Lung-MAP	Advanced NSCLC	Tested biomarker-driven therapies within NSCLC cohorts [63]
Platform	ComboMATCH	Combination therapies	Built on NCI-MATCH to test combination strategies [63]

External Data Leveraging Methodologies

Recent methodological innovations propose using external data from completed studies and real-world sources to enhance statistical power when studying low-prevalence biomarkers. A permutation-based procedure enables researchers to test whether experimental therapies improve outcomes in any subpopulation while maintaining false positive control at the desired α-level [65].

This approach is particularly valuable for randomized clinical trials where treatment effects may concentrate in biomarker-defined subpopulations. The method remains valid even with unmeasured confounders or population differences between trial and external data, addressing common concerns about incorporating real-world evidence into clinical development [65].

Figure 2: Basket vs. Umbrella Trial Designs. This diagram contrasts two innovative trial methodologies used to study low-prevalence biomarkers in oncology.

Cost-Effectiveness Analysis of Detection Strategies

Population-Wide Versus Enriched Screening Approaches

Economic evaluations provide critical insights for optimizing detection strategies for low-prevalence biomarkers. A comparative analysis of BRCA1/2 testing approaches demonstrates how enrichment strategies can improve cost-effectiveness:

Table 4: Cost-Effectiveness Comparison of BRCA1/2 Testing Strategies in China

Testing Strategy	ICER (CNY/QALY)	Life Expectancy Gain	Probability of Cost-Effectiveness
Symptom-based screening only	Reference	Reference	Reference
Family-history-based testing	¥185,710/QALY	0.26 days	76.96%
Population-based testing	¥504,476/QALY	2.66 days	0.8%

The family-history-based strategy demonstrated significantly better cost-effectiveness compared to population-wide testing, with the prevalence of BRCA1/2 mutations in the general Chinese population identified as the primary variable affecting cost-effectiveness [66]. This highlights the economic importance of strategic enrichment rather than universal application for low-prevalence biomarker detection.

Resource Utilization and Implementation Efficiency

Beyond direct detection costs, implementation efficiency critically influences the feasibility of targeting low-prevalence biomarkers. The TARGET-C trial revealed that risk-adapted screening required 9.3 colonoscopies to detect one advanced neoplasm, intermediate between colonoscopy (15.4) and FIT (7.9) approaches [59].

Long-term modeling projections further demonstrated that under real-world adherence conditions, colonoscopy was most cost-effective, while under perfect adherence, risk-adapted screening became most cost-effective [59]. This underscores how adherence patterns and health system factors significantly influence the optimal strategy for rare biomarker detection.

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 5: Key Research Reagent Solutions for Low-Prevalence Biomarker Studies

Research Tool	Function	Application Examples
Next-generation sequencing panels	Comprehensive genomic profiling to identify multiple biomarker classes simultaneously	Detection of TMB, MSI, gene fusions, and mutations in tissue or liquid biopsies [61]
Digital PCR platforms	Absolute quantification of rare genetic variants with high sensitivity	Detection of low-frequency mutations in heterogeneous samples [64]
Immunohistochemistry assays	Protein expression analysis in tissue samples	Detection of mismatch repair proteins (dMMR), HER2, and other protein biomarkers [64]
Cell-free DNA extraction kits	Isolation of circulating tumor DNA from blood samples	Liquid biopsy applications for minimal residual disease detection [64]
Multiplex immunofluorescence	Simultaneous detection of multiple protein markers in tissue sections	Tumor microenvironment characterization and immune cell profiling [64]
Bioinformatics pipelines	Analysis and interpretation of complex genomic data	Variant calling, TMB calculation, MSI determination [61]

Addressing the low-prevalence biomarker challenge in tumor-agnostic therapy requires integrated methodological approaches. The evidence reviewed suggests several strategic imperatives:

First, risk-adapted patient enrichment strategies significantly improve detection efficiency and cost-effectiveness compared to universal testing approaches. The composite risk model used in colorectal cancer screening and family-history-based BRCA testing demonstrate how pre-selection can optimize resource utilization [59] [66].

Second, innovative trial designs including basket, umbrella, and platform trials enable efficient evaluation of targeted therapies across multiple tumor types, accelerating development while maintaining methodological rigor [63].

Third, comprehensive biomarker evaluation frameworks encompassing analytical validation, qualification, and utilization analysis ensure that low-prevalence biomarkers meet stringent evidence standards required for clinical application [62].

Finally, real-world evidence and external data leveraging methodologies can enhance statistical power and provide clinical insights beyond traditional clinical trials, particularly important for understanding therapeutic performance across diverse tumor types [61] [65].

As tumor-agnostic therapeutics continue to evolve, addressing the low-prevalence biomarker challenge will require continued innovation in detection technologies, trial methodologies, and implementation strategies to ensure that precision oncology benefits extend to all patients with targetable molecular alterations, regardless of their rarity.

The ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a standardized, validated tool designed to stratify the magnitude of clinically meaningful benefit that can be anticipated from anticancer therapies [67]. Its primary purpose is to assist both oncologists in communicating likely treatment benefits to patients and public health decision-makers in prioritizing therapies for reimbursement and resource allocation [67]. Developed through a rigorous methodological process, the scale provides a clear and unbiased evaluation of clinical benefit based on published peer-reviewed data, creating an essential backbone for value assessments of cancer medicines [67]. By offering a transparent framework for evaluating new treatments, the ESMO-MCBS addresses critical challenges in oncology drug assessment, including varying levels of evidence maturity, differential weighting of survival endpoints, and appropriate consideration of toxicity and quality of life impacts.

The ongoing evolution of the ESMO-MCBS reflects the changing landscape of cancer treatment and evidence generation. The most recent version, ESMO-MCBS v2.0, incorporates significant enhancements that improve the accuracy, fairness, and utility of treatment assessments [68]. These updates include a new evaluation form for single-arm de-escalation studies in the adjuvant setting and the addition of toxicity annotations that provide forewarning of severe toxicities without automatically penalizing the grading of medicines [68]. This refinement ensures the scale remains aligned with current clinical practice while maintaining methodological rigor in evaluating both curative and non-curative treatments across diverse cancer types and settings.

ESMO-MCBS Methodology and Scoring Framework

Core Scoring Methodology

The ESMO-MCBS employs a structured scoring approach that evaluates therapies based on their demonstrated efficacy across key clinical endpoints. The scale uses different evaluation forms for curative settings (Form 1) and non-curative settings (Forms 2a and 2b), recognizing the fundamentally different therapeutic goals and benefit expectations in these contexts [67]. For curative approaches, the scale prioritizes overall survival (OS) and disease-free survival (DFS) improvements, while in non-curative settings, it evaluates both OS and progression-free survival (PFS) gains, with proper consideration of the prognostic context [67].

A fundamental requirement for ESMO-MCBS application is that studies must report statistically significant benefit (p-value <0.05) for at least one primary endpoint to be eligible for grading [67]. The scoring incorporates both absolute gains in survival and hazard ratios (HR), with HR evaluation based on the lower limit of the 95% confidence interval, while median survival gains are calculated using point estimates [67]. This dual consideration ensures that both the magnitude of benefit and the precision of the estimate contribute to the final score. The scale further stratifies scoring based on disease prognosis, applying different thresholds for diseases with better versus worse prognosis, such as differentiating between PFS in the control arm greater than or less than 6 months, and OS greater than or less than 12 months [67].

Adjustments for Toxicity and Quality of Life

The ESMO-MCBS incorporates explicit adjustments for quality of life (QoL) and toxicity, recognizing that these factors significantly influence the net therapeutic benefit experienced by patients [67]. The framework includes both upgrading for improved QoL or reduced bothersome toxicities and downgrading for incremental toxicities associated with new treatments [67]. Specifically, the scale allows for one-level upgrading if clinical trials demonstrate either improved QoL or reduced grade 3-4 toxicities (excluding alopecia and myelosuppression), focusing instead on chronic issues such as nausea, diarrhea, and fatigue that substantially impact patients' daily lives [67].

Conversely, the scoring downgrades therapies by one level if they demonstrate improved PFS without accompanying OS advantage and without confirmed QoL benefit [67]. This adjustment mechanism addresses situations where PFS advantages may not translate into meaningful patient benefits. The latest version, ESMO-MCBS v2.0, enhances this approach through toxicity annotations that clearly signal the likelihood of severe toxicities without automatically penalizing the medicine's grading, particularly important in curative settings where toxicity trade-offs may vary significantly between patients [68].

Table 1: ESMO-MCBS Scoring Framework and Adjustment Criteria

Assessment Category	Key Metrics Evaluated	Scoring Adjustments
Curative Setting (Form 1)	DFS HR, 3-year survival difference	Mature survival data may make DFS scoring redundant [67]
Non-Curative OS (Form 2a)	OS HR, median OS gain, % survivors	Upgrade for QoL improvement or reduced toxicity [67]
Non-Curative PFS (Form 2b)	PFS HR, median PFS gain	Downgrade if no OS advantage AND no QoL benefit [67]
Toxicity Assessment	Grade 3-4 toxicities (excluding alopecia/myelosuppression)	Downgrade for incremental toxicities [67]
Quality of Life	Improved QoL or delayed deterioration in QoL	Upgrade for statistically significant QoL improvement [67]

Visualizing the ESMO-MCBS Scoring Logic

The diagram below illustrates the logical workflow and decision-making process employed in the ESMO-MCBS scoring framework, particularly for therapies evaluated in the non-curative setting:

Comparative Analysis with Other Value Frameworks

ESMO-MCBS versus ASCO Value Framework

A formal comparative assessment conducted through collaboration between ESMO and ASCO evaluated the concordance between the ESMO-MCBS (version 1.1) and the ASCO Value Framework Net Health Benefit score (version 2) when applied to 102 randomized controlled trials in the non-curative setting [69]. The study revealed a Spearman's rank correlation coefficient of 0.68, indicating moderate to strong agreement between the two frameworks [69]. The correlation was slightly higher for overall survival endpoints (0.71) compared to progression-free survival endpoints (0.67) [69].

Despite this overall correlation, analysis identified 37 studies with discordant scoring between the two frameworks [69]. The major factors contributing to these discordances included different approaches to evaluating relative versus absolute gain for survival endpoints, crediting tail-of-the-curve gains, and assessing toxicity impacts [69]. The ESMO-MCBS places particular emphasis on the magnitude of absolute survival gains and incorporates explicit toxicity and quality of life adjustments, while the ASCO framework employs alternative weighting methodologies for these components. This comparative analysis highlights how different conceptualizations of "value" can lead to varying assessments of the same clinical evidence, underscoring the importance of transparency in value assessment methodologies.

Unique Differentiators of ESMO-MCBS

The ESMO-MCBS incorporates several distinctive methodological features that differentiate it from other value assessment frameworks. A primary differentiator is its specific stratification for disease prognosis, with different scoring thresholds applied based on whether the median overall survival in the control arm is greater than or less than 12 months, or whether progression-free survival in the control arm exceeds 6 months [67]. This approach acknowledges that the same absolute survival gain may represent different magnitudes of clinical benefit in contexts of varying prognosis.

Another critical differentiator is the framework's explicit handling of maturity of data, particularly relevant in an era of accelerated drug approvals [68]. The ESMO-MCBS clearly indicates cases where underlying data such as progression-free survival and overall survival results remain immature or pending, providing essential transparency for interpreting preliminary results [68]. Furthermore, the scale continues to evolve to address methodological gaps, with version 2.0 introducing a new evaluation form for single-arm de-escalation studies in the adjuvant setting, expanding the tool's applicability to novel trial designs [68]. These methodological refinements ensure the framework remains relevant to contemporary drug development paradigms while maintaining rigorous standards for evaluating clinical benefit.

Table 2: Comparative Analysis of Cancer Drug Value Assessment Frameworks

Framework Feature	ESMO-MCBS	ASCO Value Framework
Primary Purpose	Assist oncologists and public health decision-makers [67]	Inform physician-patient communication and clinical decision-making [69]
Core Methodology	Structured forms for curative/non-curative settings with scoring thresholds [67]	Points-based system with bonus points for tail of curve survival and palliative care [69]
Toxicity Consideration	Explicit downgrading for incremental toxicities [67]	Toxicity adjustment within net health benefit calculation [69]
QoL Integration	Upgrading for improved QoL or delayed deterioration [67]	Incorporated as clinical benefit score modifier [69]
Prognostic Stratification	Different scoring based on control arm survival (e.g., OS <12 or >12 months) [67]	Not explicitly stratified by prognosis [69]
Handling Immature Data	Clear indication of immature data; affects scoring eligibility [67] [68]	Can be applied but with limitations in evidence strength [69]

Application in Cost-Effectiveness Analysis of Cancer Testing Approaches

Linking Clinical Benefit to Economic Evaluation

The ESMO-MCBS provides a critical foundation for cost-effectiveness analyses by establishing a standardized measure of clinical benefit that can be integrated with economic considerations. The scale serves as a filter for prioritizing therapies for formal health technology assessment, with ESMO suggesting that "medicines and therapies that fall into the ESMO-MCBS A+B for curative therapies and 4+5 for non-curative therapies should be highlighted for accelerated assessment of value and cost-effectiveness" [67]. This approach enables healthcare systems to focus limited resources on conducting detailed economic evaluations for treatments that have already demonstrated substantial clinical benefit.

A key application of this principle appears in comprehensive genomic profiling (CGP) versus small panel testing in advanced non-small-cell lung cancer. A 2025 cost-effectiveness analysis using real-world data found that CGP improved average overall survival by 0.10 years compared with small panel testing, but was associated with higher healthcare costs due to more patients receiving targeted therapies [3]. The resulting incremental cost-effectiveness ratio (ICER) was $174,782 per life-year gained in the United States and $63,158 in Germany [3]. When the ESMO-MCBS is applied to evaluate the targeted therapies enabled by CGP, it provides the crucial clinical benefit component needed to contextualize these economic findings, helping decision-makers determine whether the additional clinical benefit justifies the increased costs.

Case Study: Cost-Effectiveness Analysis of Sugemalimab in Gastric Cancer

A recent cost-effectiveness analysis of sugemalimab plus chemotherapy versus chemotherapy alone for advanced gastric cancer in China demonstrates the practical integration of clinical benefit assessment with economic evaluation [5]. This analysis utilized a partitioned survival model with three health states (progression-free survival, disease progression, and death) based on the GEMSTONE-303 Phase III clinical trial, which demonstrated a median overall survival of 15.6 months in the sugemalimab group compared to 12.6 months in the chemotherapy-only group [5]. The study calculated an incremental cost-effectiveness ratio (ICER) of $80,573.50 per quality-adjusted life year (QALY) for patients with PD-L1 CPS ≥5, exceeding China's willingness-to-pay threshold of $40,343.68 per QALY [5].

This case study illustrates how clinical trial data evaluated by tools like the ESMO-MCBS directly informs economic modeling. The transition probabilities between health states were derived from reconstructed survival curves from the clinical trial, with utility values of 0.80 for progression-free survival and 0.58 for progressed disease state obtained from published literature [5]. The probabilistic sensitivity analysis demonstrated that the probability of sugemalimab plus chemotherapy being cost-effective at the WTP threshold was 0% for the PD-L1 CPS ≥5 subgroup [5]. This comprehensive approach connects the clinical benefit demonstrated in trials (which would be graded by ESMO-MCBS) directly to economic considerations, providing a complete value assessment for healthcare decision-makers.

Research Toolkit for Clinical Benefit and Cost-Effectiveness Analysis

Table 3: Essential Research Reagents and Methodological Tools for Clinical Benefit and Economic Evaluation

Research Tool	Primary Function	Application Context
ESMO-MCBS Scorecards	Visual tool displaying ESMO-MCBS scores and supporting data [70]	Standardized communication of clinical benefit assessments to stakeholders
Partitioned Survival Model	Three-state model (PFS, PD, Death) for cost-effectiveness analysis [5]	Estimating long-term costs and outcomes from clinical trial data
GetData Graph Digitizer	Data extraction from published survival curves [5]	Reconstructing patient-level data from published Kaplan-Meier curves
Log-Logistic Distribution	Survival function estimation beyond trial follow-up [5]	Extrapolating survival outcomes for lifetime cost-effectiveness models
EQ-5D Questionnaire	Health-related quality of life utility measurement [5]	Assigning utility weights to health states for QALY calculation
Probabilistic Sensitivity Analysis	Assessment of model parameter uncertainty [5]	Evaluating robustness of cost-effectiveness results to parameter variation

The ESMO-MCBS continues to evolve through planned revisions and updates that address emerging challenges in cancer drug evaluation. The recent release of ESMO-MCBS v2.0 incorporates 13 critical amendments that impact the scores of 13.6% of evaluated studies and add toxicity annotations to 45.5% of studies in the curative setting [68]. These enhancements reflect the framework's ongoing adaptation to the changing treatment landscape, particularly the need to evaluate therapies approved through accelerated pathways with immature survival data [68]. The addition of toxicity annotations represents a particularly significant advancement, as it provides forewarning of severe toxicities without automatically penalizing the medicine's grading, acknowledging that toxicity trade-offs may vary between patients, especially when cure is possible [68].

Future developments will likely focus on expanding the framework's applicability to novel therapeutic modalities and trial designs, including greater incorporation of real-world evidence to complement traditional clinical trial data [3]. As cancer testing approaches become more sophisticated and comprehensive, the integration of ESMO-MCBS evaluations with cost-effectiveness analyses will become increasingly important for healthcare systems facing constrained resources. The framework provides a methodologically robust foundation for prioritizing cancer interventions that deliver meaningful clinical benefits to patients, serving as a crucial screening tool before undertaking detailed economic evaluations. By offering a standardized approach to assessing clinical benefit, the ESMO-MCBS enables more transparent and consistent value assessments across different cancer types and therapeutic approaches, ultimately supporting the goal of optimizing cancer care resource allocation to maximize patient outcomes.

The Promise of Integrated AI and Point-of-Care Testing (POCT) for Resource-Limited Settings

The disparity in cancer outcomes between high-income countries (HICs) and low- and middle-income countries (LMICs) represents one of the most pressing challenges in global health. In LMICs, limited access to centralized laboratory infrastructure, a shortage of specialized healthcare professionals, and financial constraints contribute to mortality rates as high as 70%, significantly higher than in HICs [71]. The mortality-to-incidence ratio (MIR) starkly illustrates this divide: 0.36-0.48 in HICs compared to 0.66-0.70 in LMICs [71]. This gap is largely attributable to late-stage diagnoses, where treatment is more costly and less effective. The World Health Organization reports that early detection can reduce total cancer treatment expenses by 50% [71], highlighting the urgent need for accessible diagnostic solutions in resource-limited settings.

Integrated artificial intelligence (AI) and point-of-care testing (POCT) emerges as a transformative approach to this challenge. AI technologies—encompassing machine learning, deep learning, and natural language processing—offer robust solutions for enhancing diagnostic accuracy and workflow efficiency [72]. When combined with POCT, which brings testing closer to patients, these technologies can democratize access to high-quality cancer diagnostics. This integration is particularly powerful for LMICs, where it enhances accessibility and reduces healthcare disparities [72]. The conceptual "OncoCheck" model exemplifies this approach, combining liquid biopsy with POCT and AI to achieve high-sensitivity diagnostics without requiring advanced infrastructure [71]. This comparison guide evaluates the performance, cost-effectiveness, and implementation requirements of integrated AI-POCT systems against traditional diagnostic approaches for cancer detection in resource-limited settings.

Performance Comparison: AI-POCT Versus Traditional Diagnostic Pathways

Diagnostic Accuracy and Clinical Utility

Integrated AI-POCT systems demonstrate significant advantages over traditional diagnostic methods across multiple cancer types, particularly in screening and early detection applications. The performance metrics in the table below summarize comparative effectiveness data from recent implementations and studies.

Table 1: Performance Comparison of AI-POCT vs. Traditional Diagnostic Methods

Cancer Type	Diagnostic Method	Key Performance Metrics	Study/Context
Breast Cancer	AI-supported mammography screening	Detection rate: 6.7/1000 (vs. 5.7/1000 without AI); 17.6% higher detection [73]	Prospective implementation (12 sites, Germany)
	Traditional double reading	Detection rate: 5.7/1000; Recall rate: 38.3/1000 [73]	Standard care comparison
Multiple Cancers	AI-powered POCT (conceptual)	95% sensitivity for malaria detection; 94% accuracy for anemia screening [72]	Sub-Saharan Africa; Rural India
Lung Cancer	AI + Low-dose CT	Sensitivity: 97.7%; Specificity: 98.4% [74]	Cost-effectiveness analysis
	Low-dose CT only	Sensitivity: 77.9%; Specificity: 87.7% [74]	Baseline comparison
Various Cancers	Liquid Biopsy + AI-POCT (OncoCheck)	Cost: $149-187 (vs. $6,081 for MR mammography) [71]	Economic comparison for breast cancer

The performance advantages of AI-POCT systems extend beyond raw detection rates. In the large-scale PRAIM implementation study of AI-supported mammography screening across 12 German sites, the AI group achieved a higher cancer detection rate without increasing the recall rate—a crucial combination that indicates both improved sensitivity and specificity [73]. The positive predictive value (PPV) of recall was 17.9% in the AI group compared to 14.9% in the control group, and the PPV of biopsy was 64.5% versus 59.2% in the control group [73]. These metrics demonstrate that AI integration not only finds more cancers but does so with greater precision, reducing unnecessary procedures and associated healthcare costs.

Operational Efficiency and Workflow Impact

AI-POCT systems significantly optimize diagnostic workflows through automation and decision support capabilities. In the PRAIM study, the AI system incorporated a "normal triaging" feature that automatically classified 56.7% of mammograms as highly unsuspicious, allowing radiologists to focus their attention on potentially abnormal cases [73]. This triaging function has profound implications for resource-limited settings where specialist availability is constrained. Additionally, the "safety net" feature identified highly suspicious examinations that initial human reading had missed, triggering alerts for radiologists to review their decisions [73]. This safety net led to 204 additional breast cancer diagnoses that might otherwise have been missed [73].

Similar workflow advantages are demonstrated in other clinical contexts. AI-driven decision support systems have reduced antibiotic misuse by 40% through real-time data synthesis [72], while predictive analytics have decreased device downtime by 20% in resource-limited settings [72]. These efficiency gains translate directly to improved patient throughput, reduced waiting times, and more effective use of scarce healthcare resources—critical advantages in LMICs where the ratio of physicians to patients can be as low as 0.2 per 1000 people compared to 3.7 per 1000 in high-income European nations [71].

Economic Analysis: Cost-Effectiveness of Integrated AI-POCT Systems

Direct Cost Comparisons and Budget Impact

Economic evaluations demonstrate that AI-POCT integration offers significant cost advantages over traditional diagnostic pathways, particularly through reduced procedural requirements and more efficient resource utilization. The table below summarizes key economic findings from recent studies across different cancer types and settings.

Table 2: Economic Comparison of Cancer Diagnostic Approaches

Economic Metric	AI-POCT Approach	Traditional Approach	Context/Notes
Per-patient screening cost	14-19.5% reduction [34]	Baseline cost	Diabetic retinopathy screening
Incremental Cost-Effectiveness Ratio (ICER)	£4,847-£5,544 per QALY [34]	>£20,000 per QALY	Atrial fibrillation screening (NHS threshold: £20,000)
Liquid biopsy cost	$149-187 [71]	$6,081 (MR mammography)	Breast cancer detection
AI system cost threshold	Up to $1,240 per patient [74]	-	Lung cancer screening (WTP: $100,000/QALY)
Treatment cost difference	Early-stage: Baseline	Late-stage: 2-4x more expensive [71]	WHO data on cancer treatment costs

Systematic reviews of economic evaluations confirm that AI interventions generally improve diagnostic accuracy, enhance quality-adjusted life years (QALYs), and reduce costs—largely by minimizing unnecessary procedures and optimizing resource use [75]. Several AI interventions have achieved incremental cost-effectiveness ratios (ICERs) well below accepted thresholds, making them economically attractive alternatives to traditional diagnostic methods [75] [34]. For example, in atrial fibrillation screening, a machine learning-based risk prediction algorithm achieved ICERs ranging between £4,847 and £5,544 per QALY gained—substantially lower than the NHS threshold of £20,000 per QALY gained—by effectively reducing the number of screenings required [34].

The economic advantage of liquid biopsy combined with POCT is particularly striking. Compared to traditional MR mammography costing $6,081 per test, liquid biopsy costs between $149 and $187 [71]. This dramatic cost difference makes routine screening financially feasible in settings where traditional methods would be prohibitively expensive. One study found that a reliable biomarker-based blood test could reduce detection costs in the USA by 50% [71], with potential annual savings of $200-500 million even if only a single case per year was prevented through earlier detection.

Long-Term Economic Value and System-Wide Impact

Beyond immediate per-test savings, integrated AI-POCT systems generate substantial long-term economic value through earlier detection and treatment initiation. The Markov model simulation for lung cancer screening demonstrated that AI support at the initial low-dose CT scan was cost-effective up to a price of $1,240 per patient screening, given a willingness-to-pay threshold of $100,000 per QALY [74]. In the base case scenario, CT with AI integration resulted in a negative incremental cost-effectiveness ratio compared to CT alone, indicating both lower costs and higher effectiveness [74].

This economic advantage persists despite the higher initial technology investment required for AI-POCT systems. The long-term value derives from multiple factors: reduced false positives and associated follow-up costs, earlier stage detection enabling less expensive treatments, and improved workflow efficiency allowing healthcare providers to serve more patients [75] [74]. Treating late-stage cancers is typically 2-4 times more expensive than early-stage interventions [71], making the early detection capability of AI-POCT systems particularly valuable for reducing overall healthcare expenditures.

It is important to note, however, that many economic evaluations rely on static models that may overestimate benefits by not capturing the adaptive learning of AI systems over time [75]. Additionally, indirect costs, infrastructure investments, and equity considerations are often underreported in these analyses [75]. Despite these limitations, the consistent direction of evidence across multiple studies and clinical contexts strongly suggests that AI-POCT integration offers favorable economics compared to traditional diagnostic pathways.

Technical and Experimental Protocols

Integrated AI-POCT Workflow Implementation

The implementation of integrated AI-POCT systems follows a structured workflow that combines sample collection, point-of-care analysis, and AI-powered interpretation. The diagram below illustrates this integrated diagnostic pathway.

The workflow begins with minimally invasive sample collection, typically blood or other accessible bodily fluids [71]. For the OncoCheck model, liquid biopsy components include circulating tumor DNA (ctDNA), RNA, circulating tumor cells (CTCs), and extracellular vesicles/exosomes [71]. These samples undergo processing through POCT devices that analyze specific biomarkers without requiring centralized laboratory infrastructure. The resulting data is then processed by AI algorithms for pattern recognition, risk stratification, and diagnostic interpretation. Finally, the system provides clinical decision support to healthcare providers, enabling informed treatment decisions at the point of care.

Experimental Validation Methodologies

Robust validation of integrated AI-POCT systems requires carefully designed experimental protocols that assess both technical performance and clinical utility. The PRAIM study on AI-supported mammography screening provides an exemplary methodology [73]. This prospective, multicenter, observational implementation study compared AI-supported double reading against standard double reading without AI support. The study enrolled 463,094 women screened across 12 sites, with 260,739 in the AI-supported group and 201,079 in the control group [73]. Radiologists voluntarily chose whether to use the AI system on a per-examination basis, with the AI group defined as examinations where at least one radiologist used the AI-supported viewer.

The AI system incorporated two key features: "normal triaging" that identified examinations with high probability of being cancer-free, and a "safety net" that flagged highly suspicious examinations potentially missed by radiologists [73]. Performance metrics included cancer detection rate, recall rate, positive predictive value of recall, and positive predictive value of biopsy. The researchers used overlap weighting based on propensity scores to control for identified confounders, including reader set and AI prediction [73].

Similar methodological rigor should be applied to validate AI-POCT systems in resource-limited settings. Recommended validation parameters include:

• Analytical Performance: Sensitivity, specificity, positive and negative predictive values against gold standard references
• Clinical Utility: Impact on stage at diagnosis, time to treatment initiation, and patient outcomes
• Operational Efficiency: Throughput, turnaround time, and resource utilization compared to traditional pathways
• Economic Impact: Total cost of care, cost per correct diagnosis, and budget impact on healthcare systems

The Scientist's Toolkit: Research Reagent Solutions for AI-POCT Development

The development and implementation of integrated AI-POCT systems requires specific reagents, hardware components, and computational resources. The table below details essential research tools and their functions in creating and validating these diagnostic platforms.

Table 3: Essential Research Reagents and Solutions for AI-POCT Development

Tool Category	Specific Examples	Function in AI-POCT Development
Liquid Biopsy Components	ctDNA isolation kits, CTC capture devices, exosome isolation reagents [71]	Enable non-invasive sampling and biomarker isolation for POCT devices
POCT Platform Reagents	Microfluidic chips, surface functionalization chemistries, detection antibodies [71]	Facilitate biomarker detection and signal generation at point of care
Reference Standard Materials	Synthetic biomarkers, validated clinical samples, standardized control materials [73]	Provide ground truth for algorithm training and system validation
AI Training Datasets	Curated imaging databases, genomic datasets, clinical outcome annotations [76] [73]	Serve as training inputs for developing and refining diagnostic algorithms
Computational Infrastructure	Cloud computing platforms, federated learning frameworks, encrypted data storage [77] [78]	Enable algorithm development while maintaining data privacy and security

Liquid biopsy components form the foundation of many AI-POCT systems, allowing non-invasive access to tumor-derived materials including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes [71]. These components enable the detection of genetic, epigenetic, and protein-based cancer biomarkers from easily obtainable fluids like blood, urine, and cerebrospinal fluid [71]. POCT platform reagents then facilitate the conversion of biomarker presence into detectable signals through microfluidic processing, surface binding interactions, and visual or electronic readouts.

Reference standard materials are particularly crucial for algorithm validation, as they provide the "ground truth" against which AI performance is measured. In the PRAIM mammography study, this involved using proven cancer cases and normal controls with confirmed outcomes [73]. Similarly, comprehensive AI training datasets—such as the curated mammography images used to develop the Vara MG system [73]—enable algorithms to learn the subtle patterns distinguishing normal tissue from early malignancies. Finally, appropriate computational infrastructure, potentially including federated learning approaches that maintain data privacy [77], supports algorithm development and deployment while addressing regulatory requirements for data protection in healthcare settings.

Implementation Challenges and Regulatory Considerations

Despite their significant promise, integrated AI-POCT systems face substantial implementation challenges in resource-limited settings. Key barriers include data privacy risks, algorithmic opacity, infrastructural gaps, and regulatory complexities [72]. The global regulatory landscape for AI-enabled medical devices is particularly fragmented, with different jurisdictions taking markedly different approaches to AI governance [78]. The EU's Artificial Intelligence Act classifies many medical AI systems as "high-risk," subjecting them to stringent requirements for transparency, human oversight, and post-market surveillance [77] [78]. Meanwhile, the U.S. Food and Drug Administration has authorized over 900 AI/ML-enabled medical devices through established pathways while developing new frameworks specifically for adaptive AI systems [77].

Algorithmic bias represents another critical challenge, as training datasets that inadequately represent diverse patient populations can perpetuate or exacerbate existing healthcare disparities [78]. This concern is particularly acute in global health contexts where AI systems developed in one region may be deployed in populations with significantly different demographic, genetic, or socioeconomic characteristics [78]. An AI diagnostic tool trained primarily on data from European or North American populations may perform poorly when applied to patients in sub-Saharan Africa or Southeast Asia, creating both technical and ethical challenges [78].

Infrastructure limitations in LMICs, including unreliable electricity, limited internet connectivity, and equipment maintenance challenges, can further hinder implementation [72] [71]. Successful deployment requires robust technical support, training for healthcare workers, and sustainable business models that ensure long-term viability. Explainable AI frameworks and blockchain encryption have been proposed as potential solutions to build clinician trust and ensure regulatory compliance [72], though these approaches require further validation in resource-limited contexts.

Integrated AI and point-of-care testing represents a transformative approach to cancer diagnostics in resource-limited settings. The evidence compiled in this comparison guide demonstrates that AI-POCT systems can achieve diagnostic performance comparable or superior to traditional methods while offering significant economic advantages through reduced costs and more efficient resource utilization. The conceptual OncoCheck model, combining liquid biopsy, POCT, and AI, exemplifies the potential of this integrated approach to deliver equitable cancer care through hospital-at-home models that function within real-world health systems [71].

As the field advances, key priorities for researchers and developers should include: (1) validating AI-POCT systems in diverse population groups to minimize algorithmic bias; (2) developing robust regulatory frameworks that ensure safety while facilitating appropriate adoption; (3) creating sustainable implementation models that address infrastructure limitations in LMICs; and (4) generating high-quality evidence from prospective studies that document real-world clinical and economic outcomes. By harmonizing technological innovation with accessibility, AI-enhanced POCT emerges as a cornerstone of proactive, patient-centered healthcare, poised to democratize diagnostics and drive sustainable health equity worldwide [72].

Optimizing Adherence and Follow-Up to Maximize Screening Program Value

Cancer screening is a multi-step process that extends beyond the initial test to include timely follow-up and surveillance. The full benefit of screening is only realized when every step is completed. However, significant portions of the population fail to complete the screening continuum, undermining program effectiveness and cost-efficiency [79]. Research from the multi-institution PROSPR II consortium reveals critical gaps: for cervical cancer, only 41.8% of women received timely screening, 37.3% completed recommended surveillance, and 61.2% followed through with diagnostic testing [79]. Similar deficiencies exist for colorectal and lung cancers, with surveillance completion rates of 45.5% and 80.5%, respectively [79]. These gaps represent a fundamental challenge in cancer control that this review addresses through comparative analysis of screening approaches and their impact on adherence and follow-up.

Quantitative Comparison of Screening Modalities and Adherence

Performance Metrics for Colorectal Cancer Screening Tests

Table 1: Performance comparison of quantitative versus qualitative FIT tests in community-based colorectal cancer screening

Performance Metric	Quantitative FIT (qnFIT)	Qualitative FIT (qlFIT)	P-value
Positivity Rate	5.87%	12.86%	< 0.001
CRC Detection Rate at Colonoscopy	13.29%	7.52%	0.043
Positive Predictive Value for CRC	6.12%	3.20%	0.024
Number Needed to Scope to Detect One CRC	7.52	13.29	0.043

Table 2: Adherence comparison across colorectal cancer screening modalities

Screening Modality	Adherence Rate	Study Details	Traditional Screening Adherence Range
Blood-based Test (Shield)	>90%	Expanded cohort of 20,000 patients [80]	28-71% [80]
Patient Preference for Blood Test	43.9%	Survey of screening-eligible individuals for CRC and lung cancer [80]	N/A

Completion Rates Across the Cancer Screening Continuum

Table 3: Completion rates across the cancer screening continuum by cancer type (PROSPR II data)

Cancer Type	Timely Screening	Surveillance Testing	Diagnostic Testing	Treatment Initiation
Cervical	41.8%	37.3%	61.2%	Data unavailable
Colorectal	82.4%	45.5%	73.5%	94.1%
Lung	73.8%	80.5%	80.7%	Data unavailable

Methodological Approaches to Screening Adherence Research

PROSPR II Consortium Methodology

The Population-based Research to Optimize the Screening Process (PROSPR II) consortium represents a major National Cancer Institute-funded initiative to evaluate and improve cancer screening processes across diverse healthcare settings [79].

Study Design and Population: PROSPR II collected data from ten healthcare systems across the United States, including Kaiser Northern California, Kaiser Southern California, Kaiser Washington, Parkland/UT-Southwestern, Partners CancerCare, Kaiser Colorado, University of Pennsylvania, Marshfield Clinic, Kaiser Hawaii, and Henry Ford Cancer Institute [79]. This design incorporated a variety of healthcare delivery systems—large HMOs, small private practices, and safety net hospitals—to accurately represent the U.S. cancer screening landscape.

Data Collection and Analysis: Screening data from 2018 was harmonized and integrated across participating institutions. Fred Hutch Cancer Center served as the data coordinating center, facilitating research question development, project design, and leading data analyses [79]. The study included participants with both private and public insurance (Medicare, Medicaid, CHIP).

Outcome Measures: Researchers evaluated multiple steps in the screening continuum: (1) initial preventive screenings at appropriate ages; (2) regular surveillance for high-risk individuals; (3) completion of recommended diagnostic tests after screening; and (4) initiation of treatment following diagnosis [79].

Comparative FIT Study Protocol

The performance comparison between quantitative and qualitative fecal immunochemical tests followed a rigorous community-based screening protocol [81] [82].

Participant Recruitment: The study enrolled 7,097 residents from Shanghai, China, with 5,841 participants aged 50-74 years ultimately completing both qlFIT and qnFIT tests. Participants included both Shanghai household registration residents and non-Shanghai household registration residents who had lived in Shanghai for at least six months [82].

Testing and Follow-up Procedures: All participants positive on either FIT test were referred for colonoscopy. Researchers compared positivity rates, colonoscopy uptake, detection rates at colonoscopy, positive predictive value, detection rate in population, and number needed to scope [81].

Analytical Methods: The quantitative FIT used immunoturbidimetry technology providing detailed hemoglobin concentration measurements, while the qualitative FIT employed colloidal gold immunochromatography technology with a binary positive/negative result based on predefined thresholds. The conventional cutoff of 100 ng/mL was used for both tests [82].

Statistical analysis included appropriate tests for significance with P-values < .05 considered statistically significant.

Blood-based Screening Adherence Study Methodology

The evaluation of blood-based screening adherence employed both real-world clinical data and patient preference surveys [80].

Real-world Adherence Cohort: Researchers analyzed an expanded cohort of 20,000 patients to assess adherence to the Shield blood-based colorectal cancer screening test. This test detects colorectal cancer-associated alterations in blood and is FDA-approved for average-risk adults aged 45+ [80].

Patient Preference Assessment: A separate study led by Cedars-Sinai researchers used conjoint analysis to assess preferences of over 1,700 people in the U.S. for various screening methods for both colorectal and lung cancers [80].

Visualizing the Screening Continuum and Intervention Points

Screening Continuum with Adherence Interventions

This diagram illustrates the sequential nature of cancer screening and critical dropout points where patients are lost from the care continuum, along with evidence-based interventions targeting each step.

Organizational Determinants of Screening Success

Effective screening programs share common organizational features that optimize adherence and follow-up. Research indicates that successful interventions incorporate centralized coordination, active invitation systems, and integrated quality assurance mechanisms [83]. Community-based outreach and culturally tailored education prove particularly effective for increasing participation among underserved populations [83].

Digital tools, including reinforcement learning-based reminders and mobile applications, demonstrate higher effectiveness when integrated within broader organizational ecosystems rather than deployed as standalone solutions [83]. Audit and feedback mechanisms modestly improve adherence, especially when aligned with quality improvement initiatives [83].

Systematic reviews identify that barriers to screening uptake include being unmarried, experiencing higher deprivation, lower socioeconomic status, and rural living conditions [84]. Conversely, facilitators include older age, family history of cancer, previous screening participation, disease knowledge, positive screening attitudes, higher education, having children, higher income, health insurance, urban residence, access to care, and primary care physician recommendations [84].

Essential Research Reagents and Tools

Table 4: Key research reagents and solutions for screening adherence studies

Research Tool	Primary Function	Application in Screening Research
Quantitative FIT (qnFIT)	Measures exact hemoglobin concentration in stool samples	Comparative performance studies; optimizing cutoff thresholds for specific screening objectives [81] [82]
Qualitative FIT (qlFIT)	Provides binary positive/negative result based on predefined hemoglobin threshold	Baseline comparison for new technologies; settings with limited laboratory infrastructure [81] [82]
Blood-based Screening Tests	Detects cancer-associated alterations in blood samples	Adherence studies; patient preference assessments; alternative screening modality research [80]
Electronic Health Record (EHR) Systems	Tracks patient screening history and sends automated reminders	Studying organizational interventions; evaluating recall system effectiveness [79] [83]
Ovatools Risk Prediction Model	Calculates ovarian cancer probability based on CA125 and age	Risk-based triage studies; evaluating personalized screening pathways [85]
Patient Preference Assessment Tools	Quantifies patient attitudes toward different screening modalities	Understanding adherence drivers; designing patient-centered screening programs [80]

Maximizing screening program value requires addressing the entire screening continuum rather than focusing solely on initial uptake. The evidence demonstrates that no single intervention suffices; rather, integrated approaches combining optimized test modalities, organizational structures, digital tools, and patient-centered strategies yield the greatest improvements in adherence and follow-up.

Quantitative FIT tests offer superior efficiency for colorectal cancer screening, while blood-based tests demonstrate remarkable potential for improving initial adherence. Organizational strategies that standardize processes while maintaining flexibility for personalized care show consistent benefits across cancer types. Future research should focus on implementing and evaluating these integrated approaches across diverse healthcare settings to ensure screening programs deliver their full potential value in cancer prevention and control.

Mitigating Algorithmic Bias and Ensuring Ethical AI Deployment in Diagnostics

Artificial Intelligence (AI) is revolutionizing clinical diagnostics, offering tools that can analyze medical images, predict disease risk, and support complex clinical decision-making. In oncology and other critical fields, AI promises improved diagnostic accuracy, streamlined workflows, and personalized treatment plans [86] [87]. However, this transformative potential is coupled with a significant risk: the perpetuation and amplification of existing healthcare disparities through algorithmic bias. Bias in AI diagnostics can lead to fatal outcomes, misdiagnoses, and a dangerous lack of generalization when applied to diverse patient populations [86]. For researchers and drug development professionals, understanding and mitigating this bias is not merely an ethical imperative but a fundamental requirement for developing valid, generalizable, and cost-effective medical technologies. This guide explores the sources and manifestations of bias in diagnostic AI, provides a comparative analysis of performance data, and outlines experimental protocols and ethical frameworks essential for ensuring equitable AI deployment in cancer diagnostics and beyond.

Typology of Bias in Medical AI

Bias in healthcare AI is a systematic and unfair difference in how predictions are generated for different patient populations, potentially leading to disparate care delivery [88]. These biases can be categorized based on their origin within the AI model lifecycle. The following table summarizes the primary types and their impacts, with a particular focus on diagnostic applications.

Table 1: Types and Impacts of Bias in Diagnostic AI

Bias Type	Origin Stage	Definition	Example in Diagnostics
Data Bias [86] [88] [89]	Data Collection & Preparation	Arises from unrepresentative, incomplete, or mislabeled training data.	Skin lesion algorithms trained predominantly on images of white patients have significantly lower accuracy for Black patients, who have a higher mortality rate from melanoma [86].
Algorithmic Bias [86] [90]	Model Development	Embedded in the model's design, optimization goals, or feature selection.	An AI used for population health management falsely prioritized white patients over sicker Black patients because it used health costs as a proxy for health needs [86].
Human Bias [88]	Conceptualization & Data Collection	Subconscious attitudes, stereotypes, or institutional practices introduced by humans.	Implicit Bias: Women experiencing heart attacks are more likely to be misdiagnosed, a pattern learned by AI trained on historical data [88]. Systemic Bias: Underrepresentation of certain racial groups in oncology biobanks, leading to AI models less effective for those populations [91].
Interaction Bias [90]	Deployment & Use	Emerges from the way users interact with the AI system over time.	A model performing well in a high-income urban hospital might fail in a rural setting due to differences in patient populations, equipment, or clinical workflows—a form of temporal and practice variability [90].

Quantifying the Burden of Bias

The prevalence of bias in medical AI is alarmingly high. A 2023 systematic evaluation found that 50% of contemporary healthcare AI studies demonstrated a high risk of bias, often due to absent sociodemographic data, imbalanced datasets, or weak algorithm design. Only 1 in 5 studies were considered low-risk [88]. Another study focusing on neuroimaging-based AI models for psychiatric diagnosis found that 83% had a high risk of bias, with 97.5% of studies including subjects only from high-income regions [88]. This lack of representativity severely limits the global applicability and fairness of diagnostic tools.

Comparative Analysis of AI Diagnostic Performance

Objective comparison of AI diagnostic tools requires evaluating their performance across diverse datasets and against expert systems. The following data highlights how performance can vary and be influenced by bias.

AI vs. Expert Diagnostic Systems

A recent study compared the diagnostic performance of two generative AI large language models (LLMs)—ChatGPT-4 and Gemini 1.5—against a long-established diagnostic decision support system (DDSS), DXplain, using 36 complex, unpublished clinical cases [87].

Table 2: Diagnostic Performance Comparison: AI vs. Expert System

System	Correct Diagnosis in Top 25 (with Lab Data)	Correct Diagnosis in Top 25 (without Lab Data)	Key Characteristics	Strengths & Weaknesses
DXplain (DDSS)	72% [87]	56% [87]	- Knowledge base of 2,600+ diseases & 6,100+ findings [87]- Transparent, explainable logic [87]- Deterministic (consistent outputs) [87]	Strengths: More consistent, higher ranking of correct diagnosis, built-in explanation tools foster trust [87].Weaknesses: Can miss rare diagnoses by favoring common diseases [87].
ChatGPT-4	64% [87]	42% [87]	- Generalist LLM, processes narrative input [87]- Opague "black-box" reasoning [87]- Non-deterministic (outputs can vary) [87]	Strengths: Captured some diagnoses missed by DDSS; flexible input [87].Weaknesses: Lower consistency, potential for generating false information [87].
Gemini 1.5	58% [87]	39% [87]	- Generalist LLM, processes narrative input [87]- Opague "black-box" reasoning [87]- Non-deterministic (outputs can vary) [87]	Strengths: Captured some diagnoses missed by DDSS; flexible input [87].Weaknesses: Lowest performance in this test; opaque reasoning [87].

The study concluded that while the dedicated DDSS was more consistent, the LLMs provided valuable diagnostic suggestions in cases the expert system missed, advocating for a hybrid approach to combine the strengths of both [87].

Impact of Diverse Data on Algorithmic Performance

The critical role of representative data is exemplified in dermatology AI. Convolutional neural networks (CNNs) that achieve dermatologist-level accuracy on images of white skin can see their diagnostic accuracy drop by approximately half when applied to images of Black patients [86]. This performance gap directly correlates with a disparity in outcomes: the 5-year survival rate for melanoma is only 70% for Black patients compared to 94% for white patients [86]. This underscores that mitigating data bias is not just a technical issue, but one of patient safety and health equity.

Experimental Protocols for Bias Detection and Mitigation

Robust experimental design is essential for identifying and mitigating bias throughout the AI lifecycle. The following protocols provide a framework for researchers.

Protocol for Evaluating Algorithmic Fairness

This protocol is designed to assess whether an AI model performs equitably across predefined demographic subgroups.

Objective: To quantify performance disparities of a diagnostic AI model across groups based on race, sex, age, and socioeconomic status. Materials:

• Test Dataset: A hold-out dataset with comprehensive demographic annotations. The dataset must be distinct from training/validation sets.
• AI Model: The trained diagnostic model to be evaluated.
• Ground Truth Labels: Expert-validated diagnoses for all samples in the test set.
• Computational Environment: Sufficient computing resources (GPU recommended) for model inference and statistical analysis (e.g., Python with scikit-learn, fairness-toolkits).

Methodology:

• Stratified Sampling: Partition the test dataset into subgroups based on demographic variables (e.g., 'White', 'Black', 'Asian'; 'Male', 'Female'; age brackets).
• Model Inference: Run the AI model on the entire test set to obtain its predictions (e.g., binary classification: disease present/absent).
• Performance Metric Calculation: For the overall test set and for each demographic subgroup, calculate key performance metrics:
  • Accuracy: (TP+TN)/(TP+TN+FP+FN)
  • Sensitivity (Recall): TP/(TP+FN)
  • Specificity: TN/(TN+FP)
  • Positive Predictive Value (Precision): TP/(TP+FP)
  • Area Under the Receiver Operating Characteristic Curve (AUC-ROC)
• Disparity Measurement: Quantify the difference in performance metrics between subgroups. Common methods include:
  • Difference in Equality of Opportunity: Max(|SensitivityGroupA - SensitivityGroupB|, ...)
  • Demographic Parity Difference: Max(|PPVGroupA - PPVGroupB|, ...)
  • Statistical tests (e.g., t-tests) to confirm significance of observed differences.

Interpretation: A significant drop in sensitivity for a particular subgroup indicates a higher rate of false negatives for that group, which could lead to underdiagnosis. Similarly, a drop in specificity indicates more false positives [86] [89] [92].

Protocol for Bias Mitigation via TWIX (Task-Weakly-supervised Interpretability)

This protocol, inspired by a method used to mitigate bias in surgical AI, uses interpretability to force the model to focus on clinically relevant features [89].

Objective: To reduce bias in an AI model by training it to identify and weight the importance of reliable features in the input data. Materials:

• Base AI Model: The initial model exhibiting bias (e.g., a CNN for image analysis).
• Training Data: The original dataset used to train the base model.
• Annotation of Key Features: Weak labels indicating regions of interest (e.g., in medical images, text reports highlighting critical findings).

Methodology:

• Model Modification: Add an auxiliary output branch to the base model architecture. This branch is tasked with predicting the importance or relevance of different parts of the input (e.g., image patches, clinical variables) for the final diagnosis.
• Multi-Task Training: Train the modified model using a combined loss function (Lcombined):
  • Ltask: The standard loss for the primary task (e.g., cross-entropy for diagnostic classification).
  • LTWIX: A loss that penalizes the model for incorrectly predicting the importance of input features.
  • Lcombined = Ltask + λ * LTWIX, where λ is a hyperparameter balancing the two objectives.
• Validation: Evaluate the refined model using the fairness evaluation protocol above on a separate validation set to measure reduction in performance disparities.

Interpretation: The TWIX method acts as a regularizer, preventing the model from latching onto spurious, unreliable, or subgroup-specific correlations that cause bias, thereby improving generalizability and fairness [89].

The following diagram illustrates the logical workflow of a comprehensive bias mitigation strategy, integrating the concepts of the A4R-OAI ethical framework and continuous lifecycle management.

Diagram: AI Ethics & Lifecycle Management. This diagram integrates the A4R-OAI ethical framework (vertical steps) with the continuous AI lifecycle (horizontal cycle), illustrating that ethics and bias mitigation must be embedded throughout [91].

The Researcher's Toolkit: Essential Reagents and Solutions

Developing and testing fair AI diagnostics requires a suite of methodological tools and resources. The following table details key solutions for bias detection and mitigation.

Table 3: Research Reagent Solutions for AI Bias Mitigation

Tool / Solution	Function	Application in Diagnostic AI Research
Standardized Demographic Data Fields [92]	Ensures consistent collection and reporting of population variables.	Collect a minimum set: Age, Sex/Gender, Race, Ethnicity. Avoid combining categories (e.g., race and ethnicity). Enables stratified analysis and testing.
Fairness Metrics Toolkits (e.g., AIF360, Fairlearn) [88] [92]	Provides standardized statistical metrics to quantify bias.	Used in the Experimental Protocol for Fairness to measure disparities in performance (e.g., demographic parity, equalized odds) between patient subgroups.
Risk of Bias (ROB) Assessment Tools (e.g., PROBAST) [88]	A structured tool to evaluate the risk of bias and applicability of prediction model studies.	Critical for the systematic review and meta-analysis of existing AI diagnostic models to gauge the reliability of published results.
Synthetic Data Generation [86]	Algorithmically generates data to augment underrepresented classes in training sets.	Can be used to create synthetic medical images or records for rare diseases or underrepresented demographics, helping to balance training data.
Post-hoc Interpretation Models [91] [87]	Provides approximate explanations for "black-box" AI decisions after the prediction is made.	Increases transparency for clinicians by generating visual heatmaps on images or listing key clinical factors that influenced an AI's diagnostic suggestion.
Real-World Performance Monitoring Systems [89]	Tracks AI model performance after deployment in live clinical settings.	Part of the Revision principle in A4R-OAI. Detects concept drift and emergent biases when the AI is applied to new populations over time.

The integration of AI into diagnostics presents a powerful paradox: the capacity to both exacerbate and ameliorate healthcare disparities. The path forward requires a deliberate, collaborative, and rigorous approach from researchers, clinicians, and regulators. As the data shows, achieving fairness is not a single action but a continuous process embedded throughout the AI lifecycle—from the initial conceptualization and data curation to deployment and long-term monitoring [88] [91]. By adopting standardized evaluation protocols like those outlined here, leveraging emerging mitigation strategies like TWIX [89], and committing to ethical frameworks like A4R-OAI [91], the research community can steer the development of diagnostic AI. The goal is to ensure these powerful tools fulfill their promise of delivering not only more efficient and accurate but also more equitable and just healthcare for all patient populations.

Comparative Effectiveness and Validation of Emerging Technologies

Cancer was historically regarded as a single disease, but it is now understood to be a collection of hundreds of diseases, each driven by unique genomic characteristics. Even tumors originating from the same anatomical location can possess distinct DNA alterations that dictate their behavior and treatment response [93]. This biological understanding has triggered a significant shift away from traditional 'one-size-fits-all' treatment approaches, such as chemotherapy, toward therapies that specifically target the genetic changes driving cancer growth [93]. This evolution in cancer care necessitates equally sophisticated diagnostic approaches, primarily divided into two methodologies: sequential single-gene testing (SGT) and comprehensive genomic profiling (CGP).

Sequential single-gene testing, often called "hot spot testing," investigates alterations in a single gene or a small subset of genes. In contrast, comprehensive genomic profiling utilizes next-generation sequencing (NGS) to analyze hundreds of cancer-related genes simultaneously in a single assay [93] [94]. CGP is designed to detect multiple variant classes—including base substitutions, insertions and deletions, copy number alterations, and gene rearrangements or fusions—as well as complex genomic signatures like tumor mutational burden (TMB) and microsatellite instability (MSI) [93] [94]. The critical question for researchers and clinicians is which approach delivers superior performance, clinical utility, and cost-effectiveness in a real-world setting. This article provides a data-driven comparison to address this question.

Methodological Comparison: Testing Architectures and Workflows

The fundamental difference between CGP and SGT lies in their technical architecture and workflow. Understanding these methodologies is key to interpreting their respective outputs and limitations.

Single-Gene Testing (SGT) Workflow: This approach relies on sequential testing using individual platforms for each biomarker.

• Techniques Used: Common SGT methodologies include fluorescent in situ hybridization (FISH) for gene rearrangements, polymerase chain reaction (PCR)-based assays for detecting specific point mutations, and immunohistochemistry (IHC) for protein expression analysis [95] [96].
• Inherent Limitation: Each test is typically designed to detect a predefined alteration and may not identify other types of genomic variants within the same gene. For example, FISH for ALK rearrangements will not detect ALK resistance mutations, and PCR for EGFR may be limited to a set of known "hotspot" mutations, potentially missing novel or complex variants [95] [94].

Comprehensive Genomic Profiling (CGP) Workflow: This NGS-based approach consolidates multiple tests into a single, multiplex assay.

• Techniques Used: CGP involves the parallel sequencing of millions of DNA and RNA fragments from a tumor sample. For example, the OmniSeq INSIGHT assay sequences the full coding regions of 523 genes from DNA and 55 genes from RNA to detect fusions, in addition to analyzing 59 genes for copy number alterations [95] [96].
• Consolidated Data Output: This process generates a comprehensive report detailing multiple variant classes and genomic signatures from a single tissue sample, typically within 2 to 3 weeks [93].

The workflow divergence is visually summarized in the diagram below.

Clinical Performance and Detection Rates: Empirical Evidence

A critical measure of a diagnostic test's value is its ability to accurately identify clinically actionable alterations that inform treatment decisions. Empirical evidence from multiple studies demonstrates a clear performance advantage for CGP.

Case Series Evidence in NSCLC

A case series from a large reference laboratory provides compelling evidence of CGP's superior detection capability. In a study of 561 patients with advanced non-small cell lung cancer (NSCLC), 150 (27%) had prior negative SGT results. Subsequent CGP testing identified highly actionable genomic variants in a subset of these patients that SGT had missed [95] [96].

Table 1: Actionable Alterations Missed by Single-Gene Testing but Detected by CGP

Case	Single-Gene Test Results	Comprehensive Genomic Profiling Results	Clinical Implication
1	Negative for ALK (FISH)	Two ALK fusions (EML4-ALK, ALK-MAP4K3) and an ALK SNV (G1202R)	Eligible for ALK-targeted therapy; G1202R is a known resistance mutation [95] [96].
2	Negative for EGFR (PCR)	EGFR exon 20 insertion	Eligible for EGFR exon 20-targeting therapies [95] [96].
3	Negative for MET (FISH showed polysomy)	MET exon 14 skipping alteration	Eligible for MET inhibitor therapy [95] [96].
4	Not reported for BRAF and KRAS	BRAF V600E and KRAS Q61R mutations	BRAF V600E makes patient eligible for combined BRAF/MEK inhibition [96].

Broader Genomic Profiling in Breast Cancer

The advantage of a broader profiling approach is further supported by research in HR+/HER2- breast cancer. A 2025 prospective, multicenter study comparing a single-gene PIK3CA assay with the 77-gene AVENIO ctDNA expanded panel found that while concordance for PIK3CA was high (92.6%), the broader panel identified additional actionable alterations in a significant number of patients. This included ESR1 mutations in 17.5% of patients and other PI3K pathway alterations in 40.6% of patients, substantially expanding potential treatment options [97].

Quantitative Outcomes: Survival, Cost-Effectiveness, and Tissue Use

Beyond detection rates, the ultimate test of a diagnostic strategy is its impact on patient outcomes and healthcare system efficiency. Data shows that CGP improves survival and is cost-effective compared to SGT.

Survival and Cost-Effectiveness Analysis

A 2025 cost-effectiveness analysis using real-world data from the Syapse study compared CGP versus small panel (SP) testing in patients with advanced NSCLC in the United States and Germany. The findings are summarized below [3] [11].

Table 2: Cost-Effectiveness Analysis of CGP vs. Small Panel (SP) Testing

Parameter	United States	Germany
Average Overall Survival Benefit with CGP	+0.10 years	+0.10 years
Incremental Cost-Effectiveness Ratio (ICER)	$174,782 per life-year gained	€63,158 per life-year gained
ICER (Scenario: More Patients Receiving Treatment)	$86,826 per life-year gained	€29,235 per life-year gained
Conclusion	CGP is a cost-effective strategy compared to SP testing	CGP is a cost-effective strategy compared to SP testing

The study noted that higher costs associated with CGP were attributable to a greater percentage of patients receiving effective, matched targeted therapies, which also led to improved survival [3] [11]. Other studies have confirmed that sequential single-gene testing is less cost-effective than panel testing with CGP and that patients treated with targeted therapy based on CGP results have better outcomes, including improved overall survival [93].

Tissue Conservation and Turnaround Time

The efficiency of diagnostic approaches is also measured by practical considerations like tissue use and speed.

• Tissue Conservation: A key limitation of SGT is the consumption of precious biopsy tissue. An iterative testing approach increases the likelihood of exhausting finite tissue samples, potentially necessitating a repeat invasive biopsy [95] [94]. CGP consolidates multiple tests into one, thereby preserving tissue for additional analyses if needed.
• Turnaround Time (TAT): While SGT is often perceived as faster, a case series revealed that TAT from sample receipt to report was similar for both methods (e.g., 7 days for CGP vs. 7-13 days for various SGTs). However, the total time from sample collection to a conclusive treatment decision is often shorter with CGP because it avoids the protracted timeline of running multiple sequential tests [95] [96]. A study on resected NSCLC reported a median TAT of 28 days for an in-house CGP test versus 10 days for the targeted ODxTT test, though this can vary by institution and testing platform [98].

Research Reagent Solutions and Experimental Models

For scientists designing studies to compare testing modalities, the following key reagents and tools are essential.

Table 3: Essential Research Reagents and Tools for CGP/SGT Comparison Studies

Reagent / Tool	Function in Experimental Protocol	Example Products / Platforms
FFPE Tumor Tissue Sections	Standard source material for DNA/RNA extraction; enables correlation with histopathology.	N/A (Universal specimen type)
NGS-Based CGP Panels	Multiplex assays for simultaneous detection of SNVs, indels, CNAs, fusions, and genomic signatures.	OmniSeq INSIGHT, TruSight Oncology 500, AVENIO ctDNA Expanded Panel, FoundationOne CDx [95] [97] [94]
Single-Gene Assays	Platform-specific tests for detecting single or limited alterations for head-to-head comparison.	FISH (ALK, ROS1, RET), SNaPshot Multiplex PCR (BRAF, KRAS, EGFR), IHC (PD-L1) [95] [96]
Bioinformatic Analysis Pipelines	Software for processing NGS data, variant calling, annotation, and interpreting clinical actionability.	Often platform-specific; public databases (CIViC, OncoKB) used for clinical interpretation [93]
Molecular Tumor Board (MTB)	A multidisciplinary team (oncologists, pathologists, geneticists) to interpret complex CGP results and recommend therapies.	Standard clinical practice for translating CGP findings into treatment plans [99]

Implementation in Research and Clinical Pathways

Integrating CGP into research and clinical practice requires strategic planning. The following pathway illustrates a proposed algorithm for leveraging both targeted and comprehensive testing.

This algorithm is supported by a 2025 study which found that in-house CGP showed high concordance with a targeted panel like ODxTT (94.1%) and served as a powerful complementary tool. The authors supported a strategy where CGP is incorporated for patients with negative or inconclusive targeted test results to maximize opportunities for individualized therapy [98].

Despite its advantages, challenges to the broad implementation of CGP remain, including perceptions of cost, variable turnaround times, confusion about reimbursement, and the complexity of interpreting the large volume of data generated [93]. These challenges can be addressed through decision-support software, the establishment of molecular tumor boards, and the growing trend of bringing CGP in-house at specialist cancer centers to ensure secure specimen handling and potentially quicker turnaround times [93].

The collective evidence from recent clinical studies and cost-effectiveness analyses firmly establishes that comprehensive genomic profiling outperforms sequential single-gene testing across multiple dimensions. CGP demonstrates superior detection of clinically actionable alterations, leading to improved patient survival through better matching with targeted therapies. While associated with higher initial costs due to increased use of effective treatments, CGP proves to be a cost-effective strategy over the care continuum. For researchers and drug development professionals, these findings underscore the importance of adopting broad-panel NGS approaches in clinical trial design and biomarker discovery to fully capture the genomic complexity of cancer and identify patient subgroups most likely to benefit from novel investigational therapies.

In the era of precision oncology, comprehensive genomic profiling has become mandatory for optimal cancer management. For decades, traditional tissue biopsy has served as the unchallenged gold standard for cancer diagnosis and molecular characterization. However, the emergence of liquid biopsy, a minimally invasive approach that analyzes tumor-derived biomarkers from bodily fluids, presents a transformative alternative. This comparison guide objectively examines the technical capabilities, clinical outcomes, economic implications, and appropriate clinical contexts for both methodologies within cancer diagnostic workflows. The dynamic interplay between these approaches is reshaping diagnostic pathways, with emerging evidence suggesting that integrating both modalities may optimize patient outcomes beyond what either can achieve alone.

Methodology and Technical Comparison

Fundamental Technical Principles

Traditional Tissue Biopsy involves the physical removal of tumor tissue, typically via surgical excision, core needle biopsy, or fine-needle aspiration. This provides a histopathological gold standard, allowing assessment of tumor architecture, stromal components, immune cell infiltration, and precise tumor classification through microscopic examination. The tissue undergoes formalin fixation and paraffin embedding (FFPE) before DNA extraction and analysis, a process that can introduce artifacts but preserves spatial context essential for diagnosis.

Liquid Biopsy utilizes blood samples (typically 10-20 mL) to isolate and analyze circulating tumor biomarkers, primarily circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs). ctDNA consists of short DNA fragments (70-200 bp) released into the bloodstream through tumor cell apoptosis or necrosis, while CTCs represent intact, viable cancer cells shed from primary or metastatic sites. Plasma isolation requires precise centrifugation to separate cell-free DNA from cellular components, followed by extraction and highly sensitive detection methods to identify rare tumor-derived signals against abundant background normal DNA [100] [101].

Analytical Performance Characteristics

Table 1: Technical Performance Comparison of Tissue vs. Liquid Biopsy

Parameter	Traditional Tissue Biopsy	Liquid Biopsy
Invasiveness	Invasive surgical procedure	Minimally invasive (blood draw)
Tumor Heterogeneity Assessment	Limited to sampled region (spatial constraint)	Captures heterogeneity from multiple sites
Turnaround Time	Moderate (14-28 days)	Faster (7-14 days)
Repeatability	Limited by patient condition and tumor accessibility	Easily repeated for serial monitoring
Tissue/Architectural Information	Provides complete histopathology	No architectural information
Sensitivity for Early-Stage Disease	High (direct tissue examination)	Limited (low ctDNA shed)
Analytical Sensitivity	High for abundant tissue	Varies (0.01% VAF for NGS, 0.001% for ddPCR)
Preanalytical Requirements	Complex tissue preservation	Standardized blood collection tubes
Comprehensive Genomic Profiling	Yes (ample DNA from tissue)	Limited if ctDNA levels are low

The detection sensitivity of liquid biopsy is highly dependent on tumor burden and cancer type. In advanced malignancies, ctDNA can constitute >10% of total cell-free DNA, while in early-stage disease, this may fall to <0.1%, challenging detection limits. Technological advances in next-generation sequencing (NGS) and digital PCR have enabled detection of mutant alleles at variant allele frequencies as low as 0.01%, though clinical validation at these extremes remains ongoing [100] [102].

Clinical Outcomes and Therapeutic Decision-Making

Clinical Validation Studies

The phase II ROME trial provides compelling evidence regarding the clinical utility of integrating both biopsy modalities. This study enrolled 1,794 patients with advanced solid tumors who had progressed on second- or third-line therapy. Researchers performed centralized NGS on both tissue (FoundationOne CDx) and liquid biopsies (FoundationOne Liquid CDx), with a molecular tumor board identifying actionable alterations for 400 patients who then received tailored therapy [103].

The trial demonstrated a concordance rate of only 49% between tissue and liquid biopsies, with 35% of actionable alterations detected exclusively in tissue and 16% exclusively in liquid biopsy. This complementarity translated directly to survival outcomes: patients receiving therapy based on concordant alterations detected in both biopsy types achieved significantly improved median overall survival (11.1 months vs. 7.7 months; HR=0.74) and progression-free survival (4.9 months vs. 2.8 months; HR=0.55) compared to standard-of-care treatment [103].

Clinical Applications and Limitations

Table 2: Clinical Applications and Limitations by Biopsy Type

Clinical Scenario	Tissue Biopsy Utility	Liquid Biopsy Utility
Initial Diagnosis	Gold standard; essential for histology	Not suitable as primary diagnostic tool
Actionable Mutation Detection	Comprehensive; detects all alteration types	Limited for fusion genes, copy number alterations
Therapy Resistance Monitoring	Limited by invasiveness of repeat sampling	Excellent for real-time detection of resistance mechanisms
Minimal Residual Disease (MRD)	Not feasible	Emerging as sensitive tool for recurrence risk stratification
Tumor Heterogeneity Assessment	Limited spatial sampling	Captures global heterogeneity across disease sites
Early Detection/Screening	Not applicable	Promising in high-risk populations (under investigation)

Discordance between biopsy modalities often reflects biological reality rather than technical failure. The ROME trial analysis revealed that 43.3% of discordant cases stemmed from genuine differences in detection of molecular alterations, while 35% involved discordant tumor mutational burden assessment. Specific pathways, particularly PI3K/PTEN/AKT/mTOR and ERBB2, demonstrated especially high discordance rates, highlighting the impact of tumor evolution and heterogeneity on genomic profiling [103].

Cost-Effectiveness and Healthcare System Implementation

Economic Evaluation Evidence

A comprehensive cost-effectiveness analysis from Brazil's public healthcare system perspective evaluated liquid biopsy using the EarlyCDT-Lung autoantibody test for lung cancer screening in high-risk individuals. Compared to standard clinical diagnosis without screening, the liquid biopsy strategy resulted in an incremental cost of $570,120 and incremental effectiveness of 7.56 quality-adjusted life years (QALYs), yielding an incremental cost-effectiveness ratio (ICER) of $75,433.63 per QALY gained [33] [104].

This ICER far exceeded Brazil's willingness-to-pay threshold ($7,017.54-$21,052.62/QALY), indicating that liquid biopsy screening was not cost-effective in this context. The analysis concluded that the strategy would only become cost-effective in scenarios where lung cancer prevalence exceeds 4.0%, highlighting the critical relationship between test performance, disease prevalence, and economic viability [33].

Implementation Barriers and Facilitators

A 2025 scoping review of factors influencing liquid biopsy implementation identified four major categories of barriers: (1) laboratory and personnel requirements; (2) disease specificity considerations; (3) biomarker-based test limitations; and (4) policy and regulation challenges. The majority of implementation barriers were concentrated in the pre-analytical phase, reflecting a persistent lack of standardization across technologies and platforms [105].

Physician surveys reveal that reimbursement policies significantly influence adoption. In Taiwan, where National Health Insurance reimburses EGFR mutations detected through tissue but not liquid biopsy, 40% of physicians preferred liquid biopsy only when tissue was unavailable. Hematologic oncologists demonstrated stronger preference for liquid biopsy for minimal residual disease testing compared to thoracic medicine specialists (4.2±0.83 vs. 3.1±0.60; p=0.01) [102].

Experimental Workflows and Research Applications

Representative Experimental Protocol: ROME Trial

The ROME trial provides a robust methodological template for comparative biopsy studies:

Patient Population: 1,794 patients with advanced solid tumors (non-small cell lung cancer, colorectal cancer, breast cancer, etc.) who had received second- or third-line treatment.

Sample Collection:

• Tissue Biopsy: FFPE tumor blocks from diagnostic biopsies with tumor content >20%
• Liquid Biopsy: Two 10mL blood draws in Streck Cell-Free DNA Blood Collection Tubes

Sample Processing:

• Tissue: Macrodissection, DNA extraction, NGS using FoundationOne CDx panel (324 genes)
• Liquid Biopsy: Double centrifugation at 1,600×g and 16,000×g, cfDNA extraction, NGS using FoundationOne Liquid CDx panel (311 genes)

Analysis: Centralized molecular tumor board reviewed alterations using OncoKB levels of evidence. Concordance defined as detection of identical actionable alterations in both samples [103].

Figure 1: ROME Trial Integrated Biopsy Analysis Workflow

Essential Research Reagent Solutions

Table 3: Key Research Reagents and Platforms for Comparative Biopsy Studies

Reagent/Platform	Primary Function	Application Context
Streck Cell-Free DNA BCT Tubes	Blood sample stabilization	Preserves ctDNA integrity for up to 7 days at room temperature
FoundationOne CDx	Comprehensive genomic profiling	Tissue-based NGS (324 genes) for therapy selection
FoundationOne Liquid CDx	Liquid biopsy genomic profiling	Plasma-based NGS (311 genes) for blood-based genotyping
QIAamp DSP DNA FFPE Tissue Kit	DNA extraction from FFPE	Optimized recovery of fragmented DNA from archived tissue
QIAamp Circulating Nucleic Acid Kit	cfDNA/ctDNA isolation	High-sensitivity extraction from plasma samples
OncoKB	Evidence-based variant interpretation	Clinical actionability annotation for molecular alterations
Digital PCR Systems	Ultra-sensitive mutation detection	MRD monitoring and low-frequency variant validation

The comparative analysis reveals that liquid and tissue biopsies offer complementary rather than competing clinical value. Tissue biopsy remains indispensable for initial diagnosis and histopathological characterization, while liquid biopsy excels in longitudinal monitoring, resistance mechanism detection, and capturing global tumor heterogeneity. The integration of both modalities, as demonstrated in the ROME trial, can significantly improve survival outcomes by expanding the detection of actionable alterations.

Future development should focus on standardizing pre-analytical protocols, validating liquid biopsy in minimal residual disease settings, and establishing cost-effective implementation pathways across healthcare systems. As technological sensitivity improves and costs decrease, liquid biopsy may assume expanded roles in cancer screening and early detection, though tissue biopsy will maintain its fundamental role in establishing primary diagnosis. The ongoing refinement of both approaches promises to advance precision oncology through more comprehensive tumor genomic profiling.

In clinical practice, the discovery of pulmonary nodules presents a significant diagnostic challenge. Defined as rounded opacities measuring up to 3 cm in diameter, these nodules are identified in nearly a quarter of computed tomography (CT) scans, with over 1.5 million detected annually in the United States alone [106]. While the majority of these nodules (approximately 95%) are benign, their early identification is crucial as they may represent early-stage lung cancer, which has a dramatically improved five-year survival rate of up to 75% when detected at stage 1A [107]. The primary clinical dilemma lies in balancing the probability of malignancy against the potential harm from pursuing benign nodules, which can lead to unnecessary invasive procedures, patient anxiety, and substantial healthcare costs [108].

Current guidelines from organizations including the Fleischner Society, British Thoracic Society, and American College of Chest Physicians recommend management strategies based on clinical risk factors and imaging characteristics, but these recommendations often rely on low-quality evidence and are followed by only about 40% of clinicians [108]. Low-dose computed tomography (LDCT) screening, while sensitive (93.8%) for detecting cancerous pulmonary nodules, suffers from much lower specificity (73.4%), as nodular images can result from various non-cancerous processes [109]. This diagnostic uncertainty has spurred the development of non-invasive tests that can be used following LDCT to improve predictive value, with CyPath Lung emerging as a promising solution that combines flow cytometry and machine learning to analyze sputum samples [109].

CyPath Lung Technology and Mechanism of Action

Technical Foundation and Analytical Approach

CyPath Lung represents a technological advancement in non-invasive lung cancer diagnostics by leveraging automated flow cytometry enhanced by artificial intelligence. The test utilizes a multi-parameter approach to identify cell populations in sputum that indicate malignancy, incorporating a fluorescent porphyrin molecule—tetra(4-carboxyphenyl)porphyrin (TCPP)—that is preferentially taken up by cancer and cancer-associated cells [110] [109]. This proprietary methodology allows for the detection of malignant cells exfoliated from the bronchial epithelium into sputum, providing a direct window into the lung environment.

The analytical process begins with sputum collection over three consecutive days to ensure adequate cellular material for analysis. Samples are then processed using a standardized protocol that includes dissociation with a mixture of 0.1% dithiothreitol and 0.5% N-acetyl-l-cysteine to break down mucus, followed by filtration through a 100-micron nylon strainer and washing in Hank's Balanced Salt Solution [109]. The resulting single-cell suspension is labeled with Fixable Viability Stain 510 to exclude dead cells, antibodies to distinguish leukocyte subsets (including CD45-PE, CD66b-FITC for granulocytes, and CD3-Alexa Fluor 700 for T cells), and the TCPP porphyrin to identify cancer-associated cells [109]. The labeled cell suspension is analyzed by flow cytometry, with data processed through an automated pipeline that combines population identification with machine learning algorithms to classify samples as cancer or non-cancer.

Molecular Mechanism and Cellular Targeting

The fundamental mechanism underlying CyPath Lung's specificity involves the selective uptake of TCPP porphyrin by malignant cells. Research has identified that this uptake occurs through the CD320 receptor and clathrin-mediated endocytosis, pathways that appear to be dysregulated in cancer cells [110]. This selective incorporation mechanism enables the discrimination between normal and malignant cells in sputum samples, forming the biological basis for the test's diagnostic capability.

The CD320 receptor, also known as the transcobalamin II receptor, normally facilitates cellular uptake of vitamin B12 but demonstrates altered expression and function in malignant cells. The discovery that TCPP porphyrin is incorporated into cancer cells through this receptor represents a significant advancement in understanding porphyrin-cancer cell interactions [110]. Further research has shown that simultaneous knockdown of CD320 and LRP2 receptors is selectively toxic to cancer cells but not normal cells, supporting the significance of this pathway in malignant cell biology [110].

Experimental Validation and Performance Data

Clinical Study Design and Methodology

The validation of CyPath Lung followed a rigorous clinical study design detailed in a publication in Respiratory Research [109]. The study enrolled participants from multiple sites, including Atlantic Health System, Mt. Sinai Hospital, Radiology Associates of Albuquerque, South Texas Veterans Healthcare System, and Waterbury Pulmonary Associates. Participants were divided into two groups: a non-cancer group comprising high-risk individuals (aged 52-79, current or former smokers with at least 20 pack-year history) with LDCT results not suspicious for cancer, and a cancer group consisting of patients with physician-evaluated high suspicion of lung cancer confirmed by biopsy after sputum collection.

The analytical process involved several methodical stages. A set of 171 sputum samples analyzed on an LSRII flow cytometer formed the primary dataset, with 168 used for training and testing the model and developing the analysis pipeline. The final model was validated on 150 LSRII samples that passed quality control [109]. To ensure robustness, a second independent set of 45 samples was analyzed on a Navios EX flow cytometer, with 32 passing quality control and used to validate the model's generality across different instruments and research teams. This comprehensive approach allowed researchers to develop a predictive model through iterative evaluation of random training and test sets until a robust model was identified.

Diagnostic Performance Results

CyPath Lung has demonstrated consistently high performance across multiple studies, with particularly impressive results for small nodules where diagnostic uncertainty is greatest. The test's performance metrics are summarized in the table below.

Table 1: CyPath Lung Diagnostic Performance Characteristics

Parameter	Overall Performance	Performance for Nodules <20 mm	Independent Validation Set
Sensitivity	82%	92%	83%
Specificity	88%	87%	77%
Accuracy	Not specified	88%	Not specified
Area Under Curve (AUC)	0.89 (95% CI 0.83-0.89)	0.94 (95% CI 0.89-0.99)	0.85 (95% CI 0.71-0.98)
Negative Predictive Value	96%	Not specified	95%
Positive Predictive Value	61%	Not specified	45%

Data compiled from Lemieux et al. Respiratory Research 2023 [109] and CyPath Physician website [110]

The exceptional performance for nodules smaller than 20 mm is particularly noteworthy, as these smaller nodules present the greatest diagnostic challenge in clinical practice. The high sensitivity (92%) and specificity (87%) for small nodules, coupled with the strong negative predictive value (95%), position CyPath Lung as a valuable rule-out test that could potentially prevent unnecessary invasive procedures in patients with benign nodules [110] [109].

Comparative Performance Against Alternative Diagnostic Methods

Understanding how CyPath Lung compares to existing diagnostic approaches is essential for contextualizing its clinical utility. The following table provides a comparative analysis of various modalities used in lung nodule management.

Table 2: Comparative Performance of Lung Nodule Assessment Methods

Diagnostic Method	Sensitivity	Specificity	Advantages	Limitations
LDCT Screening	93.8% [109]	73.4% [109]	High sensitivity for nodule detection; mortality benefit demonstrated in trials	Low specificity leads to false positives; overdiagnosis concerns
PET-CT	Varies by nodule size and characteristics	Varies by nodule size and characteristics	Metabolic activity assessment; whole-body staging	Limited resolution for sub-centimeter nodules; false positives in inflammatory conditions
CyPath Lung	82-92% [109]	77-88% [109]	Non-invasive; high NPV; specifically validated for small nodules (<20 mm)	Requires adequate sputum sample; not a stand-alone screening tool
Transthoracic Needle Biopsy	~90% (varies by nodule location and size)	~95% (varies by nodule location and size)	Tissue diagnosis with molecular profiling capability	Invasive with risk of pneumothorax; not suitable for all nodule locations
Bronchoscopy	~70-80% (varies by navigation technology)	High	Direct visualization; tissue sampling	Invasive; sedation risks; lower yield for peripheral lesions

The comparative analysis reveals CyPath Lung's distinctive profile as a non-invasive test with high sensitivity and specificity, particularly for the diagnostically challenging small nodules. Its high negative predictive value (96%) enables confident rule-out of malignancy, potentially reducing unnecessary invasive procedures [109].

Cost-Effectiveness Analysis Framework and Economic Impact

Principles of Cost-Effectiveness Analysis in Healthcare

Cost-effectiveness analysis represents a quantitative method for comparing the "return on investment" of healthcare interventions, enabling decision-makers to estimate a policy's capacity to maximize health outcomes for each unit of expenditure [111]. In healthcare evaluation, this methodology follows a structured approach: first, establishing the analysis perspective (societal, payer, or healthcare system) and target population; second, determining the scope of costs; third, selecting appropriate effectiveness criteria; fourth, identifying data sources and estimating policy impact; and finally, conducting the cost-effectiveness analysis itself through modeling techniques [111].

The primary metric in cost-effectiveness analysis is the incremental cost-effectiveness ratio (ICER), which relates the difference in costs to the difference in effectiveness between an intervention and its comparators. In healthcare, effectiveness is typically measured in quality-adjusted life years (QALYs), which incorporate both survival duration and health-related quality of life [107]. Decision-makers then compare the ICER against a willingness-to-pay threshold, often based on a country's per capita gross domestic product, to determine whether an intervention provides sufficient value for money [112].

Economic Evaluation of CyPath Lung

Recent research has evaluated the economic impact of incorporating CyPath Lung into the standard of care for patients with pulmonary nodules. A study published in the Journal of Health Economics and Outcomes Research employed economic modeling to analyze the potential savings, revealing that adding CyPath Lung to the diagnostic pathway would have saved nearly $895 million for private payers and $379 million for Medicare in 2022 alone [113]. These substantial savings primarily resulted from reductions in follow-up diagnostic assessments and invasive procedures for patients with benign nodules, demonstrating how non-invasive diagnostics can reduce unnecessary interventions and their associated risks.

The economic value of CyPath Lung derives from its position in the diagnostic pathway following LDCT detection of small to intermediate-sized nodules. By providing a highly accurate non-invasive method for classifying these nodules, it helps resolve clinical uncertainty and directs invasive procedures toward patients with a higher probability of malignancy. This triaging function optimizes resource utilization within the healthcare system while minimizing patient exposure to procedural risks [113].

Comparative Cost-Effectiveness of Lung Cancer Detection Strategies

The cost-effectiveness of lung cancer detection strategies varies significantly based on population risk factors, healthcare system contexts, and specific implementation protocols. The table below summarizes economic evaluations of different approaches across various settings.

Table 3: Cost-Effectiveness of Lung Cancer Detection Strategies Across Healthcare Systems

Detection Strategy	Population/Setting	Incremental Cost-Effectiveness Ratio	Key Economic Findings
LDCT Screening	High-risk population, Brazil [112]	R$9,579 per life year gained	Cost-effective (below threshold of R$143,406)
LDCT Screening	Chinese population, triennial ages 55-80 [107]	Below 71,453 CNY/QALY	Most cost-effective strategy; robust across sensitivity analyses
CyPath Lung plus Standard of Care	US healthcare system [113]	Cost-saving	Projected savings of $895M (private) and $379M (Medicare) annually
LDCT Screening	US Medicare beneficiaries	Various estimates in literature	Generally cost-effective for high-risk populations

The comparative economic analysis reveals that both LDCT screening and complementary tests like CyPath Lung can provide value within specific clinical contexts. The cost-effectiveness of LDCT screening depends heavily on the specific implementation strategy, with triennial screening from age 55-80 emerging as the most efficient approach in the Chinese healthcare system [107]. CyPath Lung demonstrates a different economic value proposition—rather than functioning as a primary screening tool, it enhances the efficiency of existing screening programs by improving triage and reducing unnecessary procedures [113].

Research Reagents and Technical Toolkit

The development and implementation of CyPath Lung rely on a specific set of research reagents and technical components that enable its unique diagnostic capabilities. The following table details these essential materials and their functions within the experimental and clinical workflow.

Table 4: Key Research Reagents and Technical Components for CyPath Lung Methodology

Reagent/Component	Function	Technical Specification
TCPP Porphyrin	Selective labeling of cancer and cancer-associated cells	meso-tetra(4-carboxyphenyl)porphyrin; fluorescent marker
CD45-PE Antibody	Pan-leukocyte marker for immune cell identification	PE-conjugated antibody against human CD45 antigen
CD66b-FITC Antibody	Granulocyte subset identification	FITC-conjugated antibody against human CD66b
CD3-Alexa Fluor 700	T lymphocyte identification	Alexa Fluor 700-conjugated antibody against human CD3
Fixable Viability Stain 510	Exclusion of dead cells from analysis	Fluorescent dye that covalently binds non-viable cells
Dithiothreitol (DTT)	Mucus dissociation	0.1% concentration in sputum processing protocol
N-acetyl-l-cysteine	Mucus dissociation	0.5% concentration in sputum processing protocol
Hank's Balanced Salt Solution	Cell washing and suspension	Isotonic buffer for maintaining cell viability
Flow Cytometer	Cellular analysis platform	LSRII or Navios EX systems with appropriate laser configuration

This specialized reagent panel enables the multi-parameter analysis central to CyPath Lung's diagnostic algorithm. The combination of cellular viability assessment, leukocyte subset identification, and cancer-specific porphyrin uptake creates a comprehensive cellular profile that machine learning algorithms can process to distinguish malignant from benign samples [109].

Visualizing Workflows and Analytical Frameworks

CyPath Lung Experimental Workflow

The analytical process for CyPath Lung follows a systematic workflow from sample collection through computational analysis, as visualized in the following diagram:

Figure 1: CyPath Lung Experimental Workflow from Sample Collection to Clinical Reporting

This workflow illustrates the integrated process that transforms raw sputum samples into clinically actionable information. The methodology emphasizes standardized processing to ensure reproducibility, multiparametric cellular analysis to capture biological complexity, and automated interpretation to eliminate operator bias [109].

Cost-Effectiveness Analysis Framework

The economic evaluation of novel diagnostics like CyPath Lung follows a structured analytical framework that systematically assesses both costs and health outcomes, as shown in the following diagram:

Figure 2: Cost-Effectiveness Analysis Framework for Novel Diagnostics Evaluation

This structured approach ensures comprehensive consideration of all relevant economic and clinical parameters when evaluating novel diagnostics. The framework emphasizes the importance of perspective selection, appropriate outcome measurement, and rigorous sensitivity analysis to validate findings under different assumptions and scenarios [111].

The validation of CyPath Lung represents a significant advancement in the diagnostic approach to pulmonary nodules, particularly for the challenging subset of small (less than 20 mm) nodules where clinical uncertainty is greatest. Through its innovative combination of flow cytometry, selective porphyrin labeling, and machine learning, this non-invasive test demonstrates performance characteristics that address specific limitations in current LDCT-based screening pathways, particularly the low specificity that leads to unnecessary invasive procedures [109].

From a health economic perspective, CyPath Lung exemplifies how complementary diagnostics can enhance the efficiency of existing screening programs rather than replacing them. The substantial projected savings for healthcare payers [113] result from the test's ability to triage patients more effectively, directing invasive procedures toward those with a higher probability of malignancy while sparing those with benign nodules from unnecessary interventions and risks. This economic value proposition, combined with strong diagnostic performance for early-stage lesions, positions CyPath Lung as a promising tool for optimizing lung cancer diagnostic pathways.

Future developments in this field will likely focus on further refining diagnostic algorithms through expanded training datasets, validating performance across diverse patient populations, and potentially expanding the technological approach to detect other pulmonary pathologies beyond lung cancer. As healthcare systems increasingly emphasize value-based care, the integration of rigorously validated complementary diagnostics like CyPath Lung represents a promising strategy for improving patient outcomes while optimizing resource utilization in cancer diagnosis and management.

The integration of artificial intelligence into clinical workflows represents a paradigm shift in oncology, offering unprecedented opportunities to enhance diagnostic precision, optimize resource allocation, and reduce healthcare costs. As global cancer incidence continues to rise—projected to reach 35 million cases by 2050—healthcare systems face unsustainable cost escalations that demand innovative solutions [114]. AI technologies, particularly machine learning and deep learning algorithms, are transitioning from experimental prototypes to clinically validated tools with demonstrable economic benefits. Recent systematic reviews examining cost-effectiveness and budget impact of clinical AI interventions across diverse healthcare settings reveal that these technologies improve diagnostic accuracy, enhance quality-adjusted life years, and reduce costs largely by minimizing unnecessary procedures and optimizing resource use [75].

The validation of AI's effectiveness through prospective studies and real-world evidence has created a compelling case for its widespread adoption. This analysis examines the cost-effectiveness of AI-driven approaches compared to traditional methods across the cancer care continuum, with specific focus on clinical workflow integration, validation methodologies, and economic impact assessment. By synthesizing data from recent studies and clinical trials, this review provides researchers, scientists, and drug development professionals with evidence-based insights into the value proposition of AI in oncology workflows.

Comparative Effectiveness of AI Versus Traditional Methods

Diagnostic Performance Metrics

Substantial evidence now demonstrates that AI-based diagnostic tools frequently match or surpass human expert performance across multiple cancer types. The integration of computer-aided diagnosis systems into clinical workflows has significantly enhanced detection capabilities while maintaining diagnostic accuracy.

Table 1: Diagnostic Performance Comparison of AI vs. Traditional Methods in Cancer Detection

Cancer Type	AI Method	Traditional Method	Performance Metric	AI Result	Traditional Result
Lung Cancer	Convolutional Neural Networks	Radiologist Interpretation	Sensitivity/Specificity	87% [114]	Lower than AI [114]
Colorectal Cancer	AI-aided Polyp Detection	Standard Colonoscopy	Detection Sensitivity	97% [114]	Lower than AI [114]
Prostate Cancer	Validated AI System	Radiologist Assessment	AUC	0.91 [114]	0.86 [114]
Breast Cancer	Deep Learning Techniques	Conventional ML Methods	Accuracy	>96% [114]	Lower than DL [114]
Cervical Cancer	AI-assisted Cytology	Manual Reading	Sensitivity for CIN2+	5.8% higher [114]	Baseline

The performance advantages of AI systems translate into tangible clinical benefits. For instance, a meta-analysis of AI algorithms for lung cancer diagnosis demonstrated a combined sensitivity and specificity of 87%, significantly reducing misdiagnosis rates compared to manual pathology section analysis [114]. Similarly, international studies have validated AI systems for prostate cancer detection with superior AUC (0.91) compared to radiologists (0.86), detecting more cases of Gleason grade group 2 or greater cancers at the same specificity [114].

Clinical Workflow Efficiency

AI integration substantially enhances workflow efficiency across oncology settings. The implementation of ambient AI scribes has demonstrated a 40% relative reduction in self-reported physician burnout at Mass General Brigham through reduced after-hours documentation burden [115]. Similarly, AI-driven sepsis detection systems at Cleveland Clinic yielded a ten-fold reduction in false positives alongside a 46% increase in identified sepsis cases, with alerts triggering before antibiotic administration in seven times as many cases [115].

These efficiency gains translate into economic benefits by optimizing resource utilization. Systematic analyses confirm that AI improves diagnostic accuracy and enhances quality-adjusted life years while reducing costs through minimizing unnecessary procedures and optimizing resource use [75]. Several interventions have achieved incremental cost-effectiveness ratios well below accepted thresholds, establishing their value within healthcare economic frameworks [75].

Economic Validation: Cost-Effectiveness and Budget Impact

Cost-Effectiveness Analysis of AI Interventions

Comprehensive economic evaluations utilizing cost-effectiveness analysis, cost-utility analysis, and cost-minimization analysis demonstrate the financial viability of AI integration in clinical workflows. A systematic review of 19 studies spanning oncology, cardiology, ophthalmology, and infectious diseases revealed that AI interventions consistently show favorable economic profiles across diverse clinical contexts [75].

Table 2: Economic Evaluations of AI Interventions in Clinical Workflows

Clinical Domain	AI Intervention	Comparator	Economic Method	Key Finding	Reference
ICU Management	ML tool for discharge prediction	Standard intensivist-led discharge	CEA/CUA	Cost savings by preventing readmissions [75]	-
Sepsis Detection	ML algorithm for early detection	Standard clinical practice	CEA	~€76 saved per patient [75]	-
Colonoscopy Screening	AI-aided polyp detection	Standard colonoscopy	CEA	Cost-effective via improved diagnostics [75]	-
Diabetic Retinopathy	Decision-support systems	Traditional screening	CEA	Cost-effective in multinational study [75]	-
Cervical Cancer Screening	HPV self-sampling	VIA	Cost-utility analysis	Higher QALYs vs. VIA [116]	-

The economic advantage of AI emerges from multiple mechanisms. In oncology, AI-based prognostic models enable more accurate patient risk stratification, facilitating earlier interventions and more tailored treatment regimens that reduce resource utilization [75]. Similarly, AI-driven diagnostic processes minimize unnecessary procedures through improved accuracy, creating substantial cost savings while maintaining or improving patient outcomes [75].

Budget Impact and Healthcare System Economics

Beyond cost-effectiveness, budget impact analysis examines the financial consequences of adopting AI interventions within specific healthcare settings. Industry forecasts suggest AI could reduce hospital operating costs by approximately 10-20%, potentially saving $300-900 billion annually by 2050 through improved efficiencies [115]. Strategic analyses project that by 2035, over $1 trillion per year in healthcare spending might shift toward AI-driven, virtualized care models [115].

The economic case is further strengthened by AI's potential to control escalating clinical trial costs. The AI in clinical trials market is growing exponentially, projected to reach $38.03 billion by 2029 at a compound annual growth rate of 39.2% [117]. This growth is driven by AI's ability to streamline drug discovery, create better-designed clinical trials, and improve patient outcomes at reduced costs [117]. With the average cost of developing a new drug among top biopharma companies rising to approximately $2.3 billion in 2023 [117], AI-driven efficiencies present compelling economic value.

Methodological Frameworks for AI Validation

Experimental Design for AI Workflow Validation

Robust validation of AI tools requires sophisticated methodological frameworks that address both clinical efficacy and integration feasibility. The teacher-student distillation approach has emerged as a particularly valuable methodology for developing shareable AI models while protecting patient privacy [118].

Diagram 1: AI Validation via Teacher-Student Framework

This privacy-preserving methodology enables robust validation while addressing data security concerns. In this approach, a "teacher" model is trained on protected health information to extract clinical outcomes, which then generates labels for a publicly available, de-identified dataset. A "student" model is subsequently trained on this public data to predict the teacher-assigned labels, creating a shareable model without direct exposure to sensitive data [118]. This framework has demonstrated exceptional performance with AUROCs > 0.90 across outcomes when evaluated on external datasets from Memorial Sloan Kettering Cancer Center [118].

Implementation Science and Workflow Integration

Successful AI implementation requires careful attention to workflow integration and usability. Prospective studies should evaluate seamless EHR integration, clinical decision support alert fatigue, and workflow adaptation requirements. Empirical evidence indicates that approximately 80% of hospitals now use vendor-supplied AI modules integrated with their electronic health record systems [115], reflecting growing standardization of implementation pathways.

The validation of AI tools must extend beyond algorithmic performance to encompass real-world usability metrics. Key implementation science frameworks address:

• Interoperability standards ensuring compatibility with existing health IT infrastructure
• Clinical workflow mapping to minimize disruption and maximize adoption
• Provider training protocols establishing competency benchmarks
• Continuous monitoring systems tracking performance drift and model decay

Recent surveys indicate that 66% of U.S. physicians now use AI tools in clinical practice, representing a 78% increase from 2023 [115]. This rapid uptake underscores the importance of effective implementation strategies in realizing AI's potential benefits.

The validation of AI clinical workflows requires specialized computational resources and methodological tools. The following reagents represent critical components for conducting rigorous AI validation studies.

Table 3: Essential Research Reagents for AI Clinical Workflow Validation

Reagent/Resource	Specifications	Functional Role	Exemplar Applications
Electronic Health Record Systems	OMOP Common Data Model or i2b2 standards	Structured data extraction and harmonization	Multisite validation studies [118]
Medical Imaging Repositories	DICOM-compliant with standardized annotations	Training and testing image analysis algorithms	AI radiology assessment [114]
Genomic Databases	TCGA, GENIE BPC with clinical annotations	Multimodal data integration for precision oncology	Outcome prediction models [118]
High-Performance Computing	GPU clusters (NVIDIA A100/H100)	Accelerated model training and inference	Deep learning applications [119]
Federated Learning Platforms	Privacy-preserving distributed training	Multi-institutional collaboration without data sharing	Teacher-student frameworks [118]
Clinical NLP Pipelines	Transformer architectures (BERT, ClinicalBERT)	Unstructured text processing for outcome extraction	EHR phenotyping [118]
Model Monitoring Frameworks	Continuous performance assessment	Detection of model drift and degradation	Real-world performance tracking [119]

These research reagents enable the comprehensive validation of AI systems across the development lifecycle. High-performance computing resources, particularly GPU clusters, facilitate the accelerated training of complex deep learning models on large-scale medical datasets [119]. Similarly, standardized electronic health record systems structured according to common data models enable reproducible research across institutions while maintaining data integrity [118].

Limitations and Methodological Challenges

Despite promising results, significant challenges persist in AI validation methodologies. Current economic evaluations often rely on static models that may overestimate benefits by not capturing the adaptive learning of AI systems over time [75]. Additionally, indirect costs, infrastructure investments, and equity considerations are frequently underreported, suggesting that reported economic benefits may be overstated [75].

The heterogeneity of validation frameworks presents another significant challenge. Different studies utilize varied:

• Reference standards for ground truth determination
• Statistical measures for performance quantification
• Time horizons for outcome assessment
• Perspectives for economic evaluation (healthcare system vs. societal)

Furthermore, algorithmic bias remains a concern, as models trained on non-representative datasets may perpetuate or exacerbate healthcare disparities [120]. Robust validation must therefore include subgroup analyses across racial, ethnic, socioeconomic, and geographic dimensions to ensure equitable performance across population groups.

The validation of AI in clinical workflows through prospective studies demonstrates compelling evidence of both clinical effectiveness and cost-saving potential. AI systems consistently show diagnostic performance comparable or superior to human experts while generating substantial economic benefits through optimized resource utilization and streamlined workflows. The teacher-student framework and other methodological advances enable robust validation while addressing critical concerns regarding data privacy and model generalizability.

Future research should prioritize standardized validation frameworks incorporating dynamic economic modeling, long-term outcome assessment beyond immediate cost savings, and equity-focused analyses ensuring benefits extend across diverse populations. As AI continues its integration into clinical workflows, ongoing validation remains essential to realize its full potential in transforming cancer care delivery while containing healthcare costs.

For researchers and drug development professionals, these findings underscore the importance of incorporating AI validation strategies into clinical trial designs and health economic assessments. The accumulating evidence base provides a robust foundation for investment decisions and implementation planning as healthcare organizations navigate the evolving landscape of AI-enabled oncology care.

Cancer represents a leading cause of mortality and morbidity worldwide, placing substantial economic pressure on healthcare systems. The cost-effectiveness of cancer screening strategies varies significantly across countries due to differences in healthcare system structures, reimbursement policies, implementation approaches, and population risk factors. This comparison guide objectively analyzes cost-effectiveness variations across three distinct healthcare environments: the United States (decentralized, insurance-based system), Germany (social health insurance system), and Sweden (tax-funded universal healthcare system). Understanding these differences is crucial for researchers, policymakers, and drug development professionals working to optimize resource allocation and improve cancer outcomes. This analysis synthesizes current economic evidence to illuminate how structural and policy factors influence the value proposition of cancer screening technologies across diverse contexts, framed within the broader thesis of cost-effectiveness analysis methodologies for cancer testing approaches.

Comparative Analysis of Screening Cost-Effectiveness by Country

Table 1: Cost-Effectiveness of Breast Cancer Screening Modalities Across Countries

Screening Modality	Target Population	U.S. Context	German Context	Swedish Context	Cost-Effectiveness Range
Mammography	Women aged 50-69	Decentralized, variable guidelines [121]	Organized programs	Organized, population-based [121]	EUR 3,000-8,000 per QALY [122] [123]
Mammography	Women under 50	Multiple guidelines (e.g., USPSTF: 40+) [121]	Limited evidence	Limited evidence	~EUR 105,000 per life year saved [122]
MRI Screening	High-risk populations (BRCA1/2)	Recommended for high-risk [121]	Part of stratified approaches	Part of stratified approaches	EUR 18,201-33,534 per QALY [122] [123]
PSA-based Screening	Men 50-70	Shared decision-making (55-69) [121]	PSA-RAS emerging [124]	Selective, risk-based [121]	PSA-RAS dominant in Germany [124]

Table 2: Structural Factors Influencing Screening Cost-Effectiveness

Factor	United States	Germany	Sweden
System Organization	Decentralized, opportunistic [121]	Transitioning to organized programs	Organized, population-based [121]
Funding Mechanism	Insurance-based, variable coverage [121]	Statutory health insurance [124]	Tax-funded universal healthcare [121]
Coverage Rates	Variable, disparities by SES [121]	Moderate, improving	High (>80% breast screening) [121]
Approach to New Technologies	Early adoption, higher prices [125] [126]	Step-wise, evidence-based [124]	Cautious, evidence-based [121]
Inequality Impact	Significant SES-based disparities [121]	Moderate inequalities	Lower inequalities

The tabulated data reveals distinct patterns in cancer screening cost-effectiveness across the three countries. In the U.S., despite spending approximately $584 per capita on cancer care (double the median of other high-income countries), this expenditure does not translate to proportionally improved cancer outcomes [125]. This suggests systemic inefficiencies in the decentralized, opportunistic screening approach. Germany demonstrates a methodical transition toward organized screening programs, with emerging evidence supporting risk-adapted strategies. Microsimulation studies indicate that PSA-based risk-adaptive screening (PSA-RAS) for men aged 50-70 may represent a cost-efficient approach, potentially saving approximately €1.2 million per 100,000 men compared to no screening [124]. Sweden exemplifies the population-based organized screening model, achieving over 80% participation in breast cancer screening through systematic invitations and quality assurance [121]. This efficient approach contributes to Sweden's lower per capita cancer spending while maintaining favorable outcomes.

Experimental Protocols and Methodologies

Health Economic Evaluation Framework

The cost-effectiveness evidence presented in this comparison derives from rigorous methodological approaches, primarily utilizing health economic modeling techniques.

Modeling Techniques: Most economic evaluations employ decision-analytic models, including Markov models and microsimulation approaches. For example, the German prostate cancer screening analysis used a well-calibrated microsimulation model (Swedish Prostata) from a statutory health insurance perspective to evaluate lifetime outcomes including cancer incidence, mortality, overdiagnosis, biopsies, life-years, and quality-adjusted life-years (QALYs) [124].

Cost Standardization: To enable cross-country comparisons, economic evaluations typically implement comprehensive standardization processes. The systematic review of European breast cancer screening conducted a three-step standardization: (1) healthcare-specific inflation adjustment using country-specific medical care Consumer Price Indices; (2) currency conversion using averaged exchange rates; and (3) purchasing power parity (PPP) adjustment using healthcare-specific PPP rates from Eurostat-OECD joint methodology [122] [123]. All costs were converted to 2020 EUR for comparability.

Perspective and Time Horizon: Analyses typically adopt healthcare system or societal perspectives with lifetime time horizons. Costs and outcomes are discounted annually, typically at 3-5%, in accordance with national guidelines for health technology assessment [124] [127].

Outcome Measures: The primary outcome measure for most cost-effectiveness analyses is the incremental cost-effectiveness ratio (ICER), expressed as cost per quality-adjusted life year (QALY) gained or cost per life-year saved. Willingness-to-pay thresholds vary by country, influencing determinations of cost-effectiveness [122] [124].

Microsimulation Modeling for Prostate Cancer Screening in Germany

The German prostate cancer screening study provides a detailed example of robust methodology [124]:

Model Structure: The analysis employed a microsimulation model that simulated individual life courses, cancer development, progression, detection, and survival. The model incorporated natural history parameters, test characteristics, treatment pathways, and survival outcomes.

Screening Strategies Evaluated: The study assessed 10 screening strategies, including PSA-based risk-adaptive screening (PSA-RAS) with and without magnetic resonance imaging (MRI) in men starting at age 45 or 50 and stopping at 60 or 70, digital rectal examination (DRE) for ages 45-75 years, and no screening.

Data Sources: Model parameters were derived from German cancer registry data, the German diagnostic-related group schedule, fee-for-service catalogues, published literature, and expert opinion. The model was calibrated to German epidemiological data.

Analysis Framework: The analysis took a statutory health insurance perspective and evaluated lifetime costs and outcomes with annual discounting of 3%. Probabilistic sensitivity analyses were conducted to account for parameter uncertainty.

Diagram 1: Microsimulation Modeling Workflow for Cancer Screening Evaluation. This diagram illustrates the sequential components of microsimulation modeling used in health economic evaluations of cancer screening strategies.

Visualization of Cost-Effectiveness Analysis Framework

Diagram 2: Conceptual Framework for Cancer Screening Cost-Effectiveness Analysis. This diagram illustrates the key components and flow of information in cost-effectiveness analyses of cancer screening strategies, from input parameters to output metrics.

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Methodological Components for Cancer Screening Cost-Effectiveness Research

Research Component	Function	Exemplars
Modeling Platforms	Simulation of disease progression and intervention effects	TreeAge Pro, R, Python, SAS, Excel with VBA
Epidemiologic Data Sources	Parameter estimation for disease natural history	Cancer registries (e.g., German Centre for Cancer Registry Data [124], SEER, NORDCAN)
Cost Databases	Resource use valuation for economic analysis	Country-specific fee schedules (e.g., German diagnostic-related group schedule [124]), Medicare Fee Schedules [128], hospital price transparency data
Utility Weights	Quality of life adjustment for QALY calculation	EQ-5D population surveys, literature-based estimates [124]
Quality Assessment Tools	Methodological rigor evaluation	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist [122] [123]

Discussion

The comparative analysis reveals fundamental structural factors underlying cost-effectiveness variations. The U.S. healthcare system demonstrates a paradox of high spending without commensurate outcomes, partly attributable to its decentralized screening approach, price variation, and disparities in access [125] [121] [128]. Germany exhibits a more structured methodology with emerging evidence supporting risk-adapted screening protocols, though it continues to transition from opportunistic to organized programs [124]. Sweden exemplifies the population-based organized screening model, achieving high coverage and efficiency through systematic implementation [121].

These differences highlight the critical importance of considering healthcare system context when evaluating the transferability of cost-effectiveness findings across countries. Methodological factors also significantly influence results, including the perspective of analysis, discount rates, time horizon, and outcome measures. Recent evidence suggests that many cost-effectiveness analyses fail to adequately account for real-world price variation, potentially skewing value conclusions [128].

Future research directions include evaluating emerging screening technologies, particularly multi-cancer early detection (MCED) tests, which present both promise and challenges for integration into existing screening paradigms [126] [129]. Additionally, addressing evidence gaps for underrepresented regions and populations remains a priority for achieving equitable cancer screening outcomes globally. As genomic medicine continues to advance, its cost-effective integration across the cancer care continuum—from prevention to treatment—requires further economic evaluation to guide sustainable implementation [127].

Conclusion

The evidence synthesized from recent studies confirms that a one-size-fits-all approach to cancer testing is economically unsustainable. The cost-effectiveness of any diagnostic strategy is highly contextual, dependent on cancer type, biomarker prevalence, clinical actionability, and local healthcare economics. Foundational principles highlight that while genomic testing costs are falling, targeted therapy remains a major cost driver, though it can be offset by improved outcomes and avoidance of ineffective treatments. Methodological applications demonstrate that comprehensive genomic profiling, though initially more costly, can be cost-effective compared to small panels by better guiding therapy, particularly in cancers like NSCLC. Furthermore, AI-assisted workflows and novel diagnostics like CyPath Lung show significant potential to reduce costs by minimizing unnecessary procedures and streamlining pathologist workload. Troubleshooting reveals that success hinges on strategic implementation—using clinical utility frameworks, optimizing for specific high-benefit patient subgroups, and integrating point-of-care solutions for underserved populations. Finally, comparative validations underscore that emerging technologies like liquid biopsy and AI are not merely futuristic concepts but are presently delivering tangible value. Future directions for biomedical research must focus on generating robust real-world evidence, developing innovative trial endpoints like the PFS2/PFS1 ratio for molecularly guided therapies, and creating sustainable economic models that support the equitable adoption of these transformative technologies across all healthcare systems.

References

• 1. The Cost Effectiveness of Genomic Medicine in Cancer Control [https://pmc.ncbi.nlm.nih.gov/articles/PMC12053027/]
• 2. Cost-Effectiveness of a Multicancer Early Detection Test in ... [https://www.ajmc.com/view/cost-effectiveness-of-a-multicancer-early-detection-test-in-the-us]
• 3. Cost-Effectiveness Analysis of Comprehensive Genomic ... [https://pubmed.ncbi.nlm.nih.gov/40701291/]
• 4. Cost-effectiveness of genetic risk-stratified screening for ... [https://www.sciencedirect.com/science/article/pii/S0960977625005831]
• 5. Sugemalimab plus chemotherapy versus ... [https://www.nature.com/articles/s41598-025-18030-w]
• 6. Cost-effectiveness analysis of first-line treatments for ... [https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1644426/full]
• 7. Precision cancer medicine 2025: some concerns - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC12439214/]
• 8. Assessing the Cost-Effectiveness of Next-Generation ... [https://pubmed.ncbi.nlm.nih.gov/38729563/]
• 9. Assessing the Cost-Effectiveness of Next-Generation ... [https://www.sciencedirect.com/science/article/pii/S109830152402357X]
• 10. Cost-Effectiveness of Precision Medicine [https://www.theabopm.org/blog/3kspn7eivyssghzkczxtt1m4vmsjxz]
• 11. Cost-Effectiveness Analysis of Comprehensive Genomic ... [https://www.sciencedirect.com/science/article/abs/pii/S1525157825001655]
• 12. Economic evaluation of personalised versus conventional ... [https://pubmed.ncbi.nlm.nih.gov/40210464/]
• 13. The economic costs of precision medicine for clinical ... [https://www.nature.com/articles/s41698-024-00711-w]
• 14. Cost-effectiveness assessment of liquid biopsy for early ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12306772/]
• 15. Quality-adjusted life year [https://en.wikipedia.org/wiki/Quality-adjusted_life_year]
• 16. Problems and solutions in calculating quality-adjusted life ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC317370/]
• 17. How to use a cost utility analysis to evaluate your digital health product. [https://www.gov.uk/guidance/cost-utility-analysis-health-economic-studies]
• 18. Quality-Adjusted Life Years QALY in Cost-Effectiveness ... [https://www.mapi-trust.org/resources/blog/qaly]
• 19. Incremental cost-effectiveness ratio [https://en.wikipedia.org/wiki/Incremental_cost-effectiveness_ratio]
• 20. and QALYs : An Overview | Clinical Lab Products ICERs [https://clpmag.com/resource-center/research/qalys-icers-overview/]
• 21. Understanding the global measurement of willingness to pay ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7048225/]
• 22. The impact of willingness - to - pay on price reduction... threshold [https://pmc.ncbi.nlm.nih.gov/articles/PMC11037021/]
• 23. The US Oncology Network in The News [https://usoncology.com/news/research-presented-at-asco-2025-demonstrates-significant-cost-savings-in-community-oncology-setting-with-pharmacist-driven-interventions/]
• 24. Microcosting Study of Genomic Profiling for Precision ... [https://www.sciencedirect.com/science/article/pii/S1525157825001710]
• 25. The cost and cost trajectory of genome sequencing and ... [https://pubmed.ncbi.nlm.nih.gov/40856105/]
• 26. How Expensive Is Targeted Therapy? Cancer Rx Cost ... [https://int.livhospital.com/how-expensive-is-targeted-therapy-cancer-rx/]
• 27. A comparative analysis of 2D and 3D experimental data for ... [https://www.nature.com/articles/s41598-023-42486-3]
• 28. Cost and scalability key drivers of expanded gene therapy ... [https://www.statnews.com/sponsor/2025/05/01/cost-and-scalability-key-drivers-of-expanded-gene-therapy-access/]
• 29. Precision Oncology Research Report 2025: Market to Hit ... [https://finance.yahoo.com/news/precision-oncology-research-report-2025-090800765.html]
• 30. Factors for a broad technology assessment of ... [https://www.sciencedirect.com/science/article/abs/pii/S1040842824001847]
• 31. Liquid Biopsy: The Challenges of a Revolutionary ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12154446/]
• 32. Liquid biopsy- A pivotal test to help navigate clinical ... [https://www.sciencedirect.com/science/article/pii/S2950195425000396]
• 33. Cost-effectiveness assessment of liquid biopsy for early ... [https://pubmed.ncbi.nlm.nih.gov/40729354/]
• 34. Systematic review of cost effectiveness and budget impact ... [https://www.nature.com/articles/s41746-025-01722-y]
• 35. AI in Cancer Diagnostics Market Grows at 9.35% CAGR ... [https://www.towardshealthcare.com/insights/ai-in-cancer-diagnosis-transforming-cancer-care]
• 36. Comparing the Cost-Effectiveness of Innovative Colorectal ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7850547/]
• 37. Partitioned Survival and State Transition Models for ... [https://www.sciencedirect.com/science/article/pii/S1098301520343564]
• 38. Partitioned Survival and State Transition Models for ... [https://pubmed.ncbi.nlm.nih.gov/33248517/]
• 39. CISNET: MISCAN - Colon (Erasmus/MSK) | SRP/DCCPS/NCI/NIH [https://cisnet.cancer.gov/resources/model-registry/colorectal-models/MISCAN-colon.html]
• 40. The MISCAN-COLON simulation model for the ... - PubMed - NIH [https://pubmed.ncbi.nlm.nih.gov/10066353/]
• 41. a case study of Osimertinib versus pemetrexed-platinum [https://bmccancer.biomedcentral.com/articles/10.1186/s12885-024-11971-x]
• 42. "Cost-Effectiveness of Genomic Profiling in Lung Cancer" [https://www.linkedin.com/posts/scott-j-spencer_cost-effectiveness-analysis-of-comprehensive-activity-7364716437032136705-HPLV]
• 43. A novel dual-target Septin9 methylation assay for improved ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11290180/]
• 44. The performance of the SEPT9 gene methylation assay ... [https://www.nature.com/articles/s41598-017-03321-8]
• 45. The Cost‐Effectiveness of a Multi‐Target Stool DNA‐Based ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12021674/]
• 46. Performance of circulating methylated Septin9 gene DNA ... [https://www.sciencedirect.com/science/article/pii/S0009898122013535]
• 47. Novel Noninvasive Tests for Colorectal Cancer Screening [https://pubmed.ncbi.nlm.nih.gov/39982693/]
• 48. CT Colonography Most Cost-Effective Colorectal Cancer ... [https://www.neimanhpi.org/press-releases/ct-colonography-most-cost-effective-colorectal-cancer-screening-strategy-for-black-adults/]
• 49. Artificial intelligence-assisted prostate cancer diagnosis for ... [https://www.nature.com/articles/s43856-025-01185-y]
• 50. Can this cutting-edge AI tool change the way we diagnose ... [https://prostatecanceruk.org/about-us/news-and-views/2025/11/ai-diagnosis-and-treatment-research]
• 51. Artificial Intelligence Across the Prostate Cancer Pathway [https://pmc.ncbi.nlm.nih.gov/articles/PMC12591259/]
• 52. Market AI - Size, Share And Market Trends 2034 in Pathology 2025 [https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-pathology-global-market-report]
• 53. [2407.17734] Cost - effective Instruction Learning for Pathology Vision... [https://arxiv.org/abs/2407.17734]
• 54. How AI Works — In One Simple Flow ( In ) Pathology 2025 [https://www.linkedin.com/pulse/how-ai-pathology-works-one-simple-flow-2025-startup-market-trends-t3nee]
• 55. Journal of Medical Internet Research - Public Awareness of and... [https://www.jmir.org/2025/1/e59591]
• 56. Advancements in artificial intelligence for prostate cancer [https://www.sciencedirect.com/science/article/pii/S2214388225000074]
• 57. Incorporating diagnostic testing into economic evaluations ... [https://pubmed.ncbi.nlm.nih.gov/40627429/]
• 58. GRAIL PATHFINDER 2 Results Show Galleri® Multi ... [https://grail.com/press-releases/grail-pathfinder-2-results-show-galleri-multi-cancer-early-detection-blood-test-increased-cancer-detection-more-than-seven-fold-when-added-to-uspstf-a-and-b-recommended-screenings/]
• 59. Effectiveness and cost-effectiveness of risk-adapted colorectal ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12642085/]
• 60. Cost-Effectiveness Analysis of Implementing a ... [https://www.sciencedirect.com/science/article/pii/S2773065425000768]
• 61. Real-world evidence provides clinical insights into tissue ... [https://www.nature.com/articles/s41467-025-57941-0]
• 62. The Biomarker Evaluation Process - NCBI [https://www.ncbi.nlm.nih.gov/books/NBK220290/]
• 63. Tumor-Agnostic Therapies in Practice - PubMed Central - NIH [https://pmc.ncbi.nlm.nih.gov/articles/PMC11899253/]
• 64. Biomarker-based clinical trials: study design and regulatory ... [https://memoinoncology.com/biomarker-based-clinical-trials-study-design-and-regulatory-requirements/]
• 65. Leveraging External Data for Testing Experimental ... [https://arxiv.org/abs/2506.04128]
• 66. Cost-effectiveness analysis of population-based BRCA1/2 ... [https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1479966/full]
• 67. ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5115817/]
• 68. ESMO releases updated scale to measure clinical benefit ... [https://www.news-medical.net/news/20250523/ESMO-releases-updated-scale-to-measure-clinical-benefit-of-cancer-treatments.aspx]
• 69. Comparative Assessment of Clinical Benefit Using the ... [https://pubmed.ncbi.nlm.nih.gov/30707056/]
• 70. The ESMO-Magnitude of Clinical Benefit Scale ... [https://www.sciencedirect.com/science/article/pii/S2949820125000608]
• 71. Socioeconomic impact of artificial intelligence–driven point-of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12325499/]
• 72. Artificial intelligence (AI) in point-of-care testing [https://www.sciencedirect.com/science/article/pii/S0009898125002207]
• 73. Nationwide real-world implementation of AI for cancer ... [https://www.nature.com/articles/s41591-024-03408-6]
• 74. Cost-Effectiveness of Artificial Intelligence Support in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8997030/]
• 75. Systematic review of cost effectiveness and budget impact of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12381244/]
• 76. Current AI technologies in cancer diagnostics and treatment [https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-025-02369-9]
• 77. AI Medical Devices: 2025 Status, Regulation & Challenges [https://intuitionlabs.ai/articles/ai-medical-devices-regulation-2025]
• 78. Healthcare AI 2025 - Chambers Global Practice Guides [https://practiceguides.chambers.com/practice-guides/healthcare-ai-2025]
• 79. Lack of insurance, follow-ups undercut cancer screening ... [https://www.fredhutch.org/en/news/center-news/2025/11/lack-of-insurance-follow-ups-undercut-cancer-screening-wins.html]
• 80. Press Release [https://investors.guardanthealth.com/press-releases/press-releases/2025/Guardant-Health-to-Share-Data-Supporting-Critical-Role-of-Blood-Based-Testing-in-Improving-Cancer-Screening-Adherence-at-ACG-2025/default.aspx]
• 81. Performance comparison of quantitative and qualitative ... [https://pubmed.ncbi.nlm.nih.gov/40835037/]
• 82. Performance comparison of quantitative and qualitative ... [https://www.sciencedirect.com/science/article/abs/pii/S0016510725019121]
• 83. Organizational Determinants, Outcomes Related to ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12153609/]
• 84. Barriers to cancer screening uptake and approaches ... [https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1575820/full]
• 85. Cost-effectiveness of CA125- and age-informed risk-based ... [https://www.nature.com/articles/s41416-025-03166-3]
• 86. Addressing bias in big data and AI for health care [https://pmc.ncbi.nlm.nih.gov/articles/PMC8515002/]
• 87. Comparing AI Diagnostic Tools in Medicine [https://healthmanagement.org/c/artificial-intelligence/news/comparing-ai-diagnostic-tools-in-medicine]
• 88. Bias recognition and mitigation strategies in artificial ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11897215/]
• 89. Bias in AI-based models for medical applications [https://www.nature.com/articles/s41746-023-00858-z]
• 90. Ethical and Bias Considerations in Artificial Intelligence ... [https://www.sciencedirect.com/science/article/pii/S0893395224002667]
• 91. A Process Framework for Ethically Deploying Artificial ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9746763/]
• 92. Radiologists Share Tips to Prevent AI Bias [https://www.rsna.org/news/2025/may/tips-to-prevent-ai-bias]
• 93. Comprehensive genomic profiling (CGP) in cancer care [https://diagnostics.roche.com/global/en/article-listing/lab-leaders/article/comprehensive-genomic-profiling-cgp-cancer-care.html]
• 94. Comprehensive Genomic Profiling (CGP) | Cancer ... [https://www.illumina.com/areas-of-interest/cancer/ngs-in-oncology/cgp.html]
• 95. Case report: Single gene testing and comprehensive ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11560755/]
• 96. Case report: Single gene testing and comprehensive ... [https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1445668/full]
• 97. Clinical impact of single-gene vs. panel sequencing in ... [https://www.nature.com/articles/s41523-025-00805-z]
• 98. Clinical utility of comprehensive genomic profiling versus ... [https://www.nature.com/articles/s41598-025-21559-5]
• 99. Integrating comprehensive genomic profiling in the ... [https://www.sciencedirect.com/science/article/pii/S2319417025000253]
• 100. Liquid biopsy – a narrative review with an update on current ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12333414/]
• 101. Pros: Can tissue be replaced by biopsy ? - PMC liquid biopsy [https://pmc.ncbi.nlm.nih.gov/articles/PMC5009092/]
• 102. The prospects and limitations of liquid biopsy utilization for ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11937291/]
• 103. Survival Outcomes May Improve When Treatment Is... - The ASCO Post [https://ascopost.com/news/april-2025/survival-outcomes-may-improve-when-treatment-is-guided-by-using-both-tissue-and-liquid-biopsies/]
• 104. Cost-effectiveness assessment of liquid biopsy for early ... [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0328631]
• 105. A scoping review of factors influencing the implementation of ... [https://jeccr.biomedcentral.com/articles/10.1186/s13046-025-03322-w]
• 106. Initial Pulmonary Nodule Management for the Generalist [https://www.sciencedirect.com/science/article/pii/S0025619625003933]
• 107. Cost effectiveness analysis of low dose computed ... [https://www.nature.com/articles/s41598-025-21468-7]
• 108. Lung nodules: A comprehensive review on current approach ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6784443/]
• 109. Detection of early-stage lung cancer in sputum using ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9862555/]
• 110. CyPath® Lung: CyPath® Physician [https://www.cypathlung.com/]
• 111. - Cost – Policy Evaluation: Methods and... effectiveness analysis [https://scienceetbiencommun.pressbooks.pub/pubpolevaluation/chapter/cost-effectiveness-analysis/]
• 112. Cost-Effectiveness of Lung Cancer Screening in a High ... [https://pubmed.ncbi.nlm.nih.gov/40700665/]
• 113. U.S. Medicine Magazine Spotlights CyPath® Lung as ... [https://www.morningstar.com/news/business-wire/20250903859844/us-medicine-magazine-spotlights-cypath-lung-as-promising-tool-to-improve-lung-cancer-detection-in-veterans-lower-costs-to-the-va]
• 114. Artificial Intelligence Advancements in Oncology: A Review ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12025054/]
• 115. AI in Hospitals: 2025 Adoption Trends & Statistics [https://intuitionlabs.ai/articles/ai-adoption-us-hospitals-2025]
• 116. A comparison of the cost-effectiveness of HPV (self ... [https://pubmed.ncbi.nlm.nih.gov/40975493/]
• 117. Artificial Intelligence (AI) in Clinical Market Report Trials 2025 [https://www.researchandmarkets.com/reports/5896119/artificial-intelligence-ai-in-clinical-trials]
• 118. Shareable artificial intelligence to extract cancer outcomes ... [https://www.nature.com/articles/s41467-024-54071-x]
• 119. and AI in Machine : Use Cases [ Learning ] Clinical Trials 2025 [https://www.coherentsolutions.com/insights/role-of-ml-and-ai-in-clinical-trials-design-use-cases-benefits]
• 120. AI and Cancer: The Emerging Revolution [https://www.cancerresearch.org/blog/ai-cancer]
• 121. USA vs Europe: Who Does Cancer Screening Better? [https://oncodaily.com/oncolibrary/cancer-screening-usa-vs-europe]
• 122. A Systematic Review of the Cost-Effectiveness of Screening ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12606780/]
• 123. A Systematic Review of the Cost-Effectiveness ... [https://www.mdpi.com/2072-6694/17/21/3585]
• 124. Cost effectiveness analysis of prostate cancer screening ... [https://pubmed.ncbi.nlm.nih.gov/40665795/]
• 125. Comparison of Cancer-Related Spending and Mortality ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9142870/]
• 126. Rethinking Cancer Screening in Europe: The Promise and ... [https://www.decibio.com/insights/rethinking-cancer-screening-in-europe-the-promise-and-peril-of-mced-testing]
• 127. The Cost Effectiveness of Genomic Medicine in Cancer ... [https://link.springer.com/article/10.1007/s40258-025-00949-w]
• 128. The Role of Price Variation in Economic Analyses for ... [https://link.springer.com/article/10.1007/s40258-025-01007-1]
• 129. the potential of multi-cancer early detection (MCED) ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11785667/]